{"questions": [{"id": "5a70dfd599e2c3af26000006", "body": "What is Dysphoric Milk Ejection Reflex?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21645333", "http://www.ncbi.nlm.nih.gov/pubmed/20443435", "http://www.ncbi.nlm.nih.gov/pubmed/31393168", "http://www.ncbi.nlm.nih.gov/pubmed/29115857", "http://www.ncbi.nlm.nih.gov/pubmed/19210451", "http://www.ncbi.nlm.nih.gov/pubmed/34816221", "http://www.ncbi.nlm.nih.gov/pubmed/21554642", "http://www.ncbi.nlm.nih.gov/pubmed/6892113", "http://www.ncbi.nlm.nih.gov/pubmed/2197367", "http://www.ncbi.nlm.nih.gov/pubmed/8336830"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/20443435", "text": "Dysphoric milk ejection reflex (D-MER) results in waves of negative emotions that last from shortly before initial milk ejection until baby starts to feed vigorously Symptoms may decrease by 3 months or they may continue throughout the breastfeeding period.", "offsetInBeginSection": 0, "offsetInEndSection": 257, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29115857", "text": "BACKGROUND Dysphoric milk ejection reflex (D-MER) is characterized by an abrupt dysphoria, or undesirable feeling that occurs with the MER and continues for no more than a few minutes.", "offsetInBeginSection": 0, "offsetInEndSection": 184, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29115857", "text": "After milk ejection, the dysphoria vanishes.", "offsetInBeginSection": 185, "offsetInEndSection": 229, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21645333", "text": "Dysphoric Milk Ejection Reflex (D-MER) is an abrupt emotional \"drop\" that occurs in some women just before milk release and continues for not more than a few minutes.", "offsetInBeginSection": 0, "offsetInEndSection": 166, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7250254", "text": "This suggests that, unlike what has been proposed for the rat, sleep is not a necessary component of the milk ejection reflex in the pig.", "offsetInBeginSection": 459, "offsetInEndSection": 596, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8739892", "text": "These results show that the activation of GABAB receptors located outside, but not within, the SON are capable of inhibiting the milk ejection reflex.", "offsetInBeginSection": 1369, "offsetInEndSection": 1519, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19215522", "text": "Thus, the pathways which pass through or originate from the medial septum and which are excitatory for oxytocin release appear not to be involved in the regulation of the milk ejection reflex.", "offsetInBeginSection": 885, "offsetInEndSection": 1077, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2792248", "text": "The amount of oxytocin in the perfusates further increased-during facilitation of the milk ejection reflex by intraventricular injections of oxytocin or its analogue, isotocin.", "offsetInBeginSection": 1248, "offsetInEndSection": 1424, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21554642", "text": "In lactating rats, suckling elicits the milk ejection reflex which consists of an intermittent synchronous activation of hypothalamic oxytocin neurons which releases oxytocin into the bloodstream.", "offsetInBeginSection": 0, "offsetInEndSection": 196, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21554642", "text": "However, in so far as these dorsal horn neurons may be part of the milk ejection reflex pathway, their activity, showing convergence and summation of input, and being facilitated in milk ejecting animals, indicates that the reflex does undergo a certain degree of processing at the spinal cord level.", "offsetInBeginSection": 2639, "offsetInEndSection": 2939, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a76160a83b0d9ea66000020", "body": "Which sequence-based algorithm for branch point prediction has been proposed?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28633445", "http://www.ncbi.nlm.nih.gov/pubmed/9224618", "http://www.ncbi.nlm.nih.gov/pubmed/24709818", "http://www.ncbi.nlm.nih.gov/pubmed/35727857", "http://www.ncbi.nlm.nih.gov/pubmed/18276277", "http://www.ncbi.nlm.nih.gov/pubmed/24322938", "http://www.ncbi.nlm.nih.gov/pubmed/12581553", "http://www.ncbi.nlm.nih.gov/pubmed/1598209", "http://www.ncbi.nlm.nih.gov/pubmed/18625080", "http://www.ncbi.nlm.nih.gov/pubmed/14560050"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28633445", "text": "Results We here propose a novel branch point prediction algorithm that utilizes information on the branch point sequence and the polypyrimidine tract.", "offsetInBeginSection": 409, "offsetInEndSection": 559, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28633445", "text": "An accurate computational model for branch point prediction is therefore an ongoing objective in human genome research.", "offsetInBeginSection": 287, "offsetInEndSection": 406, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9224618", "text": "A putative branch point consensus sequence for Arabidopsis thaliana resembling the well known metazoan consensus sequence has been proposed, but this is based on search of sequences similar to those in yeast and metazoa.", "offsetInBeginSection": 183, "offsetInEndSection": 403, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24709818", "text": "To map precisely the location of branch points on a genomic scale, we developed LaSSO (Lariat Sequence Site Origin), a data-driven algorithm which utilizes RNA-seq data.", "offsetInBeginSection": 173, "offsetInEndSection": 342, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24709818", "text": "LaSSO showed better sensitivity and accuracy than algorithms used for computational branch-point prediction or for empirical branch-point determination.", "offsetInBeginSection": 842, "offsetInEndSection": 994, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24709818", "text": "LaSSO thus provides an effective approach for defining high-resolution maps of branch-site sequences and intronic elements on a genomic scale.", "offsetInBeginSection": 1148, "offsetInEndSection": 1290, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26176857", "text": "Here we propose a sequence-based hybrid algorithm SNBRFinder (Sequence-based Nucleic acid-Binding Residue Finder) by merging a feature predictor SNBRFinderF and a template predictor SNBRFinderT.", "offsetInBeginSection": 352, "offsetInEndSection": 546, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26176857", "text": "SNBRFinderF was established using the support vector machine whose inputs include sequence profile and other complementary sequence descriptors, while SNBRFinderT was implemented with the sequence alignment algorithm based on profile hidden Markov models to capture the weakly homologous template of query sequence.", "offsetInBeginSection": 547, "offsetInEndSection": 862, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27293216", "text": "Based on the proposed HPCS algorithm, we implemented an m(6)A site predictor, called M6A-HPCS, which is freely available at http://csbio.njust.edu.cn/bioinf/M6A-HPCS.", "offsetInBeginSection": 1108, "offsetInEndSection": 1274, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16839417", "text": "RESULTS We proposed a novel clustering-based ensemble algorithm named EMD for de novo motif discovery by combining multiple predictions from multiple runs of one or more base component algorithms.", "offsetInBeginSection": 491, "offsetInEndSection": 687, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a9922981d1251d03b000007", "body": "How do circRNAs relate to tumorigenesis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33717646", "http://www.ncbi.nlm.nih.gov/pubmed/29263845", "http://www.ncbi.nlm.nih.gov/pubmed/32860847", "http://www.ncbi.nlm.nih.gov/pubmed/33346098", "http://www.ncbi.nlm.nih.gov/pubmed/34110722", "http://www.ncbi.nlm.nih.gov/pubmed/31001261", "http://www.ncbi.nlm.nih.gov/pubmed/33643900", "http://www.ncbi.nlm.nih.gov/pubmed/30111313", "http://www.ncbi.nlm.nih.gov/pubmed/32423867", "http://www.ncbi.nlm.nih.gov/pubmed/28991235"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28933584", "text": "Circular RNAs (circRNAs) are a type of noncoding RNAs generated from back-splicing, which have been verified to mediate multiple tumorigenesis.", "offsetInBeginSection": 0, "offsetInEndSection": 143, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29034621", "text": "intronic circRNAs).", "offsetInBeginSection": 258, "offsetInEndSection": 277, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29034621", "text": "exonic circRNAs) or introns (i.e.", "offsetInBeginSection": 224, "offsetInEndSection": 257, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29069731", "text": "Our study for the first time demonstrated that Myc transcription factor regulates the expression of circRNAs, adding a novel component of the Myc tumorigenic program and opening a window to investigate the function of certain circRNAs in tumorigenesis.", "offsetInBeginSection": 1023, "offsetInEndSection": 1275, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29069731", "text": "Based on miRNA sponge mechanism, we constructed circRNAs/miRNAs network regulated by Myc, suggesting that circRNAs may widely regulate protein expression through miRNA sponge mechanism.", "offsetInBeginSection": 639, "offsetInEndSection": 824, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28928231", "text": "CircRNAs are involved in many regulatory bioprocesses of malignance, including cell cycle, tumorigenesis, invasion, metastasis, apoptosis, vascularization, through adsorbing RNA as a sponge, binding to RNA-binding protein (RBP), modulating transcription, or influencing translation.", "offsetInBeginSection": 523, "offsetInEndSection": 805, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27363013", "text": "Accumulating evidences indicate that long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs) play important roles in tumorigenesis.", "offsetInBeginSection": 0, "offsetInEndSection": 134, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27363013", "text": "CeRNA network inferred that lncRNA H19 and circRNA MYLK could bind competitively with miRNA-29a-3p increasing target gene DNMT3B, VEGFA and ITGB1 expressions.", "offsetInBeginSection": 1121, "offsetInEndSection": 1279, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27363013", "text": "Taken together, these results suggested lncRNAs and circRNAs could implicate in the pathogenesis and development of bladder cancer.", "offsetInBeginSection": 1593, "offsetInEndSection": 1724, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27158380", "text": "Overall, our data suggest that circRNAs play an important role in the tumorigenesis of LSCC and may serve as novel and stable biomarkers for the diagnosis and progress of LSCC.", "offsetInBeginSection": 1252, "offsetInEndSection": 1428, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a8ee9d1fcd1d6a10c000027", "body": "Is there a disease or condition called Exploding Head Syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34693698", "http://www.ncbi.nlm.nih.gov/pubmed/23467433", "http://www.ncbi.nlm.nih.gov/pubmed/1896728", "http://www.ncbi.nlm.nih.gov/pubmed/32959775", "http://www.ncbi.nlm.nih.gov/pubmed/11309216", "http://www.ncbi.nlm.nih.gov/pubmed/2769286", "http://www.ncbi.nlm.nih.gov/pubmed/29694468", "http://www.ncbi.nlm.nih.gov/pubmed/33173495", "http://www.ncbi.nlm.nih.gov/pubmed/30062616", "http://www.ncbi.nlm.nih.gov/pubmed/32862013"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/2769286", "text": "Fifty patients suffering from the \"exploding head syndrome\" are described.", "offsetInBeginSection": 0, "offsetInEndSection": 74, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25773787", "text": "Exploding head syndrome episodes were accompanied by clinically significant levels of fear, and a minority (2.80%) experienced it to such a degree that it was associated with clinically significant distress and/or impairment.", "offsetInBeginSection": 916, "offsetInEndSection": 1141, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25773787", "text": "Exploding head syndrome is characterized by the perception of loud noises during sleep-wake or wake-sleep transitions.", "offsetInBeginSection": 0, "offsetInEndSection": 118, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25773787", "text": "Contrary to some earlier theorizing, exploding head syndrome was found to be a relatively common experience in younger individuals.", "offsetInBeginSection": 1142, "offsetInEndSection": 1273, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1896728", "text": "Attention has recently been drawn to a condition termed the exploding head syndrome, which is characterized by unpleasant, even terrifying sensations of flashing lights and/or sounds during reported sleep.", "offsetInBeginSection": 0, "offsetInEndSection": 205, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28622122", "text": "This case report describes the first-ever diagnosis of exploding head syndrome in a patient with longstanding epilepsy and novel nocturnal events.", "offsetInBeginSection": 146, "offsetInEndSection": 292, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20726288", "text": "Exploding head syndrome is a rare phenomenon but can be a significant disruption to quality of life.", "offsetInBeginSection": 0, "offsetInEndSection": 100, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26252589", "text": "When hypnic headache is recognized, it is eminently treatable, while exploding head syndrome is a benign condition with no reported consequences.", "offsetInBeginSection": 705, "offsetInEndSection": 850, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26252589", "text": "The rare headache disorder hypnic headache and the exploding head syndrome are also discussed.", "offsetInBeginSection": 610, "offsetInEndSection": 704, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24907167", "text": "BACKGROUND Exploding head syndrome (EHS) is characterized by attacks of a sudden noise or explosive feeling experienced in the head occurring during the transition from wake to sleep or from sleep to wake.", "offsetInBeginSection": 0, "offsetInEndSection": 205, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a9d8a651d1251d03b00001f", "body": "What is the BioArchive system?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18682250", "http://www.ncbi.nlm.nih.gov/pubmed/28716596", "http://www.ncbi.nlm.nih.gov/pubmed/12513800", "http://www.ncbi.nlm.nih.gov/pubmed/15812389", "http://www.ncbi.nlm.nih.gov/pubmed/20442203", "http://www.ncbi.nlm.nih.gov/pubmed/22519634", "http://www.ncbi.nlm.nih.gov/pubmed/29233602", "http://www.ncbi.nlm.nih.gov/pubmed/6683883", "http://www.ncbi.nlm.nih.gov/pubmed/1647798", "http://www.ncbi.nlm.nih.gov/pubmed/17308159"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28716596", "text": "Umbilical cord blood (CB) banks usually freeze and store CB for clinical transplantation using conventional controlled-rate freezer or the automated BioArchive system.", "offsetInBeginSection": 0, "offsetInEndSection": 167, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28716596", "text": "The experiment used 80\u00a0CB units: 40 were conventionally cryopreserved and the remainder were cryopreserved with a BioArchive.", "offsetInBeginSection": 355, "offsetInEndSection": 481, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28716596", "text": "CBs cryopreserved with BioArchive showed significantly higher MNC and CD34+ cell viability, and CFU-GM content than those conventionally cryopreserved.", "offsetInBeginSection": 1312, "offsetInEndSection": 1463, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12513800", "text": "The aim of this study was to investigate the cryobiological characteristics of placental cord blood (PCB) cryopereserved by using BioArchive auto-preserved liquid nitrogen system (BioArchive system).", "offsetInBeginSection": 0, "offsetInEndSection": 199, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15812389", "text": "To validate the use of the sample attached to the UCB unit as a quality-control tool for the final product, UCB units (n = 20) stored in liquid nitrogen with the Bioarchive system were analyzed.", "offsetInBeginSection": 481, "offsetInEndSection": 675, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18682250", "text": "The performance of a small-scale automated cryopreservation and storage system (Mini-BioArchive system) used in the banking of umbilical cord blood (UCB) units was evaluated.", "offsetInBeginSection": 0, "offsetInEndSection": 174, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22153685", "text": "In the third period, from January 2009 to June 2010, an automated Sepax-BioArchive procedure was used and the accepted initial TNC count was >10\u00d710(8).", "offsetInBeginSection": 877, "offsetInEndSection": 1029, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23090732", "text": "Comparisons of the viral loads of the samples from the MagNA Pure 96 system, the Chemagic system, and the QIAamp system with those from the CAP/CTM platform yielded correlation coefficients of 0.977, 0.914, and 0.967, respectively.", "offsetInBeginSection": 867, "offsetInEndSection": 1098, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23090732", "text": "The MagNA Pure 96 system demonstrated better performance than the Chemagic system for HBV nucleic acid extraction.", "offsetInBeginSection": 1253, "offsetInEndSection": 1367, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28164570", "text": "A novel automated blood culture system, DL-Bt112TM (DL) was compared with the BACTEC 9050TM (BCT) and BacT/Alert 3DTM (B3D) systems for time-to-detection (TTD) using 10 different clinical bacteria that commonly cause bloodstream infections.", "offsetInBeginSection": 153, "offsetInEndSection": 393, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a723a652dc08e987e00000a", "body": "Describe mechanism of action of Romosozumab.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28428078", "http://www.ncbi.nlm.nih.gov/pubmed/36440489", "http://www.ncbi.nlm.nih.gov/pubmed/34632110", "http://www.ncbi.nlm.nih.gov/pubmed/27569204", "http://www.ncbi.nlm.nih.gov/pubmed/28064540", "http://www.ncbi.nlm.nih.gov/pubmed/32862655", "http://www.ncbi.nlm.nih.gov/pubmed/31858345", "http://www.ncbi.nlm.nih.gov/pubmed/24665957", "http://www.ncbi.nlm.nih.gov/pubmed/36154750", "http://www.ncbi.nlm.nih.gov/pubmed/28458516"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27569204", "text": "Romosozumab is a humanized immunoglobulin G2 monoclonal antibody that binds and blocks the action of sclerostin, a protein secreted by the osteocyte and an extracellular inhibitor of canonical Wnt signaling.", "offsetInBeginSection": 0, "offsetInEndSection": 207, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28064540", "text": "Romosozumab is a promising emerging anabolic agent with a novel mechanism of action that may expand the options for treating osteoporotic patients at high risk of fracture.", "offsetInBeginSection": 1091, "offsetInEndSection": 1263, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28064540", "text": "Romosozumab is a humanized monoclonal antibody to sclerostin that binds to sclerostin, permitting the engagement of Wnt ligands with their co-receptors, resulting in an increase in bone formation and bone mineral density (BMD).", "offsetInBeginSection": 120, "offsetInEndSection": 347, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28458516", "text": "Romosozumab, a humanized monoclonal antibody that binds to sclerostin, prevents sclerostin from exerting this inhibitory effect.", "offsetInBeginSection": 329, "offsetInEndSection": 457, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28458516", "text": "Romosozumab holds significant potential, by a novel mechanism of action, to expand our ability to treat osteoporosis.", "offsetInBeginSection": 1325, "offsetInEndSection": 1442, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24665957", "text": "EXPERT OPINION Blocking sclerostin action with romosozumab is a promising new therapeutic approach to osteoanabolic therapy of osteoporosis; efficacy and safety data on large controlled studies are awaited.", "offsetInBeginSection": 819, "offsetInEndSection": 1025, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24665957", "text": "AREAS COVERED Romosozumab is the first humanized monoclonal sclerostin antibody to be tested in clinical trials.", "offsetInBeginSection": 540, "offsetInEndSection": 652, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28428078", "text": "Romosozumab, a humanized monoclonal sclerostin antibody under development for the treatment of osteoporosis, has a unique mechanism of action on bone-increasing bone formation and decreasing bone resorption.", "offsetInBeginSection": 0, "offsetInEndSection": 207, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28529724", "text": "Romosozumab, an anti-sclerostin antibody, inhibits the action of sclerostin, a canonical Wnt signal inhibitor secreted from osteocytes, and enhances canonical Wnt signaling.", "offsetInBeginSection": 1472, "offsetInEndSection": 1645, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26451332", "text": "A pharmacokinetic model with first-order absorption and dual elimination pathways was used to describe the kinetics of romosozumab, a monoclonal antibody (mAb) against sclerostin.", "offsetInBeginSection": 285, "offsetInEndSection": 464, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a76179d83b0d9ea66000021", "body": "Which algorithm has been proposed for efficient storage of WGS variant calls?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27085415", "http://www.ncbi.nlm.nih.gov/pubmed/28318110", "http://www.ncbi.nlm.nih.gov/pubmed/30965134", "http://www.ncbi.nlm.nih.gov/pubmed/35347328", "http://www.ncbi.nlm.nih.gov/pubmed/29673316", "http://www.ncbi.nlm.nih.gov/pubmed/35085778", "http://www.ncbi.nlm.nih.gov/pubmed/27964746", "http://www.ncbi.nlm.nih.gov/pubmed/33214604", "http://www.ncbi.nlm.nih.gov/pubmed/31904999", "http://www.ncbi.nlm.nih.gov/pubmed/26357316"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27085415", "text": "Together, this new selection algorithm and experimental design suggestion significantly reduce the overall cost of variant discovery through WGS experiments, making surveys for causal variants influencing disease and production even more efficient.", "offsetInBeginSection": 1158, "offsetInEndSection": 1406, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27085415", "text": "We propose a new algorithm, called inverse weight selection (IWS), that preferentially selects individuals based on the cumulative presence of rare frequency haplotypes to maximize the efficiency of WGS surveys.", "offsetInBeginSection": 380, "offsetInEndSection": 591, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28334390", "text": "Here we introduce a new WGS variant data format implemented in the R/Bioconductor package 'SeqArray' for storing variant calls in an array-oriented manner which provides the same capabilities as VCF, but with multiple high compression options and data access using high-performance parallel computing.", "offsetInBeginSection": 377, "offsetInEndSection": 678, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27964746", "text": "In WGS analysis, this results in characteristic and recognizable patterns of variant calls at positions that we term alignable scaffold-discrepant positions (ASDPs).", "offsetInBeginSection": 995, "offsetInEndSection": 1160, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27964746", "text": "METHODS We developed an algorithm that analyzes the patterns of variant calls in the 178 structurally variable regions of the GRCh38 genome assembly, and infers whether a given sample is most likely to contain sequences from the primary assembly, an alternate locus, or their heterozygous combination at each of these 178 regions.", "offsetInBeginSection": 343, "offsetInEndSection": 673, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27964746", "text": "CONCLUSIONS Our algorithm uses the information contained in the 178 structurally variable regions of the GRCh38 genome assembly to avoid spurious variant calls in cases where samples contain an alternate locus rather than the corresponding segment of the primary assembly.", "offsetInBeginSection": 1589, "offsetInEndSection": 1861, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26357316", "text": "The proposed algorithm has been incorporated into a disease-linked variant prioritization pipeline for WGS (http://gnome.tchlab.org) and its implementation is available at http://ml.ssu.ac.kr/gSearch.", "offsetInBeginSection": 1171, "offsetInEndSection": 1371, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25587064", "text": "BACKGROUND Whole-genome sequencing (WGS) and whole-exome sequencing (WES) technologies are increasingly used to identify disease-contributing mutations in human genomic studies.", "offsetInBeginSection": 0, "offsetInEndSection": 177, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28318110", "text": "For the association analysis of whole-genome sequencing (WGS) studies, we propose an efficient and fast spatial-clustering algorithm.", "offsetInBeginSection": 0, "offsetInEndSection": 133, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23831772", "text": "Here, we developed a probabilistic multinomial method for the detection of single nucleotide variants (SNVs) as well as short insertions and deletions (indels) in whole genome sequencing (WGS) and whole exome sequencing (WES) data for single sample calling.", "offsetInBeginSection": 310, "offsetInEndSection": 567, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a9924ea1d1251d03b000008", "body": "What is the association of circular RNA to breast cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33544410", "http://www.ncbi.nlm.nih.gov/pubmed/36132137", "http://www.ncbi.nlm.nih.gov/pubmed/31729134", "http://www.ncbi.nlm.nih.gov/pubmed/30454010", "http://www.ncbi.nlm.nih.gov/pubmed/34387598", "http://www.ncbi.nlm.nih.gov/pubmed/34545330", "http://www.ncbi.nlm.nih.gov/pubmed/34395434", "http://www.ncbi.nlm.nih.gov/pubmed/34307155", "http://www.ncbi.nlm.nih.gov/pubmed/34295807", "http://www.ncbi.nlm.nih.gov/pubmed/33061434"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28744405", "text": "Circular RNA (circRNA) is a key regulator in the development and progression of human cancers, however its role in breast cancer tumorigenesis is not well understood.", "offsetInBeginSection": 0, "offsetInEndSection": 166, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28744405", "text": "Overall, results identified a new functional circ-ABCB10 in breast cancer tumorigenesis, and reveal the important regulatory role of circ-ABCB10 through sponging miR-1271, providing a novel insight for breast cancer pathogenesis.", "offsetInBeginSection": 975, "offsetInEndSection": 1204, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28744405", "text": "Finally, miR-1271 rescued the function of circ-ABCB10 on breast cancer cells, confirming the sponge effect of circ-ABCB10 on miR-1271.", "offsetInBeginSection": 840, "offsetInEndSection": 974, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28349836", "text": "Circular RNA, a class of non-coding RNA, is a new group of RNAs and is related to tumorigenesis.", "offsetInBeginSection": 0, "offsetInEndSection": 96, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29109417", "text": "Overall, our results support the hypothesis of circular RNAs representing a novel factor in the dynamic epigenetic network of gene regulation, which involves the microRNAs, its mRNAs targets, and the circular RNAs-derived genes.", "offsetInBeginSection": 937, "offsetInEndSection": 1165, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29109417", "text": "Previous studies have demonstrated that some circular RNAs act as microRNA sponges, and are associated with cellular proliferation in cancer.", "offsetInBeginSection": 115, "offsetInEndSection": 256, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28803498", "text": "Additionally, we discovered a regulatory role of the circ_0006528-miR-7-5p-Raf1 axis in ADM-resistant breast cancer.", "offsetInBeginSection": 825, "offsetInEndSection": 941, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28803498", "text": "CONCLUSION These results revealed that circRNAs may play a role in breast cancer chemoresistance and that hsa_circ_0006528 might be a promising candidate for further functional analysis.", "offsetInBeginSection": 944, "offsetInEndSection": 1130, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28803498", "text": "AIM We aimed to identify circular RNAs (circRNAs) associated with breast cancer chemoresistance.", "offsetInBeginSection": 0, "offsetInEndSection": 96, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27965971", "text": "Circular RNAs are nontranslated RNAs, typically nonpolyadenylated, with a resistance to exonucleases that gives them the ability to be more stable than the common linear RNA isoforms.", "offsetInBeginSection": 153, "offsetInEndSection": 336, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a95765bfcd1d6a10c000028", "body": "What part of what body organ controls the circadian clock?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34557221", "http://www.ncbi.nlm.nih.gov/pubmed/20542067", "http://www.ncbi.nlm.nih.gov/pubmed/23604475", "http://www.ncbi.nlm.nih.gov/pubmed/24013905", "http://www.ncbi.nlm.nih.gov/pubmed/33689719", "http://www.ncbi.nlm.nih.gov/pubmed/25711020", "http://www.ncbi.nlm.nih.gov/pubmed/32223039", "http://www.ncbi.nlm.nih.gov/pubmed/30589961", "http://www.ncbi.nlm.nih.gov/pubmed/21969583", "http://www.ncbi.nlm.nih.gov/pubmed/26843619"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/23704227", "text": "Clock genes control circadian rhythms both centrally, in the suprachiasmatic nucleus of the brain and peripherally, within every organ of the body.", "offsetInBeginSection": 589, "offsetInEndSection": 736, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21763748", "text": "humoral factors, activity and body temperature rhythms) or, trough the intrinsic renal circadian clock.", "offsetInBeginSection": 1115, "offsetInEndSection": 1218, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24013905", "text": "Furthermore, this intestinal clock controls the expression of key cell cycle regulators, such as cdc2, wee1, p21, PCNA and cdk2, but only weakly influences cyclin B1, cyclin B2 and cyclin E1 expression.", "offsetInBeginSection": 620, "offsetInEndSection": 822, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24013905", "text": "The circadian clock controls cell proliferation in a number of healthy tissues where cell renewal and regeneration are critical for normal physiological function.", "offsetInBeginSection": 0, "offsetInEndSection": 162, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26144255", "text": "We conclude that the circadian clock acts to gate auxin signalling during LR development to facilitate organ emergence.", "offsetInBeginSection": 773, "offsetInEndSection": 892, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11743124", "text": "The rhythmic pattern of PHYA expression is not organ autonomous but depends upon the physical continuity or isolation of the rhythmic tissues, consistent with the presence of a transmitted signal that controls the overt expression of circadian rhythms without necessarily affecting the underlying clock.", "offsetInBeginSection": 1230, "offsetInEndSection": 1533, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11743124", "text": "Phytochrome A (phyA) provides light input signals to entrain the circadian clock.", "offsetInBeginSection": 168, "offsetInEndSection": 249, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28779094", "text": "Deficiency of an essential clock gene Bmal1 impairs day-night variations of osmotic pressure gradient in the inner medulla, suggesting that circadian clocks in the medulla part of the kidney may regulate the circadian rhythm of cortico-medullary osmotic pressure gradient, and may contribute physiological day-night rhythm of urination.", "offsetInBeginSection": 1016, "offsetInEndSection": 1352, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28707700", "text": "The suprachiasmatic nucleus houses the central circadian clock and is characterized by the timely regulated expression of clock genes.", "offsetInBeginSection": 0, "offsetInEndSection": 134, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27385482", "text": "Recently, we came to appreciate that the formation and metabolic functions of BAT, a key organ for body temperature maintenance, are under an orchestrated circadian clock regulation.", "offsetInBeginSection": 329, "offsetInEndSection": 511, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aa4f47cd6d6b54f7900000a", "body": "When is 16S rRNA Gene Sequencing used?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36374024", "http://www.ncbi.nlm.nih.gov/pubmed/32879089", "http://www.ncbi.nlm.nih.gov/pubmed/14520536", "http://www.ncbi.nlm.nih.gov/pubmed/33849786", "http://www.ncbi.nlm.nih.gov/pubmed/20223646", "http://www.ncbi.nlm.nih.gov/pubmed/23022443", "http://www.ncbi.nlm.nih.gov/pubmed/31432641", "http://www.ncbi.nlm.nih.gov/pubmed/21121044", "http://www.ncbi.nlm.nih.gov/pubmed/20065000", "http://www.ncbi.nlm.nih.gov/pubmed/35531325"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26770469", "text": "Together, these data present 16S rRNA gene sequencing as a novel VAP diagnosis tool that will further enable pathogen-specific treatment of VAP.", "offsetInBeginSection": 1588, "offsetInEndSection": 1732, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27842515", "text": "A new alternative for full-length bacterial 16S rRNA gene sequencing is offered by PacBio single molecule, real-time (SMRT) technology.", "offsetInBeginSection": 318, "offsetInEndSection": 453, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25646627", "text": "With the rapid developments in genome sequencing technologies, the focus has shifted towards the sequencing of hypervariable regions of 16S rRNA gene instead of full length gene sequencing.", "offsetInBeginSection": 111, "offsetInEndSection": 300, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21240067", "text": "RESULTS Conventional PCR based 16S rRNA gene sequencing and the alignment of the isolate 16S rRNA gene sequence with reference sequences accurately identified 100% of clinical strains of aerobic Actinomycetes.", "offsetInBeginSection": 671, "offsetInEndSection": 880, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21121044", "text": "16S rRNA gene sequencing has been widely used for probing the species structure of a variety of environmental bacterial communities.", "offsetInBeginSection": 0, "offsetInEndSection": 132, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27077030", "text": "To assess variability between laboratories in sequencing 16S rRNA, six laboratories sequenced the gene encoding the 16S rRNA from Escherichia coli O157:H7 strain EDL933 and Listeria monocytogenes serovar 4b strain NCTC11994.", "offsetInBeginSection": 410, "offsetInEndSection": 634, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27077030", "text": "The combination of PCR amplification and 16S ribosomal RNA gene (16S rRNA) sequencing has revolutionized bacteriology by enabling rapid identification, frequently without the need for culture.", "offsetInBeginSection": 217, "offsetInEndSection": 409, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18353221", "text": "CONCLUSION By improving the extract DNA method, selecting suitable primer, developing the gene amplification and sequencing procedure, direct 16S rRNA gene sequencing can identify the pathogens from clinical specimens.", "offsetInBeginSection": 1652, "offsetInEndSection": 1870, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17037387", "text": "To classify mycobacteria not identified by DNA-DNA hybridization (DDH) using sequencing of rpoB and 16S rRNA gene.", "offsetInBeginSection": 107, "offsetInEndSection": 221, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17037387", "text": "Even though sequencing of rpoB and 16S rRNA gene was utilized, it was impossible to classify M. tuberculosis complex, M. avium family, M. marinum and M. ulcerans, and M. fortitum subsp.", "offsetInBeginSection": 842, "offsetInEndSection": 1027, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a723cd12dc08e987e00000b", "body": "Can CD55 deficiency cause thrombosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35314883", "http://www.ncbi.nlm.nih.gov/pubmed/22696589", "http://www.ncbi.nlm.nih.gov/pubmed/22077430", "http://www.ncbi.nlm.nih.gov/pubmed/33398182", "http://www.ncbi.nlm.nih.gov/pubmed/11843289", "http://www.ncbi.nlm.nih.gov/pubmed/25237200", "http://www.ncbi.nlm.nih.gov/pubmed/30418410", "http://www.ncbi.nlm.nih.gov/pubmed/11920231", "http://www.ncbi.nlm.nih.gov/pubmed/19502272", "http://www.ncbi.nlm.nih.gov/pubmed/7680511"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28657829", "text": "CONCLUSIONS CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy (the CHAPLE syndrome) is caused by abnormal complement activation due to biallelic loss-of-function mutations in CD55.", "offsetInBeginSection": 1242, "offsetInEndSection": 1479, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11843289", "text": "Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal disorder characterized by a decrease or absence of glycosylphosphatidylinositol (GPI)-anchored molecules such as CD55 and CD59 from the surface of affected cells, resulting in intravascular hemolysis, cytopenia, and venous thrombosis.", "offsetInBeginSection": 0, "offsetInEndSection": 298, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16908271", "text": "Paroxysmal nocturnal hemoglobinuria (PNH) results when cells have a somatic defect in the synthesis of GPI anchors and lack CD55 and CD59, as well as CD52.", "offsetInBeginSection": 200, "offsetInEndSection": 355, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16908271", "text": "Campath-1H therapy is directed to CD52, a small mw protein that has a glycosylphosphatidylinositol (GPI) anchor, which has a conventional structure similar to other GPI anchors such as CD55 and CD59.", "offsetInBeginSection": 0, "offsetInEndSection": 199, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15004194", "text": "Complement depletion in CD55(-/-)CD59(-/-) mice with cobra venom factor prevented these effects.", "offsetInBeginSection": 1030, "offsetInEndSection": 1126, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15004194", "text": "Remarkably, although CD59 deficiency alone was inconsequential, CD55/CD59 double deficiency greatly exacerbated IRI.", "offsetInBeginSection": 753, "offsetInEndSection": 869, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26205796", "text": "Somatic mutation in the phosphatidylinositol glycan class A (PIG-A), X-linked gene, is responsible for a deficiency in glycosphosphatidylinositol-anchored proteins (GPI-AP).", "offsetInBeginSection": 99, "offsetInEndSection": 272, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26205796", "text": "The lack of one of the GPI-AP complement regulatory proteins (CD55, CD59) leads to hemolysis.", "offsetInBeginSection": 273, "offsetInEndSection": 366, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28516949", "text": "The gene product of PIGA is required for the biosynthesis of glycosylphosphatidylinositol (GPI) anchors; thus, PIGA mutations lead to a deficiency of GPI-anchored proteins, such as complement decay-accelerating factor (also known as CD55) and CD59 glycoprotein (CD59), which are both complement inhibitors.", "offsetInBeginSection": 368, "offsetInEndSection": 674, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28516949", "text": "Eculizumab, a monoclonal antibody complement inhibitor, is highly effective and the only licensed therapy for PNH.", "offsetInBeginSection": 1340, "offsetInEndSection": 1454, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a7633a89e632bc066000002", "body": "What is the purpose of the Tabix tool?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21208982", "http://www.ncbi.nlm.nih.gov/pubmed/29137598", "http://www.ncbi.nlm.nih.gov/pubmed/34179956", "http://www.ncbi.nlm.nih.gov/pubmed/36183080", "http://www.ncbi.nlm.nih.gov/pubmed/2984387", "http://www.ncbi.nlm.nih.gov/pubmed/24175235", "http://www.ncbi.nlm.nih.gov/pubmed/30799412", "http://www.ncbi.nlm.nih.gov/pubmed/27564429", "http://www.ncbi.nlm.nih.gov/pubmed/34694658", "http://www.ncbi.nlm.nih.gov/pubmed/32159477"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/21208982", "text": "Tabix is implemented as a free command-line tool as well as a library in C, Java, Perl and Python.", "offsetInBeginSection": 335, "offsetInEndSection": 433, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21208982", "text": "UNLABELLED Tabix is the first generic tool that indexes position sorted files in TAB-delimited formats such as GFF, BED, PSL, SAM and SQL export, and quickly retrieves features overlapping specified regions.", "offsetInBeginSection": 0, "offsetInEndSection": 207, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29137598", "text": "CONCLUSIONS GFF3sort is a novel tool to sort GFF3 files for tabix indexing.", "offsetInBeginSection": 942, "offsetInEndSection": 1017, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29137598", "text": "The latest version of JBrowse supports rendering sorted GFF3 files indexed by tabix, a novel strategy that is more convenient than the original conversion process.", "offsetInBeginSection": 147, "offsetInEndSection": 310, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29137598", "text": "RESULTS We developed GFF3sort, a script to sort GFF3 files for tabix indexing.", "offsetInBeginSection": 462, "offsetInEndSection": 540, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25192739", "text": "SUMMARY We describe mod_bio, a set of modules for the Apache HTTP server that allows the users to access and query fastq, tabix, fasta and bam files through a Web browser.", "offsetInBeginSection": 0, "offsetInEndSection": 171, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29087450", "text": "By using Tabix, ViewBS can visualize BS-seq for large datasets quickly.", "offsetInBeginSection": 369, "offsetInEndSection": 440, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25273104", "text": "WhopGenome can also read other Tabix-indexed files and create indices to allow fast selective access to FASTA-formatted sequence files.", "offsetInBeginSection": 786, "offsetInEndSection": 921, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9723930", "text": "The purpose of the present study was to analyze retrieval of instruction of use, mechanical problem solving, and actual tool use in patients with apraxia due to circumscribed lesions of the left hemisphere.", "offsetInBeginSection": 573, "offsetInEndSection": 779, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2282788", "text": "A general purpose window based software tool is herein described, which frees the clinical and research sectors of the responsibility of understanding and decoding these complex formats in order to import image databases from acquisition computers to image processing computers.", "offsetInBeginSection": 256, "offsetInEndSection": 534, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a9929ed1d1251d03b000009", "body": "What is maternal spindle transfer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33993847", "http://www.ncbi.nlm.nih.gov/pubmed/32347793", "http://www.ncbi.nlm.nih.gov/pubmed/32613230", "http://www.ncbi.nlm.nih.gov/pubmed/28092013", "http://www.ncbi.nlm.nih.gov/pubmed/28683668", "http://www.ncbi.nlm.nih.gov/pubmed/26481204", "http://www.ncbi.nlm.nih.gov/pubmed/11139230", "http://www.ncbi.nlm.nih.gov/pubmed/28429249", "http://www.ncbi.nlm.nih.gov/pubmed/27973714", "http://www.ncbi.nlm.nih.gov/pubmed/34184299"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27973714", "text": "Maternal spindle transfer is, in principle, morally permissible, but only when we have beforehand preselected a sperm and an egg for our reproductive purpose.", "offsetInBeginSection": 992, "offsetInEndSection": 1150, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27973714", "text": "I conclude that, according to a Habermasian perspective on prenatal genetic manipulation, maternal spindle transfer (without using a preselected sperm and egg) and pronuclear transfer are morally impermissible.", "offsetInBeginSection": 781, "offsetInEndSection": 991, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28429249", "text": "This paper examines whether there are moral differences between the mitochondrial replacement techniques that have been recently developed in order to help women afflicted by mitochondrial DNA diseases to have genetically related children\u00a0absent such conditions: maternal spindle transfer (MST) and pronuclear transfer (PNT).", "offsetInBeginSection": 0, "offsetInEndSection": 326, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28683668", "text": "In the discussions leading up to the enactment of the UK Human Fertilisation and Embryology (Mitochondrial Donation) Regulations 2015, it was repeatedly emphasised, by many commentators, that maternal spindle transfer (MST) and pronuclear transfer (PNT) did not give rise to children who could be considered as having three or more parents.", "offsetInBeginSection": 0, "offsetInEndSection": 340, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29121011", "text": "MRT aims to avoid pathogenic mtDNA transmission between generations by maternal spindle transfer, pronuclear transfer or polar body transfer: all involve the transfer of nuclear DNA from an egg or zygote containing defective mitochondria to a corresponding egg or zygote with normal mitochondria.", "offsetInBeginSection": 592, "offsetInEndSection": 888, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12398808", "text": "The meiotic spindle is crucial for normal chromosome alignment and separation of maternal chromosomes during meiosis.", "offsetInBeginSection": 0, "offsetInEndSection": 117, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8416845", "text": "To determine when the reproductive capacity of the maternal centrosome is degraded, we transfer meiosis I and meiosis II spindles from just fertilized eggs into other zygotes that are in prophase of first mitosis.", "offsetInBeginSection": 798, "offsetInEndSection": 1011, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8416845", "text": "These observations indicate that the reproductive capacity of maternal centrosomes is degraded during meiosis I, not during oogenesis.", "offsetInBeginSection": 1786, "offsetInEndSection": 1920, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8416845", "text": "Meiosis I spindles are stable during first mitosis and are disassembled in first telophase in concert with the host spindle.", "offsetInBeginSection": 1012, "offsetInEndSection": 1136, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27833197", "text": "With mitochondrial replacement, either human embryos are directly manipulated (pronuclear transfer) or germline cells are manipulated (maternal spindle transfer); changes in these could be transmitted to the offspring.", "offsetInBeginSection": 683, "offsetInEndSection": 901, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a96c74cfcd1d6a10c000029", "body": "What illness is transmitted by the Lone Star Tick, Amblyomma americanum?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28319627", "http://www.ncbi.nlm.nih.gov/pubmed/35146342", "http://www.ncbi.nlm.nih.gov/pubmed/19054615", "http://www.ncbi.nlm.nih.gov/pubmed/25618142", "http://www.ncbi.nlm.nih.gov/pubmed/17547234", "http://www.ncbi.nlm.nih.gov/pubmed/18452807", "http://www.ncbi.nlm.nih.gov/pubmed/8926996", "http://www.ncbi.nlm.nih.gov/pubmed/29488458", "http://www.ncbi.nlm.nih.gov/pubmed/17699076", "http://www.ncbi.nlm.nih.gov/pubmed/34467183"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28319627", "text": "Amblyomma americanum, also known as the lone star tick, is found in much of the eastern United States.", "offsetInBeginSection": 0, "offsetInEndSection": 102, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28319627", "text": "In addition to others, species of Rickettsia, Ehrlichia, and Borrelia are all transmitted by the lone star tick.", "offsetInBeginSection": 260, "offsetInEndSection": 372, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19054615", "text": "We reviewed scientific literature pertaining to known and putative disease agents associated with the lone star tick, Amblyomma americanum.", "offsetInBeginSection": 0, "offsetInEndSection": 139, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19874183", "text": "Borrelia lonestari, which has been suggested as a possible causative agent of southern tick-associated rash illness, naturally infects white-tailed deer (WTD; Odocoileus virginianus) and is transmitted by the lone star tick (Amblyomma americanum).", "offsetInBeginSection": 98, "offsetInEndSection": 345, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18452807", "text": "Lyme-like illness (also known as southern tick-associated rash illness [STARI] or Masters disease) is vectored by the Lone Star tick (Amblyomma americanum).", "offsetInBeginSection": 0, "offsetInEndSection": 156, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20380308", "text": "The lone star tick, Amblyomma americanum (Acari: Ixodidae), is commonly reported from people and animals throughout the eastern U.S. and is associated with transmission of a number of emerging diseases.", "offsetInBeginSection": 0, "offsetInEndSection": 202, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18447622", "text": "Amblyomma americanum, the lone star tick, comprised 99.6% of 6,502 specimens collected in suburban landscapes.", "offsetInBeginSection": 368, "offsetInEndSection": 478, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18447622", "text": "Eleven of 25 lone star tick pools tested were infected with \"Rickettsia amblyommii,\" an informally named SFGR.", "offsetInBeginSection": 623, "offsetInEndSection": 733, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23637969", "text": "Here we sought to characterize the growth characteristics and genome of Lone Star virus (LSV), an unclassified bunyavirus originally isolated from the lone star tick Amblyomma americanum.", "offsetInBeginSection": 362, "offsetInEndSection": 549, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27729288", "text": "Monocytic ehrlichiosis in people caused by the intracellular bacterium, Ehrlichia chaffeensis, is an emerging infectious disease transmitted by the lone star tick, Amblyomma americanum.", "offsetInBeginSection": 0, "offsetInEndSection": 185, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aa50086d6d6b54f7900000c", "body": "Which is the function of ubiquilins?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32549375", "http://www.ncbi.nlm.nih.gov/pubmed/19398896", "http://www.ncbi.nlm.nih.gov/pubmed/24674348", "http://www.ncbi.nlm.nih.gov/pubmed/34650520", "http://www.ncbi.nlm.nih.gov/pubmed/19148225", "http://www.ncbi.nlm.nih.gov/pubmed/28933694", "http://www.ncbi.nlm.nih.gov/pubmed/31516068", "http://www.ncbi.nlm.nih.gov/pubmed/35082119", "http://www.ncbi.nlm.nih.gov/pubmed/23459205", "http://www.ncbi.nlm.nih.gov/pubmed/35247097"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24674348", "text": "BACKGROUND Ubiquilins are proteins that function as ubiquitin receptors in eukaryotes.", "offsetInBeginSection": 0, "offsetInEndSection": 86, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19398896", "text": "Ubiquilins (UBQLN), a family of adaptor proteins with partial homology with ubiquitin, are proposed to facilitate proteasomal degradation of ubiquitinated substrates.", "offsetInBeginSection": 0, "offsetInEndSection": 166, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19398896", "text": "This protective function requires the essential autophagy regulators, Atg5 and Atg7.", "offsetInBeginSection": 406, "offsetInEndSection": 490, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22628307", "text": "Ubiquilins, a family of ubiquitin-binding proteins, are involved in all protein degradation pathways.", "offsetInBeginSection": 234, "offsetInEndSection": 335, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18307982", "text": "Our data suggest that Herp binding to ubiquilin proteins plays an important role in the ERAD pathway and that ubiquilins are specifically involved in degradation of only a subset of ubiquitinated targets, including Herp-dependent ERAD substrates.", "offsetInBeginSection": 865, "offsetInEndSection": 1111, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26152284", "text": "Ubiquilin-2 inclusions co-localized with ubiquitin, p62/SQSTM, optineurin, and occasionally TDP-43, but were negative for \u03b1-synuclein, neurofilament, tau, and FUS.", "offsetInBeginSection": 1077, "offsetInEndSection": 1241, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27345149", "text": "Loss of Ubiquilins by genetic ablation or sequestration in polyglutamine aggregates leads to accumulation of non-inserted mitochondrial membrane protein precursors.", "offsetInBeginSection": 719, "offsetInEndSection": 883, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26225865", "text": "Thus, polymorphisms in ubiquilins, which are known to influence susceptibility to neurodegenerative illnesses, might also play a role in host defense against Mtb.", "offsetInBeginSection": 1287, "offsetInEndSection": 1449, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26225865", "text": "In autophagy-deficient macrophages, UBQLN1 accumulates around Mtb, consistent with the idea that it marks bacilli that traffic through the autophagy pathway.", "offsetInBeginSection": 853, "offsetInEndSection": 1010, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25672654", "text": "Ubiquilin 2 (UBQLN2), a member of the ubiquitin-like protein family (ubiquilins), maintains protein homeostasis.", "offsetInBeginSection": 0, "offsetInEndSection": 112, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a7240aa2dc08e987e00000d", "body": "List two human monoclonal antibodies against Clostridium difficile toxins.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33995585", "http://www.ncbi.nlm.nih.gov/pubmed/20089970", "http://www.ncbi.nlm.nih.gov/pubmed/20150758", "http://www.ncbi.nlm.nih.gov/pubmed/25451052", "http://www.ncbi.nlm.nih.gov/pubmed/2428753", "http://www.ncbi.nlm.nih.gov/pubmed/23629713", "http://www.ncbi.nlm.nih.gov/pubmed/35469152", "http://www.ncbi.nlm.nih.gov/pubmed/3968199", "http://www.ncbi.nlm.nih.gov/pubmed/31628838", "http://www.ncbi.nlm.nih.gov/pubmed/9237345"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/20089970", "text": "CONCLUSIONS The addition of monoclonal antibodies against C. difficile toxins to antibiotic agents significantly reduced the recurrence of C. difficile infection.", "offsetInBeginSection": 1561, "offsetInEndSection": 1723, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20089970", "text": "METHODS We performed a randomized, double-blind, placebo-controlled study of two neutralizing, fully human monoclonal antibodies against C. difficile toxins A (CDA1) and B (CDB1).", "offsetInBeginSection": 148, "offsetInEndSection": 327, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23629713", "text": "C. difficile mediates diarrhea and colitis by releasing two toxins, toxin A and toxin B.", "offsetInBeginSection": 123, "offsetInEndSection": 211, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23629713", "text": "Recent studies indicated that human monoclonal antibodies (MAbs) against toxins A and B reduce their cytotoxic and secretory activities and prevent CDI in hamsters.", "offsetInBeginSection": 453, "offsetInEndSection": 617, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1900059", "text": "The pathogenicity of Clostridium difficile is due to the production of two toxins (toxins A and B).", "offsetInBeginSection": 0, "offsetInEndSection": 99, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1900059", "text": "These data show that passive immunity induced by monoclonal antibodies against toxin A was effective against pseudomembranous cecitis.", "offsetInBeginSection": 826, "offsetInEndSection": 960, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9237345", "text": "A specific monoclonal antibody against toxin A from Clostridium difficile was generated that did not show thermolabile binding.", "offsetInBeginSection": 0, "offsetInEndSection": 127, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1378062", "text": "Five mouse monoclonal antibodies (MAbs) against Clostridium difficile toxin B have been raised and characterized.", "offsetInBeginSection": 0, "offsetInEndSection": 113, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27336843", "text": "This study describes the protective effects conferred by novel neutralizing anti-toxin monoclonal antibodies against C. difficile toxins and their potential as therapeutic agents in treating CDI.", "offsetInBeginSection": 1358, "offsetInEndSection": 1553, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20150758", "text": "The pathogenicity of Clostridium difficile (C. difficile) is mediated by the release of two toxins, A and B.", "offsetInBeginSection": 0, "offsetInEndSection": 108, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a76344e9e632bc066000003", "body": "Which algorithms are used for compression of SAM files?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22164252", "http://www.ncbi.nlm.nih.gov/pubmed/29046896", "http://www.ncbi.nlm.nih.gov/pubmed/31869798", "http://www.ncbi.nlm.nih.gov/pubmed/23066097", "http://www.ncbi.nlm.nih.gov/pubmed/27540265", "http://www.ncbi.nlm.nih.gov/pubmed/26026138", "http://www.ncbi.nlm.nih.gov/pubmed/23533605", "http://www.ncbi.nlm.nih.gov/pubmed/24368726", "http://www.ncbi.nlm.nih.gov/pubmed/33237908", "http://www.ncbi.nlm.nih.gov/pubmed/34478503"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/29046896", "text": "In this work we propose a new reference-based compressor for SAM files, which can accommodate different levels of compression, based on the specific needs of the user.", "offsetInBeginSection": 348, "offsetInEndSection": 515, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22164252", "text": "In this paper, we present SAMZIP, a specialized encoding scheme, for sequence alignment data in SAM (Sequence Alignment/Map) format, which improves the compression ratio of existing compression tools available.", "offsetInBeginSection": 428, "offsetInEndSection": 638, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27540265", "text": "RESULTS We describe CSAM (Compressed SAM format), a compression approach offering lossless and lossy compression for SAM files.", "offsetInBeginSection": 359, "offsetInEndSection": 486, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27540265", "text": "The structures and techniques proposed are suitable for representing SAM files, as well as supporting fast access to the compressed information.", "offsetInBeginSection": 487, "offsetInEndSection": 631, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23533605", "text": "These are compared against existing algorithms for both reference based compression (CRAM, Goby) and non-reference based compression (DSRC, BAM) and other recently published competition entries (Quip, SCALCE).", "offsetInBeginSection": 333, "offsetInEndSection": 542, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23066097", "text": "The enormous size of these data motivates the development of data compression algorithms usable for the implementation of the various storage policies that are applied to the produced intermediate and final result files.", "offsetInBeginSection": 178, "offsetInEndSection": 398, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23148484", "text": "It includes a number of useful features, such as tunable performance and fidelity options, compatibility with FASTA or FASTQ files, and adherence to the SAM format.", "offsetInBeginSection": 1276, "offsetInEndSection": 1440, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24637036", "text": "The effectiveness of tampering detection algorithms is tested on a predefined large music database consisting of nearly one million of compressed audio files.", "offsetInBeginSection": 1560, "offsetInEndSection": 1718, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24368726", "text": "METHODS We developed Hierarchical mUlti-reference Genome cOmpression (HUGO), a novel compression algorithm for aligned reads in the sorted Sequence Alignment/Map (SAM) format.", "offsetInBeginSection": 351, "offsetInEndSection": 526, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24368726", "text": "CONCLUSIONS The proposed multi-reference-based compression algorithm for aligned reads outperforms existing single-reference based algorithms.", "offsetInBeginSection": 1786, "offsetInEndSection": 1928, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a992b371d1251d03b00000a", "body": "What does MetaHIT stand for?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25291122", "http://www.ncbi.nlm.nih.gov/pubmed/28357466", "http://www.ncbi.nlm.nih.gov/pubmed/24416266", "http://www.ncbi.nlm.nih.gov/pubmed/24949196", "http://www.ncbi.nlm.nih.gov/pubmed/36049754", "http://www.ncbi.nlm.nih.gov/pubmed/10241765", "http://www.ncbi.nlm.nih.gov/pubmed/8231703", "http://www.ncbi.nlm.nih.gov/pubmed/31578774", "http://www.ncbi.nlm.nih.gov/pubmed/11261249", "http://www.ncbi.nlm.nih.gov/pubmed/12177530"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24949196", "text": "RESULTS IN THIS STUDY WE CONDUCTED A SYSTEMATIC COMPARISON OF THE DNA EXTRACTION METHODS USED BY THE TWO MAJOR COLLABORATIVE EFFORTS: The European MetaHIT and the American Human Microbiome Project (HMP).", "offsetInBeginSection": 372, "offsetInEndSection": 575, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24416266", "text": "In this paper, we use publicly available data from the Human Microbiome Project (HMP) and MetaHIT, both surveys of healthy adults that include obese individuals, plus two smaller studies that specifically examined lean versus obese adults.", "offsetInBeginSection": 419, "offsetInEndSection": 658, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28357466", "text": "The goals of the Human Microbiome Project and MetaHIT include comparative studies of healthy and diseased individuals.", "offsetInBeginSection": 465, "offsetInEndSection": 583, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23140990", "text": "Advances in computing and high-throughput sequencing have enabled population-level surveys such as MetaHIT and the recently released Human Microbiome Project, detailed investigations of the microbiome in human disease, and mechanistic studies employing gnotobiotic model organisms.", "offsetInBeginSection": 354, "offsetInEndSection": 635, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23431991", "text": "The importance of microbiome constituency is so relevant that several consortia like the Human Microbiome project (HMP) and Metagenomics of the Human Intestinal Tract (MetaHIT) project are focusing mainly on the human microbiome.", "offsetInBeginSection": 459, "offsetInEndSection": 688, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24486053", "text": "Comprehensive microbial community surveys such as MetaHit and the Human Microbiome Project have described the composition and molecular functional profile of the healthy (normal) intestinal microbiome.", "offsetInBeginSection": 130, "offsetInEndSection": 331, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24349412", "text": "The stlA gene is rare when searched against human metagenome datasets such as MetaHit and the Human Microbiome Project and represents a novel and unique salt tolerance determinant which appears to be found exclusively in the human gut environment.", "offsetInBeginSection": 759, "offsetInEndSection": 1006, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24997786", "text": "Here we combined 249 newly sequenced samples of the Metagenomics of the Human Intestinal Tract (MetaHit) project with 1,018 previously sequenced samples to create a cohort from three continents that is at least threefold larger than cohorts used for previous gene catalogs.", "offsetInBeginSection": 270, "offsetInEndSection": 543, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23326225", "text": "We tested how the following factors influenced the detection of enterotypes: clustering methodology, distance metrics, OTU-picking approaches, sequencing depth, data type (whole genome shotgun (WGS) vs.16S rRNA gene sequence data), and 16S rRNA region.", "offsetInBeginSection": 310, "offsetInEndSection": 562, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23326225", "text": "We included 16S rRNA gene sequences from the Human Microbiome Project (HMP) and from 16 additional studies and WGS sequences from the HMP and MetaHIT.", "offsetInBeginSection": 563, "offsetInEndSection": 713, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a981dd0fcd1d6a10c00002e", "body": "Are sleep apnea and snoring associated with cardiac arrhythmias?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/3106890", "http://www.ncbi.nlm.nih.gov/pubmed/1630643", "http://www.ncbi.nlm.nih.gov/pubmed/22160956", "http://www.ncbi.nlm.nih.gov/pubmed/20944978", "http://www.ncbi.nlm.nih.gov/pubmed/8134159", "http://www.ncbi.nlm.nih.gov/pubmed/22520295", "http://www.ncbi.nlm.nih.gov/pubmed/18024169", "http://www.ncbi.nlm.nih.gov/pubmed/8808529", "http://www.ncbi.nlm.nih.gov/pubmed/6743016", "http://www.ncbi.nlm.nih.gov/pubmed/7774322"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/7774322", "text": "We conclude that patients with sleep apnea as a group have higher prevalence of cardiac arrhythmias than nonapneic patients and that snoring alone, without concomitant sleep apnea, is not associated with increased frequency of cardiac arrhythmias.", "offsetInBeginSection": 1446, "offsetInEndSection": 1693, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7774322", "text": "We investigated the frequency of cardiac arrhythmias in patients suspected of having sleep apnea, and related them to the severity of apnea, snoring, and nocturnal hypoxemia.", "offsetInBeginSection": 0, "offsetInEndSection": 174, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2669355", "text": "Sleep apnea and obstructive snoring are sleep related breathing disorders (SRBD).", "offsetInBeginSection": 0, "offsetInEndSection": 81, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1630643", "text": "Increasing evidence suggests that snoring and sleep apnea are associated with cerebrovascular diseases.", "offsetInBeginSection": 0, "offsetInEndSection": 103, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1630643", "text": "Potential mediators among snoring, obstructive sleep apneas, and stroke include cardiac arrhythmias and other hemodynamic disturbances, increased levels of catecholamines, and disturbances in cerebral blood flow caused by sleep apneas, as well as hypoxemic periods that may potentiate atherosclerosis.", "offsetInBeginSection": 698, "offsetInEndSection": 999, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18024169", "text": "BACKGROUND AND PURPOSE Nocturnal cardiac arrhythmias occur in patients with obstructive sleep apnea (OSA), reportedly as a consequence of the autonomic effects of recurrent apnea with subsequent oxygen desaturation.", "offsetInBeginSection": 0, "offsetInEndSection": 215, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/3313692", "text": "Hypersomnia in association with snoring usually signifies obstructive sleep apnea.", "offsetInBeginSection": 257, "offsetInEndSection": 339, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/207245", "text": "Patients with the hypersomnia-sleep apnea syndrome should be provided with a tracheal opening during sleep when severe daytime somnolence, cardiac arrhythmias, and hypertension are present.", "offsetInBeginSection": 735, "offsetInEndSection": 924, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6743016", "text": "Two morbidly obese patients were described as having severe obstructive sleep apnea syndrome with several apneic periods occurring during sleep that produced substantial oxygen desaturation and, in one patient, cardiac arrhythmias.", "offsetInBeginSection": 0, "offsetInEndSection": 231, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15653957", "text": "STUDY OBJECTIVES To compare the frequency of daytime and nocturnal cardiac arrhythmias and ST-segment depression episodes among patients with obstructive sleep apnea-hypopnea syndrome (OSAHS), snoring subjects, and healthy subjects, and to analyze the relationship between the cardiac disturbances, sleep characteristics, and sympathetic tone in patients with OSAHS.", "offsetInBeginSection": 0, "offsetInEndSection": 366, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aa80873d6d6b54f79000013", "body": "List ribosomal biogenesis proteins.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20188109", "http://www.ncbi.nlm.nih.gov/pubmed/19114035", "http://www.ncbi.nlm.nih.gov/pubmed/35456798", "http://www.ncbi.nlm.nih.gov/pubmed/30706966", "http://www.ncbi.nlm.nih.gov/pubmed/22893726", "http://www.ncbi.nlm.nih.gov/pubmed/24943357", "http://www.ncbi.nlm.nih.gov/pubmed/2043343", "http://www.ncbi.nlm.nih.gov/pubmed/30498217", "http://www.ncbi.nlm.nih.gov/pubmed/23169665", "http://www.ncbi.nlm.nih.gov/pubmed/21282979"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/18773413", "text": "One newly identified key regulator for ribosomal biogenesis and translation is the oncoprotein c-Myc, whose aberrantly excessive level and activity are highly associated with human cancers, too.", "offsetInBeginSection": 373, "offsetInEndSection": 567, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19878869", "text": "The ribosomal protein-MDM2-p53 signaling pathway provides a molecular switch that may constitute a surveillance network monitoring the integrity of ribosomal biogenesis.", "offsetInBeginSection": 574, "offsetInEndSection": 743, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28685141", "text": "These factors include snoRNPs, nucleases, ATPases, GTPases, RNA helicases, and a vast list of proteins with no predicted enzymatic activity.", "offsetInBeginSection": 313, "offsetInEndSection": 453, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20061553", "text": "In a screen for Arabidopsis thaliana mutants affected in the trafficking of C-terminal VSD containing proteins, we isolated the ribosomal biogenesis mutant rpl4a characterized by its partial secretion of vacuolar targeted proteins and a plethora of developmental phenotypes derived from its aberrant auxin responses.", "offsetInBeginSection": 191, "offsetInEndSection": 507, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20061553", "text": "We propose that the influence of auxin on ribosomal biogenesis acts as a regulatory mechanism for auxin-mediated developmental processes, and we demonstrate the involvement of this regulatory mechanism in the sorting of vacuolar targeted proteins in Arabidopsis.", "offsetInBeginSection": 742, "offsetInEndSection": 1004, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23169665", "text": "Impairment of ribosomal biogenesis can activate the p53 protein independently of DNA damage.", "offsetInBeginSection": 0, "offsetInEndSection": 92, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29143558", "text": "This ribosome biogenesis stress pathway activates p53 through sequestration of MDM2 by a subset of ribosomal proteins (RPs), thereby stabilizing p53.", "offsetInBeginSection": 370, "offsetInEndSection": 519, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29143558", "text": "Here, we identify human HEATR1, as a nucleolar protein which positively regulates ribosomal RNA (rRNA) synthesis.", "offsetInBeginSection": 520, "offsetInEndSection": 633, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20188109", "text": "Ribosome biogenesis is facilitated by a growing list of assembly cofactors, including helicases, GTPases, chaperones, and other proteins, but the specific functions of many of these assembly cofactors are still unclear.", "offsetInBeginSection": 0, "offsetInEndSection": 219, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28986221", "text": "Unlike most ribosomal proteins, which are incorporated into pre-ribosomal particles during early steps of ribosome biogenesis in the nucleus, P-stalk proteins are attached to the 60S subunit in the cytoplasm.", "offsetInBeginSection": 419, "offsetInEndSection": 627, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a7339372dc08e987e000013", "body": "List drugs that are included in the Vosevi polypill.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20549577", "http://www.ncbi.nlm.nih.gov/pubmed/27818251", "http://www.ncbi.nlm.nih.gov/pubmed/35569611", "http://www.ncbi.nlm.nih.gov/pubmed/31448738", "http://www.ncbi.nlm.nih.gov/pubmed/16783994", "http://www.ncbi.nlm.nih.gov/pubmed/35490770", "http://www.ncbi.nlm.nih.gov/pubmed/20684405", "http://www.ncbi.nlm.nih.gov/pubmed/26390808", "http://www.ncbi.nlm.nih.gov/pubmed/27538505", "http://www.ncbi.nlm.nih.gov/pubmed/33186492"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27818251", "text": "Polypill is a medication designed for preventing heart attacks through a combination of drugs.", "offsetInBeginSection": 0, "offsetInEndSection": 94, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27818251", "text": "This paper investigates a new methodology for the control dosage of a polypill recently reported containing hydrochlorothiazide, amlodipine, losartan and simvastatin in a 12.5/2.5/25/40 weight ratio.", "offsetInBeginSection": 425, "offsetInEndSection": 624, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27818251", "text": "Amlodipine, losartan and simvastatin were released from the polypill-MSN-41 system in a controlled way.", "offsetInBeginSection": 1103, "offsetInEndSection": 1206, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20549577", "text": "The Indian Polycap Study (TIPS) was the first to systematically test the clinical application of the polypill; it included ramipril, hydrochlorothiazide, atenolol, aspirin, and simvastatin.", "offsetInBeginSection": 455, "offsetInEndSection": 644, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16783994", "text": "This \"Polypill\" should be a combination of three antihypertensive drugs associated to aspirin, a statin and folic acid.", "offsetInBeginSection": 236, "offsetInEndSection": 355, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21205325", "text": "CONCLUSIONS We successfully completed a Polypill feasibility trial in Sri Lanka.", "offsetInBeginSection": 1806, "offsetInEndSection": 1886, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26390808", "text": "The polypill here represents a cardiovascular treatment regime with the incorporation of an immediate release compartment with aspirin and hydrochlorothiazide and three sustained release compartments containing pravastatin, atenolol, and ramipril.", "offsetInBeginSection": 554, "offsetInEndSection": 801, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26747390", "text": "The Fuster-CNIC-Ferrer cardiovascular (CV) polypill has been found to be the first-in-class polypill to be approved and commercialized in Europe and Latinamerican Countries.", "offsetInBeginSection": 551, "offsetInEndSection": 724, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29127755", "text": "Right combination of drugs in the polypill might be a suitable solving of CV disease and diabetes prevention for the patients with metabolic syndrome.Key words: cardiometabolic risk - cardiovascular disease prevention - metabolic syndrome - polypill.", "offsetInBeginSection": 806, "offsetInEndSection": 1056, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29127755", "text": "Right now polypill (fixed combination of antihypertensives and lipid modifying drugs) are solving in the CV disease prevention.", "offsetInBeginSection": 546, "offsetInEndSection": 673, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a7639419e632bc066000005", "body": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35713780", "http://www.ncbi.nlm.nih.gov/pubmed/34236666", "http://www.ncbi.nlm.nih.gov/pubmed/32142105", "http://www.ncbi.nlm.nih.gov/pubmed/34522290", "http://www.ncbi.nlm.nih.gov/pubmed/29036616", "http://www.ncbi.nlm.nih.gov/pubmed/34337652", "http://www.ncbi.nlm.nih.gov/pubmed/36304291", "http://www.ncbi.nlm.nih.gov/pubmed/31886228", "http://www.ncbi.nlm.nih.gov/pubmed/24133649", "http://www.ncbi.nlm.nih.gov/pubmed/18723400"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/29036616", "text": "Results Here, we present a prediction algorithm using deep neural networks to predict protein subcellular localization relying only on sequence information.", "offsetInBeginSection": 536, "offsetInEndSection": 692, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29036616", "text": "At its core, the prediction model uses a recurrent neural network that processes the entire protein sequence and an attention mechanism identifying protein regions important for the subcellular localization.", "offsetInBeginSection": 693, "offsetInEndSection": 900, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15963230", "text": "RESULTS In this paper, we propose a new algorithm called pSLIP which uses Support Vector Machines (SVMs) in conjunction with multiple physicochemical properties of amino acids to predict protein subcellular localization in eukaryotes across six different locations, namely, chloroplast, cytoplasmic, extracellular, mitochondrial, nuclear and plasma membrane.", "offsetInBeginSection": 601, "offsetInEndSection": 959, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15963230", "text": "CONCLUSION This study presents a physicochemical property based protein localization prediction algorithm.", "offsetInBeginSection": 1157, "offsetInEndSection": 1263, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19537160", "text": "Here, we present two machine learning approaches for prediction of the subcellular localization of a protein from the primary sequence information.", "offsetInBeginSection": 562, "offsetInEndSection": 709, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17428441", "text": "In this report, using a machine learning approach, the Nearest Neighbor Algorithm (NNA), we developed a prediction system for protein SL in which we incorporated a protein functional domain profile.", "offsetInBeginSection": 423, "offsetInEndSection": 621, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24133649", "text": "In this article we design a new predictor of protein subcellular localization, based on a Machine Learning model (N-to-1 Neural Networks) which we have recently developed.", "offsetInBeginSection": 243, "offsetInEndSection": 414, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24133649", "text": "The prediction of protein subcellular localization is a important step towards the prediction of protein function, and considerable effort has gone over the last decade into the development of computational predictors of protein localization.", "offsetInBeginSection": 0, "offsetInEndSection": 242, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20421687", "text": "Machine learning methods such as Support Vector Machines (SVMs) have been used in the past for the problem of protein subcellular localization, but have been shown to suffer from a lack of annotated training data in each species under study.", "offsetInBeginSection": 385, "offsetInEndSection": 626, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27323846", "text": "Several machine learning methods have been developed for computational prediction of primary protein sequences because wet experiments are costly and time consuming.", "offsetInBeginSection": 86, "offsetInEndSection": 251, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a99332a1d1251d03b00000e", "body": "How is Hsd17b1 associated with endometriosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28405865", "http://www.ncbi.nlm.nih.gov/pubmed/29664547", "http://www.ncbi.nlm.nih.gov/pubmed/15640252", "http://www.ncbi.nlm.nih.gov/pubmed/14973105", "http://www.ncbi.nlm.nih.gov/pubmed/22613790", "http://www.ncbi.nlm.nih.gov/pubmed/35563206", "http://www.ncbi.nlm.nih.gov/pubmed/25403437", "http://www.ncbi.nlm.nih.gov/pubmed/26261478", "http://www.ncbi.nlm.nih.gov/pubmed/20093485", "http://www.ncbi.nlm.nih.gov/pubmed/20586553"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/15640252", "text": "The A-allele of HSD17B1 appears to confer higher risk for endometriosis.", "offsetInBeginSection": 1377, "offsetInEndSection": 1449, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15640252", "text": "Here, we evaluated whether the risk and severity of endometriosis are associated with polymorphisms in estradiol-synthesizing enzyme genes: the Ser312Gly polymorphism in 17-beta-hydroxysteroid dehydrogenase type 1 (HSD17B1) and the Arg264Cys polymorphism in cytochrome P450, subfamily XIX (CYP19).", "offsetInBeginSection": 133, "offsetInEndSection": 430, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28405865", "text": "RESULTS Statistical analysis demonstrated that the HSD17B1 937 A>G SNP is associated with endometriosis in stages I and II.", "offsetInBeginSection": 598, "offsetInEndSection": 721, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28405865", "text": "CONCLUSION Our genetic study demonstrated HSD17B1 937 G variant as a risk factor for infertility in women with stage I and II endometriosis in Polish Caucasian patients.", "offsetInBeginSection": 1300, "offsetInEndSection": 1469, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20586553", "text": "RESULTS The HSD17B1 A/G SNP A allele increased overall endometriosis risk and the risk of stage I-II disease, while ESR1 longer (TA)(n) repeats only correlated with susceptibility to stage I-II endometriosis.", "offsetInBeginSection": 755, "offsetInEndSection": 963, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20586553", "text": "CONCLUSIONS Genetic variants in ESR1, ESR2, and HSD17B1 genes could modify susceptibility to endometriosis and might influence the fertility status in endometriosis patients.", "offsetInBeginSection": 1294, "offsetInEndSection": 1468, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22613790", "text": "The findings of our study suggest that HSD17B1 and PR polymorphisms are associated with an increased risk of endometriosis.", "offsetInBeginSection": 1079, "offsetInEndSection": 1202, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22613790", "text": "Twenty-seven studies on the association of the cytochrome P450 subfamily 17 (CYP17), estrogen receptor gene (ER), progesterone receptor gene (PR), 17-beta-hydroxysteroid dehydrogenase type 1 gene (HSD17B1), and cytochrome P450 subfamily 19 (CYP19) polymorphisms with endometriosis risk were identified.", "offsetInBeginSection": 218, "offsetInEndSection": 520, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24012197", "text": "Ratios between pro- and antiestrogenic enzymes (STS/EST and HSD17B1/HSD17B2) were more in favor of estrogens in ovarian and rectovaginal endometriosis.", "offsetInBeginSection": 1376, "offsetInEndSection": 1527, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18815356", "text": "In 8-Br-cAMP-treated hESF from eutopic endometrium of women with endometriosis, the balance in estradiol (E2) and P4 biosynthetic and metabolizing enzymes is disturbed (decreased HSD3B1 and HSD17B2, and increased HSD17B1 and aromatase), with the equilibrium being shifted towards an E2-enriched milieu.", "offsetInBeginSection": 733, "offsetInEndSection": 1035, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a9eb008d6d6b54f79000001", "body": "List the continent of origin for the brown marmorated stinkbug(Halyomorpha halys)", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22828257", "http://www.ncbi.nlm.nih.gov/pubmed/28852110", "http://www.ncbi.nlm.nih.gov/pubmed/28824354", "http://www.ncbi.nlm.nih.gov/pubmed/33106194", "http://www.ncbi.nlm.nih.gov/pubmed/34070564", "http://www.ncbi.nlm.nih.gov/pubmed/36292903", "http://www.ncbi.nlm.nih.gov/pubmed/23905725", "http://www.ncbi.nlm.nih.gov/pubmed/26463187", "http://www.ncbi.nlm.nih.gov/pubmed/34054324", "http://www.ncbi.nlm.nih.gov/pubmed/31634397"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/22828257", "text": "The brown marmorated stink bug, Halyomorpha halys, is native to Asia (China, Taiwan, Japan, and the Korean peninsula).", "offsetInBeginSection": 0, "offsetInEndSection": 118, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26955631", "text": "The brown marmorated stink bug, Halyomorpha halys (Hemiptera: Pentatomidae), is a gregarious crop pest that has rapidly spread across the world in the last two decades.", "offsetInBeginSection": 0, "offsetInEndSection": 168, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25474148", "text": "Brown marmorated stink bug, Halyomorpha halys (St\u00e5l), (Hemiptera: Pentatomidae) is an invasive polyphagous agricultural and urban nuisance pest of Asian origin that is becoming widespread in North America and Europe.", "offsetInBeginSection": 0, "offsetInEndSection": 217, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24871833", "text": "The brown marmorated stink bug, Halyomorpha halys (St\u00e5l, 1855) (Hemiptera: Heteroptera: Pentatomidae) is recorded for the first time from Hungary.", "offsetInBeginSection": 0, "offsetInEndSection": 147, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24586332", "text": "We examined the salivary gland structure of the brown marmorated stink bug (Pentatomidae: Halyomorpha halys) and developed methods for independent collection of watery saliva and sheath saliva.", "offsetInBeginSection": 0, "offsetInEndSection": 193, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27744285", "text": "Sampling soybean fields for the brown marmorated stink bug, Halyomorpha halys St\u00e5l (Hemiptera: Pentatomidae), can be challenging.", "offsetInBeginSection": 0, "offsetInEndSection": 130, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23865219", "text": "Brown marmorated stink bug (Halyomorpha halys (St\u00e5l)) is an invasive agricultural and urban pest that was first detected in the United States in the late 1990s.", "offsetInBeginSection": 226, "offsetInEndSection": 387, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26463187", "text": "The brown marmorated stink bug, Halyomorpha halys (St\u00e5l) (BMSB) is an exotic invasive insect originating in East Asia, currently causing significant damage to fruits, vegetables and other crops throughout most of the Mid-Atlantic states of the U.S.", "offsetInBeginSection": 0, "offsetInEndSection": 249, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28984006", "text": "We describe a unique microsporidian species that infects the green stink bug, Chinavia hilaris; the brown marmorated stink bug, Halyomorpha halys; the brown stink bug, Euschistus servus; and the dusky stink bug, Euschistus tristigmus.", "offsetInBeginSection": 0, "offsetInEndSection": 234, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24285660", "text": "We report the genome sequence of a novel iflavirus recovered from the transcriptome of a colony of the brown marmorated stink bug, Halyomorpha halys.", "offsetInBeginSection": 0, "offsetInEndSection": 149, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aa82180d6d6b54f79000015", "body": "Are osteoclasts specialized in bone degradation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/9819571", "http://www.ncbi.nlm.nih.gov/pubmed/35646939", "http://www.ncbi.nlm.nih.gov/pubmed/9092479", "http://www.ncbi.nlm.nih.gov/pubmed/12748652", "http://www.ncbi.nlm.nih.gov/pubmed/11193210", "http://www.ncbi.nlm.nih.gov/pubmed/16951988", "http://www.ncbi.nlm.nih.gov/pubmed/8395372", "http://www.ncbi.nlm.nih.gov/pubmed/27514812", "http://www.ncbi.nlm.nih.gov/pubmed/22941736", "http://www.ncbi.nlm.nih.gov/pubmed/2343780"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/19372577", "text": "Tumor cells in the bone microenvironment are able to initiate a vicious cycle of bone degradation by mobilizing osteoclasts, multinucleated cells specialized in bone degradation.", "offsetInBeginSection": 0, "offsetInEndSection": 178, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24992711", "text": "These observations reveal that contrarily to bone resorption, the ability of osteoclasts to dissolve minerals is dispensable for the degradation of mineralized hypertrophic cartilage during endochondral bone formation.", "offsetInBeginSection": 1646, "offsetInEndSection": 1864, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24992711", "text": "Osteoclasts are specialized in mineralized tissue degradation, with the combined ability to solubilize hydroxyapatite and to degrade extracellular matrix proteins.", "offsetInBeginSection": 482, "offsetInEndSection": 645, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9819571", "text": "Osteoclasts dissolve bone mineral by massive acid secretion and secrete specialized proteinases that degrade the organic matrix, mainly type I collagen, in this acidic milieu.", "offsetInBeginSection": 692, "offsetInEndSection": 867, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9819571", "text": "Osteoclasts are multinucleated monocyte-macrophage derivatives that degrade bone.", "offsetInBeginSection": 0, "offsetInEndSection": 81, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/14702187", "text": "Osteoclasts express specialized proteins including a vacuolar-type H+-ATPase that drives HCl secretion for dissolution of bone mineral.", "offsetInBeginSection": 1219, "offsetInEndSection": 1354, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11193210", "text": "Osteoclasts are physiological polykaryons specialized in the resorption of calcified tissue.", "offsetInBeginSection": 0, "offsetInEndSection": 92, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22941736", "text": "Osteoclasts are highly specialized cells that resorb bone and contribute to bone remodeling.", "offsetInBeginSection": 0, "offsetInEndSection": 92, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27514812", "text": "Osteoclasts, specialized cells that degrade bone, are key components of the cellular system that regulates and maintains bone homeostasis.", "offsetInBeginSection": 0, "offsetInEndSection": 138, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27620531", "text": "Skin Langerhans cells are antigen-presenting cells of the interfollicular epidermis and the upper part of the hair follicle, whereas osteoclasts are specialized bone-resorbing macrophages.", "offsetInBeginSection": 0, "offsetInEndSection": 188, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a733a672dc08e987e000014", "body": "Does temsirolimus improve survival of glioblastoma patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15998902", "http://www.ncbi.nlm.nih.gov/pubmed/19100905", "http://www.ncbi.nlm.nih.gov/pubmed/17827463", "http://www.ncbi.nlm.nih.gov/pubmed/26606910", "http://www.ncbi.nlm.nih.gov/pubmed/28259301", "http://www.ncbi.nlm.nih.gov/pubmed/24470557", "http://www.ncbi.nlm.nih.gov/pubmed/26161146", "http://www.ncbi.nlm.nih.gov/pubmed/21049085", "http://www.ncbi.nlm.nih.gov/pubmed/17538086", "http://www.ncbi.nlm.nih.gov/pubmed/22472176"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28259301", "text": "CONCLUSIONS antiangiogenic drugs did not improve overall survival in glioblastoma patients, either as first or second-line treatment, and either as single agent or in combination with chemotherapy.", "offsetInBeginSection": 1438, "offsetInEndSection": 1635, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28259301", "text": "Bevacizumab did not improve overall survival.", "offsetInBeginSection": 1017, "offsetInEndSection": 1062, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23564811", "text": "The combination of temsirolimus and antibodies to vascular endothelial factor (VEGF) has not yet been investigated, but with the hypothesis that temsirolimus might provide complimentary therapeutic benefit in combination with bevacizumab, we included patients with progressive GBM after bevacizumab in an open phase II study.", "offsetInBeginSection": 514, "offsetInEndSection": 839, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15998902", "text": "BACKGROUND Temsirolimus (CCI-779) is a small-molecule inhibitor of the mammalian target of rapamycin (mTOR) and represents a rational therapeutic target against glioblastoma multiforme (GBM).", "offsetInBeginSection": 0, "offsetInEndSection": 191, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15998902", "text": "CONCLUSION Temsirolimus is well tolerated in recurrent GBM patients.", "offsetInBeginSection": 1698, "offsetInEndSection": 1766, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28351321", "text": "We recently reported that mammalian target of rapamycin inhibitors-rapamycin, temsirolimus, torin 1, and PP242-suppressed invasion and migration promoted by tumor necrosis factor-alpha and phorbol-myristate-acetate in glioblastoma cells.", "offsetInBeginSection": 578, "offsetInEndSection": 815, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17538086", "text": "The addition of temsirolimus to interferon did not improve survival.", "offsetInBeginSection": 1823, "offsetInEndSection": 1891, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17538086", "text": "Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, may benefit patients with this disease.", "offsetInBeginSection": 121, "offsetInEndSection": 240, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17538086", "text": "CONCLUSIONS As compared with interferon alfa, temsirolimus improved overall survival among patients with metastatic renal-cell carcinoma and a poor prognosis.", "offsetInBeginSection": 1664, "offsetInEndSection": 1822, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17827463", "text": "The addition of tyrosine kinase inhibitors vatalanib (PTK787) and vandetinib (ZD6474), the integrin inhibitor cilengitide, the monoclonal antibodies bevacizumab and cetuximab, the mammalian target of rapamycin inhibitors temsirolimus and everolimus, and the protein kinase C inhibitor enzastaurin, among other agents, are in clinical investigation, building on the established chemoradiotherapy regimen for newly diagnosed glioblastoma.", "offsetInBeginSection": 1508, "offsetInEndSection": 1944, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a763b679e632bc066000006", "body": "Describe RIblast", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28459942", "http://www.ncbi.nlm.nih.gov/pubmed/31191601", "http://www.ncbi.nlm.nih.gov/pubmed/29697742", "http://www.ncbi.nlm.nih.gov/pubmed/15651245", "http://www.ncbi.nlm.nih.gov/pubmed/28433298", "http://www.ncbi.nlm.nih.gov/pubmed/28081995", "http://www.ncbi.nlm.nih.gov/pubmed/25346200", "http://www.ncbi.nlm.nih.gov/pubmed/33335339", "http://www.ncbi.nlm.nih.gov/pubmed/35944273", "http://www.ncbi.nlm.nih.gov/pubmed/6957905"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/18428249", "text": "Several support protocols describe methods for adenovirus growth and purification, biotinylation, inactivation with psoralen, and quantitation of the adenovirus particles.", "offsetInBeginSection": 279, "offsetInEndSection": 450, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11800821", "text": "We introduce two simple stochastic growth models which describe the motion of the interfaces driven through random media in two and three dimensions.", "offsetInBeginSection": 0, "offsetInEndSection": 149, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12725838", "text": "The resulting model equations are used to describe experimental surface pressure data published in the literature.", "offsetInBeginSection": 177, "offsetInEndSection": 291, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18301504", "text": "The Babinet principle is used to separate components that describe the data signal, servo signals, and three types of cross talk.", "offsetInBeginSection": 166, "offsetInEndSection": 295, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18349498", "text": "We propose describing a manipulative technique using 6 characteristics: Rate of force application: Describe the rate at which the force was applied.", "offsetInBeginSection": 0, "offsetInEndSection": 148, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18349498", "text": "Relative structural movement: Describe which structure or region was intended to remain stable and which structure or region was intended to move, with the moving structure or region being named first and the stable segment named second, separated by the word \"on.\"", "offsetInBeginSection": 581, "offsetInEndSection": 846, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24193825", "text": "We describe first a field deployable mass spectrometer, based on an ion trap analyzer, and variants of that system.", "offsetInBeginSection": 375, "offsetInEndSection": 490, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24193825", "text": "We describe four sensing and characterization technologies recently developed at Los Alamos National Laboratory; a select set of mass spectral and optical techniques is emphasized.", "offsetInBeginSection": 0, "offsetInEndSection": 180, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24193825", "text": "We then describe a hand-held, battery-operated optical spectrometer, usable in either absorption, or fluorescence excitation mode.", "offsetInBeginSection": 491, "offsetInEndSection": 621, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26579876", "text": "As anatomists we owe it to the medical and research community to correct the nomenclature to minimize confusion, and to describe the heart properly in respect to its surrounding structures.", "offsetInBeginSection": 692, "offsetInEndSection": 881, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a991ee21d1251d03b000005", "body": "Are there sex differences in the transcriptome of the mouse hippocampus?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33309016", "http://www.ncbi.nlm.nih.gov/pubmed/28302071", "http://www.ncbi.nlm.nih.gov/pubmed/26317111", "http://www.ncbi.nlm.nih.gov/pubmed/34146586", "http://www.ncbi.nlm.nih.gov/pubmed/32278894", "http://www.ncbi.nlm.nih.gov/pubmed/30214058", "http://www.ncbi.nlm.nih.gov/pubmed/30291623", "http://www.ncbi.nlm.nih.gov/pubmed/26557979", "http://www.ncbi.nlm.nih.gov/pubmed/31403726", "http://www.ncbi.nlm.nih.gov/pubmed/33532622"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28302071", "text": "Additionally, this analysis reveals sex differences in the transcriptome of the developing mouse hippocampus, and further clarifies the need to include both female and male mice in longitudinal studies involving molecular changes in the hippocampus.", "offsetInBeginSection": 1401, "offsetInEndSection": 1650, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27053151", "text": "In this study, we compared the changes relative to normal littermates in the proteome and transcriptome of the hippocampus in the C57Bl/6 mouse model of MPS VII, which has well-documented histopathological and neurodegenerative changes.", "offsetInBeginSection": 118, "offsetInEndSection": 354, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28344592", "text": "Here we define the transcriptome of developing wild type and dysbindin null Bloc1s8 mouse hippocampus in order to identify mechanisms downstream dysbindin defects.", "offsetInBeginSection": 604, "offsetInEndSection": 767, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17988385", "text": "Each CNS region (cerebral cortex, hippocampus, striatum, cerebellum and spinal cord) possessed its own unique transcriptome fingerprint that was independent of age, gender and energy intake.", "offsetInBeginSection": 422, "offsetInEndSection": 612, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25798087", "text": "By analyzing RNASeq datasets, we demonstrate region specific enrichment of populations of lncRNAs and mRNAs in the mouse hippocampus and pre-frontal cortex (PFC), the two major regions of the brain involved in memory storage and neuropsychiatric disorders.", "offsetInBeginSection": 231, "offsetInEndSection": 487, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25798087", "text": "The lncRNAs identified correspond to ~14% of the transcriptome of the hippocampus and PFC and ~70% of the lncRNAs annotated in the mouse genome (NCBIM37) and are localized along the chromosomes as varying numbers of clusters.", "offsetInBeginSection": 607, "offsetInEndSection": 832, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26557979", "text": "Trisomy of the Mmu10 segment differentially affects female and male profiles, perturbing protein levels most in the cerebellum of female Dp10 and most in the hippocampus of male Dp10.", "offsetInBeginSection": 1621, "offsetInEndSection": 1804, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27610074", "text": "Our data reveal significant transcriptional similarities and differences between the BTBR and En2 (-/-) hippocampus, indicating that transcriptome analysis of ASD mouse models may contribute to identify novel molecular targets for pharmacological studies.", "offsetInBeginSection": 2351, "offsetInEndSection": 2606, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26628058", "text": "CONCLUSIONS We uncover a critical influence of the estrous cycle on the adult rat medial prefrontal cortex transcriptome resulting in partly opposite sex differences in proestrus when compared to diestrus females, and we discovered a direct role for Early Growth Response 1 in this opposite regulation.", "offsetInBeginSection": 1234, "offsetInEndSection": 1536, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26628058", "text": "RESULTS We undertake a large-scale characterization of sex differences and their interaction with the estrous cycle in the adult medial prefrontal cortex transcriptome and report that females with high and low ovarian hormone levels exhibited a partly opposed sexually biased transcriptome.", "offsetInBeginSection": 614, "offsetInEndSection": 904, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aa0495bd6d6b54f79000002", "body": "What is the role of the blood-brain barrier?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12415123", "http://www.ncbi.nlm.nih.gov/pubmed/22130026", "http://www.ncbi.nlm.nih.gov/pubmed/35106665", "http://www.ncbi.nlm.nih.gov/pubmed/27112670", "http://www.ncbi.nlm.nih.gov/pubmed/9678995", "http://www.ncbi.nlm.nih.gov/pubmed/28986948", "http://www.ncbi.nlm.nih.gov/pubmed/15635601", "http://www.ncbi.nlm.nih.gov/pubmed/10634997", "http://www.ncbi.nlm.nih.gov/pubmed/710090", "http://www.ncbi.nlm.nih.gov/pubmed/18085720"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24501156", "text": "Caveolin-1 is related to the diminished expression of tight junction-associated proteins and metabolic pinocytosis vesicles when the blood-brain barrier is destroyed by outside invaders or malignant stimulus.", "offsetInBeginSection": 243, "offsetInEndSection": 451, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24501156", "text": "It plays an important role in physiological and pathological conditions of the blood-brain barrier and serves as a mediator in drug delivery through the blood-brain barrier.", "offsetInBeginSection": 69, "offsetInEndSection": 242, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28781208", "text": "Blood-brain barrier pathology is recognised as a central factor in the development of many neurological disorders, but much less is known about the role of the blood-brain barrier in psychiatric disorders.", "offsetInBeginSection": 0, "offsetInEndSection": 205, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28781208", "text": "We conclude that the complex nature of blood-brain barrier dysfunction in psychosis might be relevant to many aspects of disrupted neuronal and synaptic function, increased permeability to inflammatory molecules, disrupted glutamate homoeostasis, impaired action of antipsychotics, and development of antipsychotic resistance.", "offsetInBeginSection": 729, "offsetInEndSection": 1055, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19077110", "text": "The role of inflammation and the blood-brain barrier will be discussed in cerebral palsy, schizophrenia, Parkinson's disease, Alzheimer's disease and multiple sclerosis, conditions where both inflammation and blood-brain barrier dysfunction occur either during initiation and/or progression of the disease.", "offsetInBeginSection": 554, "offsetInEndSection": 860, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15920760", "text": "In conclusion, loss of flow (flow cessation/reperfusion) independent of hypoxia-hypoglycemia plays a significant role in blood-brain barrier failure by stimulating leukocyte-mediated inflammatory mechanisms.", "offsetInBeginSection": 1716, "offsetInEndSection": 1923, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15920760", "text": "Shear stress, hypoxia-hypoglycemia, and blood leukocytes play a significant role in blood-brain barrier failure during transient or permanent ischemia.", "offsetInBeginSection": 149, "offsetInEndSection": 300, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23508590", "text": "Thus, the transporter protein MRP plays a role in maintaining the blood-brain barrier and modulates the activity of opioids.", "offsetInBeginSection": 1449, "offsetInEndSection": 1573, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23508590", "text": "The ATP-binding cassette (ABC) transporter P-glycoprotein (Pgp) is involved with the barrier, both preventing the influx of agent from the blood into the brain and facilitating the efflux of compounds from the brain into the blood, raising the possibility of a similar role for other transporters.", "offsetInBeginSection": 81, "offsetInEndSection": 378, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12742070", "text": "In situ brain perfusion in the rat, indicates that blood to brain L-[14C]glutamine transport at the blood-brain barrier is primarily mediated by a pH-dependent, Na(+)-dependent, System N transporter, but that blood to choroid plexus transport is primarily via a pH-independent System N transporter and a Na(+)-independent carrier that is not System L. Transport studies in isolated rat choroid plexuses and primary cultures of choroid plexus epithelial cells indicate that epithelial L-[14C]glutamine transport is polarized (apical uptake>basolateral) and that uptake at the apical membrane is mediated by pH dependent System N transporters (identified as SN1 and SN2 by polymerase chain reaction) and the Na(+)-independent System L. Blood-brain barrier System N transport is markedly effected by cerebral ischemia and may be a good marker of endothelial cell dysfunction.", "offsetInBeginSection": 476, "offsetInEndSection": 1348, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aa824a8fcf4565872000002", "body": "What is the drug Tecfidera used against?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26195059", "http://www.ncbi.nlm.nih.gov/pubmed/26689201", "http://www.ncbi.nlm.nih.gov/pubmed/28258191", "http://www.ncbi.nlm.nih.gov/pubmed/24588595", "http://www.ncbi.nlm.nih.gov/pubmed/29263788", "http://www.ncbi.nlm.nih.gov/pubmed/23946617", "http://www.ncbi.nlm.nih.gov/pubmed/33797063", "http://www.ncbi.nlm.nih.gov/pubmed/28965011", "http://www.ncbi.nlm.nih.gov/pubmed/32629403", "http://www.ncbi.nlm.nih.gov/pubmed/31073181"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28258191", "text": "Dimethyl fumarate (DMF; trade name Tecfidera) is an oral formulation of the fumaric acid ester that is Food and Drug Administration approved for treatment of relapsing-remitting multiple sclerosis.", "offsetInBeginSection": 0, "offsetInEndSection": 197, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23946617", "text": "Dimethyl fumarate capsules (Tecfidera) for multiple sclerosis, ado-trastuzumab emtansine injection (Kadcyla) for HER-2-positive breast cancer, and ospemifene tablets (Osphena) for painful intercourse in postmenopausal women.", "offsetInBeginSection": 0, "offsetInEndSection": 224, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26199353", "text": "Recently, three progressive multifocal leukoencephalopathy (PML) cases have been reported in multiple sclerosis (MS) patients, two treated with fingolimod (Gilenya, Novartis), the third with dimethyl fumarate (Tecfidera, Biogen).", "offsetInBeginSection": 0, "offsetInEndSection": 229, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25213591", "text": "We have previously reviewed the use of \u25bcfingolimod for highly active relapsing-remitting MS1 and \u25bcteriflunomide for the management of relapsing-remitting MS in adults.2 Here, we review the evidence for \u25bcdimethyl fumarate (Tecfidera-Biogen Idec Ltd) for the treatment of adults with relapsing-remitting MS.", "offsetInBeginSection": 215, "offsetInEndSection": 526, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28965011", "text": "Ethyl pyruvate is a redox analogue of dimethyl fumarate (Tecfidera), a drug for multiple sclerosis treatment.", "offsetInBeginSection": 0, "offsetInEndSection": 109, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25520780", "text": "METHODS The Twitter resource\u00a0Topsy was searched for tweets mentioning the following MS treatments: Aubagio, Avonex, Betaferon or Betaseron, Copaxone, Extavia, Gilenya, Lemtrada, Novantrone, Rebif, Tysabri and Tecfidera between 1 Jan 2006 to 31 Jul 2014.", "offsetInBeginSection": 330, "offsetInEndSection": 584, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25888198", "text": "After considering the clinical features and measures of drug efficacy in MS clinical trials, we report the phase-III clinical trials results of: (1) 3 oral agents approved within the last 5 years, fingolimod (Gilenya), dimethylfumarate (Tecfidera), and teriflunomide (Aubagio); (2) the oral agent laquinimod; and (3) the monoclonal antibodies daclizumab, ocrelizumab, and alemtuzumab.", "offsetInBeginSection": 605, "offsetInEndSection": 989, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24494635", "text": "Recently, 2 new oral DMTs received FDA approval for the treatment of RRMS: teriflunomide (Aubagio) and dimethyl fumarate (Tecfidera).", "offsetInBeginSection": 1094, "offsetInEndSection": 1227, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24494635", "text": "In addition, oral laquinimod, several monoclonal antibodies (eg, alemtuzumab, daclizumab, and ocrelizumab), and other agents have shown preliminary beneficial results in relapsing MS in phase 3 clinical trials.", "offsetInBeginSection": 1228, "offsetInEndSection": 1438, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24494635", "text": "These well-known therapies include intramuscular (IM) interferon (IFN) beta-1a (Avonex), subcutaneous (SC) IFN beta-1a (Rebif), SC IFN beta- 1b (Betaseron; Extavia), and SC glatiramer acetate (Copaxone).", "offsetInBeginSection": 205, "offsetInEndSection": 408, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a733d2a2dc08e987e000015", "body": "Is Tocilizumab effective for Giant-Cell Arteritis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29504436", "http://www.ncbi.nlm.nih.gov/pubmed/35304369", "http://www.ncbi.nlm.nih.gov/pubmed/27182063", "http://www.ncbi.nlm.nih.gov/pubmed/24075627", "http://www.ncbi.nlm.nih.gov/pubmed/29570475", "http://www.ncbi.nlm.nih.gov/pubmed/35482901", "http://www.ncbi.nlm.nih.gov/pubmed/32359040", "http://www.ncbi.nlm.nih.gov/pubmed/33044642", "http://www.ncbi.nlm.nih.gov/pubmed/30733723", "http://www.ncbi.nlm.nih.gov/pubmed/30258504"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28745999", "text": "The effect of the interleukin-6 receptor alpha inhibitor tocilizumab on the rates of relapse during glucocorticoid tapering was studied in patients with giant-cell arteritis.", "offsetInBeginSection": 158, "offsetInEndSection": 332, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23650978", "text": "Tocilizumab is a highly effective therapeutic agent for the treatment of rheumatoid arthritis and systemic juvenile idiopathic arthritis.", "offsetInBeginSection": 0, "offsetInEndSection": 137, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23650978", "text": "It is successful in treating diseases such as the adult-onset Still's disease, amyloidosis, giant cell arteritis, multiple myeloma, polymyalgia rheumatica, relapsing polychondritis, remitting seronegative symmetrical synovitis with pitting edema-syndrome, systemic lupus erythematosus, systemic sclerosis, and Takayasu arteritis.", "offsetInBeginSection": 461, "offsetInEndSection": 790, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23650978", "text": "Furthermore, a large amount of case study data reveals that tocilizumab can be an effective therapy for not only rheumatoid arthritis but also for other mostly rare inflammatory rheumatic diseases.", "offsetInBeginSection": 138, "offsetInEndSection": 335, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24357324", "text": "Several studies have reported that tocilizumab is effective for aortitis associated with Takayasu's arteritis and giant cell arteritis.", "offsetInBeginSection": 533, "offsetInEndSection": 668, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24357324", "text": "In conclusion, tocilizumab was effective in treating glucocorticoid- and cyclophosphamide-resistant AAV-associated aortitis.", "offsetInBeginSection": 1053, "offsetInEndSection": 1177, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24357324", "text": "This is the first report demonstrating the successful treatment of AAV-associated aortitis using tocilizumab.", "offsetInBeginSection": 1178, "offsetInEndSection": 1287, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24357324", "text": "It indicates that tocilizumab may be therapeutically beneficial for not only aortitis but also AAV itself.", "offsetInBeginSection": 946, "offsetInEndSection": 1052, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27182063", "text": "CONCLUSION TCZ is effective in GCA.", "offsetInBeginSection": 508, "offsetInEndSection": 543, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22965672", "text": "Herein, we present a case with giant cell arteritis resistant to oral and intravenous steroid, intravenous cyclophosphamide and mycophenolate mofetil, but successfully treated with tocilizumab.", "offsetInBeginSection": 231, "offsetInEndSection": 424, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a76420c9e632bc066000007", "body": "What is MULTOVL?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23071271", "http://www.ncbi.nlm.nih.gov/pubmed/19702537", "http://www.ncbi.nlm.nih.gov/pubmed/11326518", "http://www.ncbi.nlm.nih.gov/pubmed/6683883", "http://www.ncbi.nlm.nih.gov/pubmed/30656893", "http://www.ncbi.nlm.nih.gov/pubmed/15734663", "http://www.ncbi.nlm.nih.gov/pubmed/31798210", "http://www.ncbi.nlm.nih.gov/pubmed/6359612", "http://www.ncbi.nlm.nih.gov/pubmed/24119119", "http://www.ncbi.nlm.nih.gov/pubmed/34740305"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/23071271", "text": "We present the MULTOVL application suite that detects and statistically analyses multiple overlaps of genomic regions in a fast and efficient manner.", "offsetInBeginSection": 0, "offsetInEndSection": 149, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23071271", "text": "The package supports the detection of multiple region intersections, unions and 'solitary' genomic regions.", "offsetInBeginSection": 150, "offsetInEndSection": 257, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23071271", "text": "The significance of actually observed overlaps is estimated by comparing them with empirical null distributions generated by random shuffling of the input regions.", "offsetInBeginSection": 258, "offsetInEndSection": 421, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a992d981d1251d03b00000b", "body": "Can nanoparticles be used for afterglow imaging?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35218098", "http://www.ncbi.nlm.nih.gov/pubmed/26253653", "http://www.ncbi.nlm.nih.gov/pubmed/33145880", "http://www.ncbi.nlm.nih.gov/pubmed/31048701", "http://www.ncbi.nlm.nih.gov/pubmed/28657119", "http://www.ncbi.nlm.nih.gov/pubmed/27594671", "http://www.ncbi.nlm.nih.gov/pubmed/29035373", "http://www.ncbi.nlm.nih.gov/pubmed/33879169", "http://www.ncbi.nlm.nih.gov/pubmed/35380810", "http://www.ncbi.nlm.nih.gov/pubmed/34291946"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28657119", "text": "This study reports the design principle, synthesis, and proof-of-concept application of organic semiconducting nanoparticles (OSNs) with ultralong phosphorescence for in vivo afterglow imaging.", "offsetInBeginSection": 266, "offsetInEndSection": 459, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20798470", "text": "The successful observation of the afterglow from water-soluble nanoparticles may open up new applications of afterglow phosphors in biological imaging, detection and treatment.", "offsetInBeginSection": 816, "offsetInEndSection": 992, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28608898", "text": "Until now, the afterglow emissions of most developed near infrared (NIR)-emitting persistent luminescent nanoparticles (NPLNPs) were located at approximately 700 nm, at the edge of the first tissue transparency window (from 650 to 900 nm), which resulted in relatively low tissue penetration and signal-to-noise ratio (SNR) for in vivo imaging.", "offsetInBeginSection": 0, "offsetInEndSection": 344, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27345100", "text": "Our preliminary study has shown that the ZnS:Ag,Co afterglow nanoparticles can significantly reduce the x-ray dosage used in activation and thus may be a very promising candidate for future x-ray excited photodynamic therapy in deep cancer treatment.", "offsetInBeginSection": 965, "offsetInEndSection": 1215, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26253653", "text": "Afterglow nanoparticles have been widely investigated as new agents for cancer imaging and as a light source for photodynamic activation for cancer treatment.", "offsetInBeginSection": 0, "offsetInEndSection": 158, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26253653", "text": "Here we report the strategies for targeting Sr3MgSi2O8:Eu(2+),Dy(3+) afterglow nanoparticles to tumor cells by conjugating with variety of targeting molecules such as folic acid, RGD peptide, and R-11 peptide.", "offsetInBeginSection": 281, "offsetInEndSection": 490, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21702453", "text": "We finally identify a novel composition (CaMgSi(2)O(6):Eu(2+),Mn(2+),Pr(3+)) for in vivo imaging, displaying a strong near-infrared afterglow centered on 685 nm, and present evidence that intravenous injection of such persistent luminescence nanoparticles in mice allows not only improved but highly sensitive detection through living tissues.", "offsetInBeginSection": 767, "offsetInEndSection": 1110, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21702453", "text": "Focusing on the use of nanophosphors for in vivo imaging and diagnosis applications, we used thermally stimulated luminescence (TSL) measurements to study the influence of trivalent lanthanide Ln(3+) (Ln = Dy, Pr, Ce, Nd) electron traps on the optical properties of Mn(2+)-doped diopside-based persistent luminescence nanoparticles.", "offsetInBeginSection": 0, "offsetInEndSection": 332, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27419003", "text": "Near-infrared (NIR) persistent phosphor ZnGa2O4:Cr3+ (ZGC) has unique deep-tissue rechargeable afterglow properties.", "offsetInBeginSection": 0, "offsetInEndSection": 116, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27419003", "text": "Herein, we report on in vivo rechargeable mesoporous SiO2/ZnGa2O4:Cr3+ (mZGC) afterglow NIR-emitting nanocomposites that are made by a simple, one-step mesoporous template method.", "offsetInBeginSection": 236, "offsetInEndSection": 415, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aa13fd3d6d6b54f79000003", "body": "List 4 drugs used to treat opioid addiction or overdose", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30092933", "http://www.ncbi.nlm.nih.gov/pubmed/20169438", "http://www.ncbi.nlm.nih.gov/pubmed/28885516", "http://www.ncbi.nlm.nih.gov/pubmed/33900810", "http://www.ncbi.nlm.nih.gov/pubmed/32507023", "http://www.ncbi.nlm.nih.gov/pubmed/35965031", "http://www.ncbi.nlm.nih.gov/pubmed/31774028", "http://www.ncbi.nlm.nih.gov/pubmed/23664112", "http://www.ncbi.nlm.nih.gov/pubmed/22490239", "http://www.ncbi.nlm.nih.gov/pubmed/23059064"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26495843", "text": "10 patients (9/10 with chronic airflow obstruction) undergoing supervised injectable opioid treatment for heroin addiction received their usual prescribed dose of injectable opioid (diamorphine or methadone) (IOT), and their usual prescribed dose of oral opioid (methadone or sustained release oral morphine) after 30 minutes.", "offsetInBeginSection": 384, "offsetInEndSection": 710, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26495843", "text": "We conclude that significant acute respiratory depression is commonly induced by opioid drugs prescribed to treat opioid addiction.", "offsetInBeginSection": 1462, "offsetInEndSection": 1593, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28358791", "text": "Methadone is an opioid prescribed for pain management and is also provided through opioid treatment programs to treat opioid use disorders.", "offsetInBeginSection": 203, "offsetInEndSection": 342, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26054008", "text": "BACKGROUND Opioid addiction and overdose is a serious problem worldwide.", "offsetInBeginSection": 0, "offsetInEndSection": 72, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26054008", "text": "Combined with environmental exposure, opioid overdose can cause profound hypothermia.", "offsetInBeginSection": 229, "offsetInEndSection": 314, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16953647", "text": "Buprenorphine has partial mu-opioid receptor agonist activity and is a kappa-opioid receptor antagonist; hence, it can substitute for other micro-opioid receptor agonists, yet is less apt to produce overdose reactions or dysphoria.", "offsetInBeginSection": 338, "offsetInEndSection": 569, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16953647", "text": "The pharmacodynamic and pharmacokinetic profiles of buprenorphine make it unique in the armamentarium of drugs for the treatment of opioid addiction.", "offsetInBeginSection": 188, "offsetInEndSection": 337, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16953647", "text": "The introduction of a sublingual formulation combining naloxone with buprenorphine further reduces the risk of diversion to illicit intravenous use.", "offsetInBeginSection": 1152, "offsetInEndSection": 1300, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28627395", "text": "The foundation of the nation's opioid overdose crisis - and the totality of the nation's drug epidemic - is widespread recreational pharmacology, the use of drugs for fun or \"self-medication.\"", "offsetInBeginSection": 392, "offsetInEndSection": 584, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21668757", "text": "OBJECTIVE To illustrate a system-level, simulation-based approach for evaluating mitigation strategies to address the dramatic rise in abuse, addiction, and overdose deaths associated with the use of pharmaceutical opioid analgesics to treat chronic pain.", "offsetInBeginSection": 0, "offsetInEndSection": 255, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aa825b1fcf4565872000003", "body": "Are stress granules membraneous?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35171482", "http://www.ncbi.nlm.nih.gov/pubmed/35625794", "http://www.ncbi.nlm.nih.gov/pubmed/31399582", "http://www.ncbi.nlm.nih.gov/pubmed/32731602", "http://www.ncbi.nlm.nih.gov/pubmed/26406374", "http://www.ncbi.nlm.nih.gov/pubmed/27460788", "http://www.ncbi.nlm.nih.gov/pubmed/23991062", "http://www.ncbi.nlm.nih.gov/pubmed/19812307", "http://www.ncbi.nlm.nih.gov/pubmed/28746974", "http://www.ncbi.nlm.nih.gov/pubmed/29298433"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/29129640", "text": "Stress granules are mRNA-protein assemblies formed from nontranslating mRNAs.", "offsetInBeginSection": 0, "offsetInEndSection": 77, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19193871", "text": "Stress granules are cytoplasmic mRNA-silencing foci that form transiently during the stress response.", "offsetInBeginSection": 0, "offsetInEndSection": 101, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19193871", "text": "Here, we show that Stau1 is recruited to stress granules upon induction of endoplasmic reticulum or oxidative stress as well in stress granules induced by translation initiation blockers.", "offsetInBeginSection": 333, "offsetInEndSection": 520, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6581717", "text": "They consist of azurophilic granules containing membraneous lamellae.", "offsetInBeginSection": 113, "offsetInEndSection": 182, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27489304", "text": "P54 DEAD box RNA helicases are components of RNA granules such as P-bodies and stress granules.", "offsetInBeginSection": 322, "offsetInEndSection": 417, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18710928", "text": "We show that specific stress stimuli induce the assembly of RNA granules in an organelle with bacterial ancestry, the chloroplast of Chlamydomonas reinhardtii.", "offsetInBeginSection": 121, "offsetInEndSection": 280, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24090136", "text": "BACKGROUND Amyotrophic lateral sclerosis (ALS)-linked fused in sarcoma/translocated in liposarcoma (FUS/TLS or FUS) is concentrated within cytoplasmic stress granules under conditions of induced stress.", "offsetInBeginSection": 0, "offsetInEndSection": 202, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26777405", "text": "Moreover, multiple ATP-driven machines affect stress granules differently, with the CCT complex inhibiting stress granule assembly, while the MCM and RVB complexes promote stress granule persistence.", "offsetInBeginSection": 614, "offsetInEndSection": 813, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26777405", "text": "Stress granules are mRNA-protein granules that form when translation initiation is limited, and they are related to pathological granules in various neurodegenerative diseases.", "offsetInBeginSection": 0, "offsetInEndSection": 176, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23074858", "text": "Stress granules--temporary RNP structures that are formed in cells under stress.", "offsetInBeginSection": 0, "offsetInEndSection": 80, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a733efc2dc08e987e000016", "body": "Describe Achenbach\u2019s syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20512338", "http://www.ncbi.nlm.nih.gov/pubmed/34491356", "http://www.ncbi.nlm.nih.gov/pubmed/17943645", "http://www.ncbi.nlm.nih.gov/pubmed/26238661", "http://www.ncbi.nlm.nih.gov/pubmed/1754834", "http://www.ncbi.nlm.nih.gov/pubmed/22413886", "http://www.ncbi.nlm.nih.gov/pubmed/14676163", "http://www.ncbi.nlm.nih.gov/pubmed/24982130", "http://www.ncbi.nlm.nih.gov/pubmed/24283429", "http://www.ncbi.nlm.nih.gov/pubmed/20609160"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/4017281", "text": "), Thrombocytopenia Absent Radii Syndrome (T.A.R.", "offsetInBeginSection": 161, "offsetInEndSection": 210, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/4017281", "text": "Various degrees of bone marrow aplasia have been described in association with distinctive congenital anomalies such as the Fanconi Pancytopenia Syndrome (F.P.S.", "offsetInBeginSection": 0, "offsetInEndSection": 161, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/4017281", "text": "Syndrome) the Aase Syndrome and Diamond-Blackfan Anemia.", "offsetInBeginSection": 211, "offsetInEndSection": 267, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6703533", "text": "Authors describe the phenotype and review the literature on this syndrome.", "offsetInBeginSection": 159, "offsetInEndSection": 233, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17326116", "text": "Although there is considerable variability, most individuals with Down syndrome have mental retardation and speech and language deficits, particularly in language production and syntax and poor speech intelligibility.", "offsetInBeginSection": 0, "offsetInEndSection": 217, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17326116", "text": "Next, we describe language development in Down syndrome, focusing on communication behaviors in the prelinguistic period, then the development of language in children and adolescents, and finally language development in adults and the aging period.", "offsetInBeginSection": 489, "offsetInEndSection": 737, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17326116", "text": "We describe language development in individuals with Down syndrome across four domains: phonology, semantics, syntax, and pragmatics.", "offsetInBeginSection": 738, "offsetInEndSection": 871, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17326116", "text": "This article describes research findings in the language and communication development of individuals with Down syndrome, first briefly describing the physical and cognitive phenotype of Down syndrome, and two communication related domains-hearing and oral motor skills.", "offsetInBeginSection": 218, "offsetInEndSection": 488, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23565480", "text": "Also included are less well-described presentations of Wolframs syndrome.", "offsetInBeginSection": 268, "offsetInEndSection": 341, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/112864", "text": "The oculocerebrofacial syndrome was described from siblings of both sexes in 1971 by Kaufman.", "offsetInBeginSection": 0, "offsetInEndSection": 93, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a774e40faa1ab7d2e000007", "body": "Is there a link between nuclear position and DNA repair pathway choice?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27266837", "http://www.ncbi.nlm.nih.gov/pubmed/33285474", "http://www.ncbi.nlm.nih.gov/pubmed/25366693", "http://www.ncbi.nlm.nih.gov/pubmed/24155929", "http://www.ncbi.nlm.nih.gov/pubmed/25463437", "http://www.ncbi.nlm.nih.gov/pubmed/28732204", "http://www.ncbi.nlm.nih.gov/pubmed/35278769", "http://www.ncbi.nlm.nih.gov/pubmed/27799300", "http://www.ncbi.nlm.nih.gov/pubmed/27604033", "http://www.ncbi.nlm.nih.gov/pubmed/28689661"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/25366693", "text": "Our results are consistent with a model in which nuclear position dictates the choice of DNA repair pathway, thus revealing a new level of regulation in DSB repair controlled by spatial organization of DNA within the nucleus.", "offsetInBeginSection": 912, "offsetInEndSection": 1137, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27266837", "text": "We aim to highlight the importance of chromatin state along with the nuclear position of the DNA lesions on the choice of DNA repair pathway and maintenance of genome integrity.", "offsetInBeginSection": 544, "offsetInEndSection": 721, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25463437", "text": "Regulation of DNA repair pathway choice is crucial to avoid genomic instability.", "offsetInBeginSection": 556, "offsetInEndSection": 636, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25463437", "text": "In yeast, DSBs are mobile and can scan the entire nucleus to be repaired in specialized DNA repair centers or if they are persistent, in order to associate with the nuclear pores or the nuclear envelope where they can be repaired by specialized repair pathways.", "offsetInBeginSection": 637, "offsetInEndSection": 898, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28689661", "text": "Thus, the spatial and temporal control of acetyl-CoA production by ACLY participates in the mechanism of DNA repair pathway choice.", "offsetInBeginSection": 974, "offsetInEndSection": 1105, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24320053", "text": "In this review, we have summarized recent advances in understanding the role of 53BP1 in regulating DNA DSBs repair pathway choice, variable diversity joining [V(D)J] recombination and class-switch recombination (CSR).", "offsetInBeginSection": 670, "offsetInEndSection": 888, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23811932", "text": "Our work indicates that cell cycle position has a key role in DNA repair pathway choice and that recruitment of chromatin regulators is tightly coupled to homologous recombination.", "offsetInBeginSection": 750, "offsetInEndSection": 930, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15650050", "text": "DNA-damaging agents activate the monoubiquitination of FANCD2, resulting in its targeting to nuclear foci that also contain BRCA1 and BRCA2/FANCD1, proteins involved in homology-directed DNA repair.", "offsetInBeginSection": 439, "offsetInEndSection": 637, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15650050", "text": "These results suggest an early role for the FANC proteins in homologous DSB repair pathway choice.", "offsetInBeginSection": 1419, "offsetInEndSection": 1517, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24155929", "text": "Little is known about the network that controls the repair pathway choice except that a licensing step for homology-mediated repair exists, called DNA-end resection.", "offsetInBeginSection": 174, "offsetInEndSection": 339, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a992eac1d1251d03b00000c", "body": "Can non ubiquitinated Tomm20 promote mitophagy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27503909", "http://www.ncbi.nlm.nih.gov/pubmed/34145219", "http://www.ncbi.nlm.nih.gov/pubmed/32829253", "http://www.ncbi.nlm.nih.gov/pubmed/32049477", "http://www.ncbi.nlm.nih.gov/pubmed/36402066", "http://www.ncbi.nlm.nih.gov/pubmed/36217215", "http://www.ncbi.nlm.nih.gov/pubmed/34844982", "http://www.ncbi.nlm.nih.gov/pubmed/35534260", "http://www.ncbi.nlm.nih.gov/pubmed/20890124", "http://www.ncbi.nlm.nih.gov/pubmed/35502680"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26071202", "text": "These results suggest that pyruvate is required for CCCP-induced PINK1/PARK2-mediated mitophagy.", "offsetInBeginSection": 1091, "offsetInEndSection": 1187, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26071202", "text": "Damaged mitochondria are targeted for degradation by an autophagy pathway known as mitophagy.", "offsetInBeginSection": 0, "offsetInEndSection": 93, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20890124", "text": "Similarly, mitochondrial-anchored ubiquitin is sufficient to recruit p62 and promote mitochondrial clustering, but does not promote mitophagy.", "offsetInBeginSection": 1210, "offsetInEndSection": 1352, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20890124", "text": "Additionally, we find VDAC1 and VDAC3 are dispensable for the recruitment of p62, mitochondrial clustering and mitophagy.", "offsetInBeginSection": 1637, "offsetInEndSection": 1758, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26943044", "text": "Here, we detected mitophagy deficits evidenced by the increased levels of mitophagy markers, including COX IV, TOMM20, and the ratio of mtDNA to genomic DNA indexed as mt-Atp6/Rpl13, in the AD brains and in the human wild type full-length tau (htau) transgenic mice.", "offsetInBeginSection": 179, "offsetInEndSection": 445, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21705204", "text": "Proteasomal degradation of the outer mitochondrial membrane (OMM) protein Mcl1 regulates apoptosis whereas Parkin-mediated ubiquitination and degradation of Mitofusins can inhibit mitochondrial fusion and promote mitophagy.", "offsetInBeginSection": 342, "offsetInEndSection": 565, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25972374", "text": "Selective autophagy adaptor proteins, including p62/SQSTM1, play pivotal roles in the targeted degradation of ubiquitinated proteins or organelles through the autophagy-lysosome system.", "offsetInBeginSection": 0, "offsetInEndSection": 185, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25972374", "text": "Our results suggest that TBK1-mediated S403 phosphorylation regulates the efficient autophagosomal engulfment of ubiquitinated mitochondria as an immediate response to the mitochondrial depolarization.", "offsetInBeginSection": 1030, "offsetInEndSection": 1231, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29097221", "text": "Our data showed that resveratrol attenuated A\u03b21-42-induced cell death and significantly enhanced mitophagy including an increase in acidic vesicular organelle number, LC3-II/LC3-I ratio, Parkin and Beclin-1 expression, and LC3 and TOMM20 co-localization in A\u03b21-42-treated PC12 cells.", "offsetInBeginSection": 491, "offsetInEndSection": 776, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25634658", "text": "Damaged mitochondria can be degraded by a selective type of autophagy, which is termed mitophagy.", "offsetInBeginSection": 98, "offsetInEndSection": 195, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aa304f1d6d6b54f79000004", "body": "Is the consumption of chocolate associated with an increase in cardiovascular disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21666964", "http://www.ncbi.nlm.nih.gov/pubmed/34483344", "http://www.ncbi.nlm.nih.gov/pubmed/29931040", "http://www.ncbi.nlm.nih.gov/pubmed/27493901", "http://www.ncbi.nlm.nih.gov/pubmed/20858571", "http://www.ncbi.nlm.nih.gov/pubmed/16794457", "http://www.ncbi.nlm.nih.gov/pubmed/24139727", "http://www.ncbi.nlm.nih.gov/pubmed/30061161", "http://www.ncbi.nlm.nih.gov/pubmed/26076934", "http://www.ncbi.nlm.nih.gov/pubmed/22684995"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27493901", "text": "BACKGROUND The consumption of chocolate and cocoa has established cardiovascular benefits.", "offsetInBeginSection": 0, "offsetInEndSection": 90, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22653982", "text": "OBJECTIVE To model the long term effectiveness and cost effectiveness of daily dark chocolate consumption in a population with metabolic syndrome at high risk of cardiovascular disease.", "offsetInBeginSection": 0, "offsetInEndSection": 185, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22653982", "text": "CONCLUSIONS The blood pressure and cholesterol lowering effects of dark chocolate consumption are beneficial in the prevention of cardiovascular events in a population with metabolic syndrome.", "offsetInBeginSection": 1308, "offsetInEndSection": 1500, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22653982", "text": "Daily dark chocolate consumption could be an effective cardiovascular preventive strategy in this population.", "offsetInBeginSection": 1501, "offsetInEndSection": 1610, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21666964", "text": "Data currently available indicate that daily consumption of cocoa-rich chocolate (rich in polyphenols) may at least partially lower cardiovascular disease risk.", "offsetInBeginSection": 505, "offsetInEndSection": 665, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23225768", "text": "CONCLUSIONS High consumption of sugar-sweetened beverages and low intake of breakfast cereals, jam and honey, sweets and chocolate and nut-based spreads seem to adversely affect clustered CVD risk.", "offsetInBeginSection": 2137, "offsetInEndSection": 2334, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21875885", "text": "The highest levels of chocolate consumption were associated with a 37% reduction in cardiovascular disease (relative risk 0.63 (95% confidence interval 0.44 to 0.90)) and a 29% reduction in stroke compared with the lowest levels.", "offsetInBeginSection": 1581, "offsetInEndSection": 1810, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16390538", "text": "BACKGROUND Consumption of chocolate has been often hypothesized to reduce the risk of cardiovascular disease (CVD) due to chocolate's high levels of stearic acid and antioxidant flavonoids.", "offsetInBeginSection": 0, "offsetInEndSection": 189, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16390538", "text": "RESULTS The body of short-term randomized feeding trials suggests cocoa and chocolate may exert beneficial effects on cardiovascular risk via effects on lowering blood pressure, anti-inflammation, anti-platelet function, higher HDL, decreased LDL oxidation.", "offsetInBeginSection": 857, "offsetInEndSection": 1114, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18827977", "text": "Accumulating evidence from the past 10 years demonstrates that moderate consumption of chocolate, especially dark chocolate, may exert protective effects against the development of cardiovascular disease.", "offsetInBeginSection": 187, "offsetInEndSection": 391, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aacd38efcf4565872000006", "body": "Is DNA polymerase \u03b8 involved in DNA repair?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25851856", "http://www.ncbi.nlm.nih.gov/pubmed/26514729", "http://www.ncbi.nlm.nih.gov/pubmed/36028228", "http://www.ncbi.nlm.nih.gov/pubmed/35753097", "http://www.ncbi.nlm.nih.gov/pubmed/28824932", "http://www.ncbi.nlm.nih.gov/pubmed/30299084", "http://www.ncbi.nlm.nih.gov/pubmed/25775267", "http://www.ncbi.nlm.nih.gov/pubmed/27453047", "http://www.ncbi.nlm.nih.gov/pubmed/24989122", "http://www.ncbi.nlm.nih.gov/pubmed/26484154"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27264557", "text": "DNA polymerase theta (pol \u03b8) is encoded in the genomes of many eukaryotes, though not in fungi.", "offsetInBeginSection": 0, "offsetInEndSection": 96, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25775267", "text": "DNA polymerase \u03b8 protects against genomic instability via an alternative end-joining repair pathway for DNA double-strand breaks.", "offsetInBeginSection": 0, "offsetInEndSection": 130, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28542210", "text": "One of these proteins, DNA Polymerase \u03b8 (Pol \u03b8), coordinates a mutagenic DSB repair pathway named microhomology-mediated end joining (MMEJ) and is also a critical component for bypass or repair of ICLs in several organisms.", "offsetInBeginSection": 171, "offsetInEndSection": 396, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24989122", "text": "Although DNA polymerase \u03b8 (Pol \u03b8) is known to carry out translesion synthesis and has been implicated in DNA repair, its physiological function under normal growth conditions remains unclear.", "offsetInBeginSection": 0, "offsetInEndSection": 193, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28695890", "text": "Here we show that DNA polymerase \u03b8, despite its minor role in chromosomal DNA repair, substantially contributes to random integration, and that cells lacking both DNA polymerase \u03b8 and DNA ligase IV, which is essential for non-homologous end joining (NHEJ), exhibit 100% efficiency of spontaneous gene targeting by virtue of undetectable levels of random integration.", "offsetInBeginSection": 267, "offsetInEndSection": 635, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28695890", "text": "Thus, DNA polymerase \u03b8-mediated end joining is the sole homology-independent repair route in the absence of NHEJ and, intriguingly, their combined absence reveals rare Alu-Alu recombination events utilizing a stretch of homology.", "offsetInBeginSection": 636, "offsetInEndSection": 866, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26514729", "text": "DNA polymerase theta (Pol \u03b8) is an error-prone A-family polymerase that is highly conserved among multicellular eukaryotes and plays multiple roles in DNA repair and the regulation of genome integrity.", "offsetInBeginSection": 0, "offsetInEndSection": 202, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26484154", "text": "The physiological function of the human DNA polymerase \u03b8 (pol \u03b8) is still unclear despite its in vitro translesion synthesis capacity during DNA damage repair process.", "offsetInBeginSection": 0, "offsetInEndSection": 169, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28668117", "text": "DNA polymerase theta (pol \u03b8) is an evolutionarily conserved protein encoded by the POLQ gene in mammalian genomes.", "offsetInBeginSection": 0, "offsetInEndSection": 115, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25851856", "text": "New research shows that DNA polymerase \u03b8 is a key player in PARP-mediated DNA damage repair and essential for the survival of cancer cells where homologous recombination is compromised.", "offsetInBeginSection": 0, "offsetInEndSection": 186, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a7341fe2dc08e987e000018", "body": "What is the link between lithium use during pregnancy and Ebstein anomaly?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/2743779", "http://www.ncbi.nlm.nih.gov/pubmed/2666104", "http://www.ncbi.nlm.nih.gov/pubmed/1346886", "http://www.ncbi.nlm.nih.gov/pubmed/16611133", "http://www.ncbi.nlm.nih.gov/pubmed/8031346", "http://www.ncbi.nlm.nih.gov/pubmed/31701245", "http://www.ncbi.nlm.nih.gov/pubmed/6518066", "http://www.ncbi.nlm.nih.gov/pubmed/22400907", "http://www.ncbi.nlm.nih.gov/pubmed/27521009", "http://www.ncbi.nlm.nih.gov/pubmed/18982835"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/8031346", "text": "DATA EXTRACTION AND SYNTHESIS In the 1970s a very strong association was suggested between maternal lithium treatment during pregnancy and Ebstein's anomaly of the heart in the offspring.", "offsetInBeginSection": 426, "offsetInEndSection": 613, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2743779", "text": "Some studies suggest that lithium might be involved as a teratogen increasing the incidence of Ebstein's anomaly in the offspring of female patients with manio-depressive psychosis and lithium-administered during pregnancy.", "offsetInBeginSection": 74, "offsetInEndSection": 297, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28591541", "text": "BACKGROUND There has been concern that exposure to lithium early in pregnancy may be associated with a marked increase in the risk of Ebstein's anomaly (a right ventricular outflow tract obstruction defect) in infants and overall congenital cardiac defects, but data are conflicting and limited.", "offsetInBeginSection": 0, "offsetInEndSection": 295, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28591541", "text": "CONCLUSIONS Maternal use of lithium during the first trimester was associated with an increased risk of cardiac malformations, including Ebstein's anomaly; the magnitude of this effect was smaller than had been previously postulated.", "offsetInBeginSection": 1719, "offsetInEndSection": 1952, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1346886", "text": "In-utero exposure to lithium during the first trimester of pregnancy might be associated with an increased risk of cardiac malformations, especially the rare Ebstein's anomaly.", "offsetInBeginSection": 99, "offsetInEndSection": 275, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1346886", "text": "Lithium carbonate is an effective drug for prophylaxis and treatment of major affective disorders.", "offsetInBeginSection": 0, "offsetInEndSection": 98, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16611133", "text": "There is a possibility that, in particular, lithium may be associated with the Ebstein anomaly but present evidence cannot definitely affirm or deny this association.", "offsetInBeginSection": 373, "offsetInEndSection": 539, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12114921", "text": "Reported neonatal problems with maternal lithium therapy include Ebstein's anomaly, poor respiratory effort and cyanosis, rhythm disturbances, nephrogenic diabetes insipidus, thyroid dysfunction, hypoglycemia, hypotonia and lethargy, hyperbilirubinemia, and large-for-gestational-age infants.", "offsetInBeginSection": 383, "offsetInEndSection": 675, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24781368", "text": "CONCLUSIONS Lithium treatment in pregnancy is associated with a higher rate of cardiovascular anomalies.", "offsetInBeginSection": 1708, "offsetInEndSection": 1812, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15702702", "text": "A profound ultrasound screening of the organs should be performed in case of lithium exposition, whereas newer studies showed no increase in risk for Ebstein anomaly.", "offsetInBeginSection": 1154, "offsetInEndSection": 1320, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a774fdcfaa1ab7d2e000008", "body": "Which protein is regulated by Tudor interacting repair regulator (TIRR)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36288694", "http://www.ncbi.nlm.nih.gov/pubmed/29844495", "http://www.ncbi.nlm.nih.gov/pubmed/33961797", "http://www.ncbi.nlm.nih.gov/pubmed/30002377", "http://www.ncbi.nlm.nih.gov/pubmed/28241136", "http://www.ncbi.nlm.nih.gov/pubmed/31911551", "http://www.ncbi.nlm.nih.gov/pubmed/28213517", "http://www.ncbi.nlm.nih.gov/pubmed/31497746", "http://www.ncbi.nlm.nih.gov/pubmed/25627688", "http://www.ncbi.nlm.nih.gov/pubmed/34287990"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28241136", "text": "Here we identify an uncharacterized protein, Tudor interacting repair regulator (TIRR), that directly binds the tandem Tudor domain and masks its H4K20me2 binding motif.", "offsetInBeginSection": 424, "offsetInEndSection": 593, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28241136", "text": "Upon DNA damage, the protein kinase ataxia-telangiectasia mutated (ATM) phosphorylates 53BP1 and recruits RAP1-interacting factor 1 (RIF1) to dissociate the 53BP1-TIRR complex.", "offsetInBeginSection": 594, "offsetInEndSection": 770, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28241136", "text": "P53-binding protein 1 (53BP1) is a multi-functional double-strand break repair protein that is essential for class switch recombination in B lymphocytes and for sensitizing BRCA1-deficient tumours to poly-ADP-ribose polymerase-1 (PARP) inhibitors.", "offsetInBeginSection": 0, "offsetInEndSection": 247, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28213517", "text": "In this study, we identified the Tudor-interacting repair regulator (TIRR) that specifically associates with the ionizing radiation-induced foci formation region of 53BP1.", "offsetInBeginSection": 627, "offsetInEndSection": 798, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20713134", "text": "In the present study, we identified the molecular interactions between Plasmodium falciparum Tudor-SN and twelve Plasmodium proteins such as Histone h2A, SPT2 (a transcriptional regulator), a Cold-shock DNA binding protein in a bacterial two-hybrid screen.", "offsetInBeginSection": 511, "offsetInEndSection": 767, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20713134", "text": "Tudor Staphylococcal Nuclease (p100 or SND1), a member of the micronuclease family is a multifunctional protein that plays a key role(s) in transcription and splicing processes in many eukaryotic cells.", "offsetInBeginSection": 0, "offsetInEndSection": 202, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22493508", "text": "Human Tudor staphylococcal nuclease (Tudor-SN) is composed of four tandem repeats of staphylococcal nuclease (SN)-like domains, followed by a tudor and SN-like domain (TSN) consisting of a central tudor flanked by two partial SN-like sequences.", "offsetInBeginSection": 0, "offsetInEndSection": 244, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29118143", "text": "A family of Tudor domain proteins regulates the piRNA pathway through direct Tudor domain-PIWI interactions.", "offsetInBeginSection": 165, "offsetInEndSection": 273, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29118143", "text": "Unlike most other Tudor domains, the extended Tudor domain of mammalian Tudor domain-containing protein 2 (TDRD2) preferentially recognizes an unmethylated arginine-rich sequence from PIWI-like protein 1 (PIWIL1).", "offsetInBeginSection": 493, "offsetInEndSection": 706, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21915143", "text": "Tudor proteins are now known to be present in PIWI complexes, where they are thought to interact with methylated PIWI proteins and regulate the PIWI-interacting RNA (piRNA) pathway in the germ line.", "offsetInBeginSection": 633, "offsetInEndSection": 831, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a9931cd1d1251d03b00000d", "body": "Does SARM1 deletion cause neurodegeneration?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27797810", "http://www.ncbi.nlm.nih.gov/pubmed/34001261", "http://www.ncbi.nlm.nih.gov/pubmed/28978465", "http://www.ncbi.nlm.nih.gov/pubmed/35431772", "http://www.ncbi.nlm.nih.gov/pubmed/31661035", "http://www.ncbi.nlm.nih.gov/pubmed/35863521", "http://www.ncbi.nlm.nih.gov/pubmed/34910914", "http://www.ncbi.nlm.nih.gov/pubmed/36054436", "http://www.ncbi.nlm.nih.gov/pubmed/36171479", "http://www.ncbi.nlm.nih.gov/pubmed/30842236"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27797810", "text": "Hence, genetic deletion of SARM1 blocks the development of vincristine-induced peripheral polyneuropathy in mice.", "offsetInBeginSection": 1936, "offsetInEndSection": 2049, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24993772", "text": "However, recent reports have indicated that neurons express the key players of innate immunity, including Toll-like receptors (TLRs) and their adaptor proteins (Sarm1, Myd88, and Trif), and may produce cytokines in response to pathogen infection.", "offsetInBeginSection": 195, "offsetInEndSection": 441, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16269331", "text": "Deletion of CSPalpha produces rapidly progressive neurodegeneration in mice, presumably because the cochaperone function of CSPalpha is essential for neuronal survival.", "offsetInBeginSection": 283, "offsetInEndSection": 451, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16269331", "text": "Alpha-synuclein and cysteine-string protein-alpha (CSPalpha) are abundant synaptic vesicle proteins independently linked to neurodegeneration.", "offsetInBeginSection": 0, "offsetInEndSection": 142, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21487023", "text": "Ectopic expression of human ALS-causing FUS/TLS mutations in Drosophila caused an accumulation of ubiquitinated proteins, neurodegeneration, larval-crawling defect and early lethality.", "offsetInBeginSection": 301, "offsetInEndSection": 485, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28095293", "text": "Injury-induced (Wallerian) axonal degeneration is regulated via the opposing actions of pro-degenerative factors such as SARM1 and a MAPK signal and pro-survival factors, the most important of which is the NAD+ biosynthetic enzyme NMNAT2 that inhibits activation of the SARM1 pathway.", "offsetInBeginSection": 0, "offsetInEndSection": 284, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23885119", "text": "SARM1, which is known to be an adaptor protein for Toll-like receptor, binds to PINK1 and promotes TRAF6-mediated lysine 63 chain ubiquitination of PINK1 at lysine 433.", "offsetInBeginSection": 636, "offsetInEndSection": 804, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23885119", "text": "These results indicate that association of PINK1 with SARM1 and TRAF6 is an important step for mitophagy.", "offsetInBeginSection": 1016, "offsetInEndSection": 1121, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23885119", "text": "Mutations in PTEN-induced putative kinase 1 (PINK1) or parkin cause autosomal recessive forms of Parkinson's disease.", "offsetInBeginSection": 0, "offsetInEndSection": 117, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23885119", "text": "In this study, we find that PINK1 forms a complex with sterile \u03b1 and TIR motif containing 1 (SARM1) and tumor necrosis factor receptor-associated factor 6 (TRAF6), which is important for import of PINK1 in the outer membrane and stabilization of PINK1 on depolarized mitochondria.", "offsetInBeginSection": 354, "offsetInEndSection": 635, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aa55b65d6d6b54f7900000e", "body": "Please list 6 symptoms of Scarlet fever.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33448168", "http://www.ncbi.nlm.nih.gov/pubmed/18923666", "http://www.ncbi.nlm.nih.gov/pubmed/12503666", "http://www.ncbi.nlm.nih.gov/pubmed/30571828", "http://www.ncbi.nlm.nih.gov/pubmed/29081840", "http://www.ncbi.nlm.nih.gov/pubmed/1919136", "http://www.ncbi.nlm.nih.gov/pubmed/18801598", "http://www.ncbi.nlm.nih.gov/pubmed/33134206", "http://www.ncbi.nlm.nih.gov/pubmed/15164635", "http://www.ncbi.nlm.nih.gov/pubmed/10961536"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/11086489", "text": "A further 6 children, outside of this class, had complaints of scarlet fever, impetigo or pharyngitis.", "offsetInBeginSection": 711, "offsetInEndSection": 813, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1919136", "text": "Reinfection or relapse cases of scarlet fever were found in 6.7% (642/9,585).", "offsetInBeginSection": 1542, "offsetInEndSection": 1619, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1919136", "text": "6.", "offsetInBeginSection": 608, "offsetInEndSection": 610, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26585817", "text": "CONCLUSION Scarlet fever pharyngotonsillitis differs from the traditional streptococcal pharyngotonsillitis, and its evaluation using clinical prediction rules such as Centor or McIsaac is questionable.", "offsetInBeginSection": 1354, "offsetInEndSection": 1556, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19868695", "text": "Scarlatinal antistreptococcic serum affords some degree of protection against virulent scarlet fever streptococci but has no protective power against hemolytic streptococci from other diseases.", "offsetInBeginSection": 987, "offsetInEndSection": 1180, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19868695", "text": "6.", "offsetInBeginSection": 867, "offsetInEndSection": 869, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2772682", "text": "The severity of symptoms and the demonstration of scarlet fever developing from infection with this organism supports antibiotic treatment of patients with group C streptococcal pharyngitis.", "offsetInBeginSection": 444, "offsetInEndSection": 634, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/3284506", "text": "An extra- and intra-hepatic bile duct dilatation has been observed in a child in the course of scarlet fever.", "offsetInBeginSection": 0, "offsetInEndSection": 109, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28468073", "text": "The ratio between numbers of scarlet fever cases and streptococcal infection was 1 \u2236 38.17.", "offsetInBeginSection": 1315, "offsetInEndSection": 1408, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19871154", "text": "The scarlet fever toxin-antitoxin reaction is discussed in relation to other flocculation reactions.", "offsetInBeginSection": 1033, "offsetInEndSection": 1133, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aacd83ffcf4565872000008", "body": "What is PARP inhibitor (PARPi) resistance?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/31421928", "http://www.ncbi.nlm.nih.gov/pubmed/30658107", "http://www.ncbi.nlm.nih.gov/pubmed/33324554", "http://www.ncbi.nlm.nih.gov/pubmed/28302823", "http://www.ncbi.nlm.nih.gov/pubmed/34439286", "http://www.ncbi.nlm.nih.gov/pubmed/30954761", "http://www.ncbi.nlm.nih.gov/pubmed/31106005", "http://www.ncbi.nlm.nih.gov/pubmed/35332131", "http://www.ncbi.nlm.nih.gov/pubmed/31118216", "http://www.ncbi.nlm.nih.gov/pubmed/35892198"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/23103855", "text": "Importantly, PARPi resistance was minimized by long-term treatment with the novel PARP inhibitor AZD2461, which is a poor P-glycoprotein substrate.", "offsetInBeginSection": 695, "offsetInEndSection": 842, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23103855", "text": "We previously reported that BRCA1-deficient mouse mammary tumors may acquire resistance to the clinical PARP inhibitor (PARPi) olaparib through activation of the P-glycoprotein drug efflux transporter.", "offsetInBeginSection": 147, "offsetInEndSection": 348, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28255272", "text": "Therefore, the concept to block PARP enzymes by PARP inhibitor (PARPi) was appreciated in cancer treatment.", "offsetInBeginSection": 253, "offsetInEndSection": 360, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28588062", "text": "High-grade epithelial ovarian carcinomas containing mutated BRCA1 or BRCA2 (BRCA1/2) homologous recombination (HR) genes are sensitive to platinum-based chemotherapy and PARP inhibitors (PARPi), while restoration of HR function due to secondary mutations in BRCA1/2 has been recognized as an important resistance mechanism.", "offsetInBeginSection": 0, "offsetInEndSection": 323, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28069876", "text": "Olaparib is an FDA-approved PARP inhibitor (PARPi) that has shown promise as a synthetic lethal treatment approach for BRCA-mutant castration-resistant prostate cancer (CRPC) in clinical use.", "offsetInBeginSection": 0, "offsetInEndSection": 191, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28242626", "text": "ATR inhibitors (ATRis) disrupt BRCA1-independent RAD51 loading to DSBs and stalled forks in PARPi-resistant BRCA1-deficient cells, overcoming both resistance mechanisms.", "offsetInBeginSection": 769, "offsetInEndSection": 938, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27454289", "text": "Patients with cancers that harbor breast cancer 1 (BRCA1) mutations initially respond well to platinum and poly(ADP-ribose) polymerase inhibitor (PARPi) therapy; however, resistance invariably arises in these patients and is a major clinical problem.", "offsetInBeginSection": 0, "offsetInEndSection": 250, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27454289", "text": "Ectopic overexpression of Rdd-BRCA1 promoted partial PARPi and cisplatin resistance.", "offsetInBeginSection": 1264, "offsetInEndSection": 1348, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26984416", "text": "Demonstration of anti-cancer activity has led to the European Medicines Agency (EMA) approval of the PARP inhibitor (PARPi) olaparib as maintenance therapy in women with BRCA-mutated (BRCAm) ovarian cancer with platinum-sensitive recurrence following response to platinum therapy and the US Food and Drug Administration (US FDA) approval of olaparib in relapsed germline BRCA-mutated (gBRCAm) ovarian cancer in women who have received at least three prior chemotherapy treatments, both occurring in 2014.", "offsetInBeginSection": 145, "offsetInEndSection": 649, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28450426", "text": "Approximately 20% of metastatic prostate cancers harbor mutations in genes required for DNA repair by homologous recombination repair (HRR) such as BRCA2 HRR defects confer synthetic lethality to PARP inhibitors (PARPi) such as olaparib and talazoparib.", "offsetInBeginSection": 0, "offsetInEndSection": 253, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a7347a02dc08e987e00001b", "body": "Gallbladder carriage is a well recognised means of spread of which bacteria?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24349565", "http://www.ncbi.nlm.nih.gov/pubmed/33370414", "http://www.ncbi.nlm.nih.gov/pubmed/31575775", "http://www.ncbi.nlm.nih.gov/pubmed/23732169", "http://www.ncbi.nlm.nih.gov/pubmed/30936374", "http://www.ncbi.nlm.nih.gov/pubmed/23077595", "http://www.ncbi.nlm.nih.gov/pubmed/29373578", "http://www.ncbi.nlm.nih.gov/pubmed/28018582", "http://www.ncbi.nlm.nih.gov/pubmed/25253258", "http://www.ncbi.nlm.nih.gov/pubmed/7903779"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28018582", "text": "BACKGROUND Asymptomatic carriage has been recognised as an important risk factor for infection caused by antibiotic resistant bacteria.", "offsetInBeginSection": 0, "offsetInEndSection": 135, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23171127", "text": "Because intestinal carriage is a key factor in the epidemiology of ESBL-producing Enterobacteriaceae, the study of the prevalence of these resistant bacteria and risk factors in young children is of particular interest.", "offsetInBeginSection": 428, "offsetInEndSection": 647, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23171127", "text": "The fecal flora of children in the community can represent a reservoir for ESBLs genes which are located on highly transmissible plasmids and the spread of these genes among bacterial pathogens is concerning.", "offsetInBeginSection": 219, "offsetInEndSection": 427, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25206941", "text": "DESIGN We screened for the presence of aerobic and anaerobic ESBL-producing bacteria and bla CTX-M in supragingival plaque samples from healthy human adults with culture-verified fecal carriage of CTX-M-producing Escherichia coli.", "offsetInBeginSection": 726, "offsetInEndSection": 956, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25206941", "text": "Enterobacteriaceae are commonly found in the gastrointestinal tract and long-term intestinal carriage is considered important for the spread of ESBL and as a source of clinical infections.", "offsetInBeginSection": 202, "offsetInEndSection": 390, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25206941", "text": "OBJECTIVE To investigate possible carriage of ESBL-producing bacteria in supragingival plaque of known fecal carriers of these bacteria.", "offsetInBeginSection": 587, "offsetInEndSection": 723, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25206941", "text": "Oral biofilm such as supragingival plaque is known to contain numerous antibiotic resistance determinants and may also represent a poorly investigated site for ESBL carriage and further spread.", "offsetInBeginSection": 391, "offsetInEndSection": 584, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26420505", "text": "An interesting biological phenomenon that is a factor for the spread of antibiotic-resistant strains, such as MRSA, is human nasal carriage.", "offsetInBeginSection": 0, "offsetInEndSection": 140, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25926879", "text": "We find that while no benefit is conferred by phage carriage in single bacterial infections, phages confer a large fitness advantage during mixed infections by mediating bacteria-bacteria competition.", "offsetInBeginSection": 612, "offsetInEndSection": 812, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22873676", "text": "Carriage means pneumococcal colonization.", "offsetInBeginSection": 172, "offsetInEndSection": 213, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a775182faa1ab7d2e000009", "body": "What is the role of tankyrases in response to Double Strand Breaks (DSBs)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27375678", "http://www.ncbi.nlm.nih.gov/pubmed/20543558", "http://www.ncbi.nlm.nih.gov/pubmed/23268447", "http://www.ncbi.nlm.nih.gov/pubmed/28357369", "http://www.ncbi.nlm.nih.gov/pubmed/23953933", "http://www.ncbi.nlm.nih.gov/pubmed/23847781", "http://www.ncbi.nlm.nih.gov/pubmed/23486281", "http://www.ncbi.nlm.nih.gov/pubmed/26615196", "http://www.ncbi.nlm.nih.gov/pubmed/28624372", "http://www.ncbi.nlm.nih.gov/pubmed/25252681"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26845027", "text": "The Mediator of DNA damage Checkpoint protein 1 (MDC1) is essential for spreading of the DDR signaling on chromatin surrounding Double Strand Breaks (DSBs) by acting as a scaffold for PI3K kinases and for ubiquitin ligases.", "offsetInBeginSection": 179, "offsetInEndSection": 402, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28477128", "text": "DNA damaging agents such as ionizing irradiation induce lesions in the DNA such as double strand breaks (DSBs).", "offsetInBeginSection": 0, "offsetInEndSection": 111, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16205111", "text": "Double strand breaks (DSBs) are arguably the most deleterious DNA lesion that a cell can sustain, and defects in the ability to detect and repair these breaks result in increased genomic instability and have been causatively linked to cancer.", "offsetInBeginSection": 0, "offsetInEndSection": 242, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20423312", "text": "Among several types of DNA lesions, the DNA double strand breaks (DSBs) are one of the most deleterious and harmful.", "offsetInBeginSection": 0, "offsetInEndSection": 116, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23209566", "text": "Recruitment of 53BP1 to chromatin flanking double strand breaks (DSBs) requires \u03b3H2AX/MDC1/RNF8-dependent ubiquitination of chromatin and interaction of 53BP1 with histone H4 methylated on lysine 20 (H4K20me).", "offsetInBeginSection": 0, "offsetInEndSection": 210, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20543558", "text": "The protein kinases ATM and DNA-PKcs play critical roles in the cellular response to DNA double strand breaks (DSBs).", "offsetInBeginSection": 0, "offsetInEndSection": 117, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11114307", "text": "Following challenge with proinflammatory stimuli or generation of DNA double strand breaks (DSBs), transcription factor NF-kappaB translocates from the cytoplasm to the nucleus to activate expression of target genes.", "offsetInBeginSection": 0, "offsetInEndSection": 216, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17088286", "text": "While PARP-1 has been firmly implicated in base excision and single strand break repair, its role in the repair of DNA double strand breaks (DSBs) remains unclear.", "offsetInBeginSection": 327, "offsetInEndSection": 490, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23144634", "text": "In contrast, the appearance of \u03b3H2AX and phosphorylated ATM at sites of laser generated double strand breaks (DSBs) is CtIP-independent.", "offsetInBeginSection": 609, "offsetInEndSection": 746, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27375678", "text": "The cellular response to DNA double strand breaks (DSBs) is a multifaceted signaling program that centers on post-translational modifications including phosphorylation, ubiquitylation and SUMOylation.", "offsetInBeginSection": 0, "offsetInEndSection": 200, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a9ac4161d1251d03b000010", "body": "Does MC1R palmitoylation reduce pigmentation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28869973", "http://www.ncbi.nlm.nih.gov/pubmed/17962522", "http://www.ncbi.nlm.nih.gov/pubmed/34362555", "http://www.ncbi.nlm.nih.gov/pubmed/23977400", "http://www.ncbi.nlm.nih.gov/pubmed/30787281", "http://www.ncbi.nlm.nih.gov/pubmed/12439754", "http://www.ncbi.nlm.nih.gov/pubmed/22572817", "http://www.ncbi.nlm.nih.gov/pubmed/31251842", "http://www.ncbi.nlm.nih.gov/pubmed/22797298", "http://www.ncbi.nlm.nih.gov/pubmed/30267482"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28869973", "text": "Here we demonstrate a potential MC1R-targeted intervention strategy in mice to rescue loss-of-function MC1R in MC1R RHC variants for therapeutic benefit by activating MC1R protein palmitoylation.", "offsetInBeginSection": 729, "offsetInEndSection": 924, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28869973", "text": "Using C57BL/6J-Mc1re/eJ mice, in which endogenous MC1R is prematurely terminated, expressing Mc1r RHC variants, we show that pharmacological activation of palmitoylation rescues the defects of Mc1r RHC variants and prevents melanomagenesis.", "offsetInBeginSection": 1206, "offsetInEndSection": 1446, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28869973", "text": "The results highlight a central role for MC1R palmitoylation in pigmentation and protection against melanoma.", "offsetInBeginSection": 1447, "offsetInEndSection": 1556, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28869973", "text": "Individuals carrying MC1R variants, especially those associated with red hair colour, fair skin and poor tanning ability (denoted as RHC variants), are associated with higher risk of melanoma.", "offsetInBeginSection": 303, "offsetInEndSection": 495, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17962522", "text": "Functional analyses show that this variant reduces MC1R activity to a level that alters hair and/or skin pigmentation in humans.", "offsetInBeginSection": 407, "offsetInEndSection": 535, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28916587", "text": "Palmitoylation-deficient MC1R variants accelerate BRAFV60E-driven melanomagenesis.", "offsetInBeginSection": 0, "offsetInEndSection": 82, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16877522", "text": "Taken together, our results strongly suggest that MC1R350 acts as a negative regulator of skin pigmentation and demonstrate for the first time that MC1R isoform-specific expression is closely related to skin pigmentation and photoprotection.", "offsetInBeginSection": 1138, "offsetInEndSection": 1379, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16988713", "text": "Here we show that ultraviolet light potently induces expression of MSH in keratinocytes, but fails to stimulate pigmentation in the absence of functional MC1R in red/blonde-haired Mc1r(e/e) mice.", "offsetInBeginSection": 390, "offsetInEndSection": 585, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16988713", "text": "However, pigmentation could be rescued by topical application of the cyclic AMP agonist forskolin, without the need for ultraviolet light, demonstrating that the pigmentation machinery is available despite the absence of functional MC1R.", "offsetInBeginSection": 586, "offsetInEndSection": 823, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18282187", "text": "We are designing potent melanocortin analogs that mimic the effects of alpha-MSH as a strategy to prevent skin cancer, particularly in individuals who express MC1R genotypes that reduce but do not abolish MC1R function, or mutations in other melanoma susceptibility genes, such as p16.", "offsetInBeginSection": 1172, "offsetInEndSection": 1457, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a96c886fcd1d6a10c00002a", "body": "A bite from the Lone Star Tick Amblyomma americanum, can cause the victim to become allergic to red meat, yes or no?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35309294", "http://www.ncbi.nlm.nih.gov/pubmed/31156631", "http://www.ncbi.nlm.nih.gov/pubmed/28319627", "http://www.ncbi.nlm.nih.gov/pubmed/32928302", "http://www.ncbi.nlm.nih.gov/pubmed/33372012", "http://www.ncbi.nlm.nih.gov/pubmed/25108787", "http://www.ncbi.nlm.nih.gov/pubmed/35146342", "http://www.ncbi.nlm.nih.gov/pubmed/31936588", "http://www.ncbi.nlm.nih.gov/pubmed/32522461", "http://www.ncbi.nlm.nih.gov/pubmed/31877783"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28319627", "text": "Amblyomma americanum, also known as the lone star tick, is found in much of the eastern United States.", "offsetInBeginSection": 0, "offsetInEndSection": 102, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24690977", "text": "A link has been discovered between the bite of the Lone Star Tick (Amblyomma americanum) and the development of sensitivity to galactose-\u03b1-1,3-galactose.", "offsetInBeginSection": 359, "offsetInEndSection": 513, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25108787", "text": "The Lone Star tick, Amblyomma americanum Linnaeus 1758 (Acari; Ixodidae), causes considerable production losses to the southern U.S. cattle industry due to reduced weight, infertility, secondary infections at bite wound sites, damaged hides, and potentially death, as these ticks tend to infest livestock in large numbers.", "offsetInBeginSection": 0, "offsetInEndSection": 322, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25108787", "text": "Increased expression of IGHG1, IL6, IL1\u03b1, and IL1RN in bovine tick bite-site biopsies suggests that Th2 differentiation may be important for the local bovine response to A. americanum ticks.", "offsetInBeginSection": 1357, "offsetInEndSection": 1548, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21940418", "text": "The EM-like eruptions, which were of unknown etiology, often followed the bite of the Lone Star tick (Amblyomma americanum) and the rash is called STARI (southern tick-associated rash illness).", "offsetInBeginSection": 194, "offsetInEndSection": 387, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17848069", "text": "Two infectious diseases, and one presumably infectious disease, each vectored by or associated with the bite of the lone star tick (Amblyomma americanum), were identified and characterized by clinicians and scientists in the United States during the 1980s and 1990s.", "offsetInBeginSection": 0, "offsetInEndSection": 266, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18447622", "text": "Amblyomma americanum, the lone star tick, comprised 99.6% of 6,502 specimens collected in suburban landscapes.", "offsetInBeginSection": 368, "offsetInEndSection": 478, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/477386", "text": "The tick (Amblyomma americanum, the \"lone star\" tick) was still attached to the erythematous, indurated skin of the upper back.", "offsetInBeginSection": 55, "offsetInEndSection": 182, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/14596284", "text": "The maculatum agent, Rickettsia parkeri (a member of the spotted fever group rickettsiae), was inoculated into a colony of the lone star tick, Amblyomma americanum, and followed for two tick generations.", "offsetInBeginSection": 0, "offsetInEndSection": 203, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19054615", "text": "We reviewed scientific literature pertaining to known and putative disease agents associated with the lone star tick, Amblyomma americanum.", "offsetInBeginSection": 0, "offsetInEndSection": 139, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aad547efcf456587200000b", "body": "What is the \"protein inference problem\"?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27975221", "http://www.ncbi.nlm.nih.gov/pubmed/23385215", "http://www.ncbi.nlm.nih.gov/pubmed/19645593", "http://www.ncbi.nlm.nih.gov/pubmed/17990506", "http://www.ncbi.nlm.nih.gov/pubmed/33900766", "http://www.ncbi.nlm.nih.gov/pubmed/22954624", "http://www.ncbi.nlm.nih.gov/pubmed/25707552", "http://www.ncbi.nlm.nih.gov/pubmed/22331862", "http://www.ncbi.nlm.nih.gov/pubmed/26935399", "http://www.ncbi.nlm.nih.gov/pubmed/22626983"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26935399", "text": "In fact, the protein inference problem can be regarded as a special protein quantification problem in the sense that truly present proteins are those proteins whose abundance values are not zero.", "offsetInBeginSection": 433, "offsetInEndSection": 628, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26935399", "text": "Thus, we argue that the protein inference problem can be viewed as a special protein quantification problem in which one protein is considered to be present if its abundance is not zero.", "offsetInBeginSection": 1180, "offsetInEndSection": 1366, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26935399", "text": "This demonstrates that it is plausible to model the protein inference problem as a special protein quantification task, which opens the door of devising more effective protein inference algorithms from a quantification perspective.", "offsetInBeginSection": 1638, "offsetInEndSection": 1869, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23385215", "text": "Based on the concept of peptide detectability, we formulate the protein inference problem as a constrained Lasso regression problem, which can be solved very efficiently through a coordinate descent procedure.", "offsetInBeginSection": 451, "offsetInEndSection": 660, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22954624", "text": "Based on this simple fact, the protein inference problem is formulated as an optimization problem: minimize the number of proteins with non-zero probabilities under the constraint that the difference between the calculated peptide probability and the peptide probability generated from peptide identification algorithms should be less than some threshold.", "offsetInBeginSection": 774, "offsetInEndSection": 1129, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22954624", "text": "Experimental results show that our method is competitive with the state-of-the-art protein inference algorithms.", "offsetInBeginSection": 1402, "offsetInEndSection": 1514, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17990506", "text": "A major challenge in shotgun proteomics has been the assignment of identified peptides to the proteins from which they originate, referred to as the protein inference problem.", "offsetInBeginSection": 0, "offsetInEndSection": 175, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19645593", "text": "The protein inference problem represents a major challenge in shotgun proteomics.", "offsetInBeginSection": 0, "offsetInEndSection": 81, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15262821", "text": "Based on a variant of kernel canonical correlation analysis, its originality is in the formalization of the protein network inference problem as a supervised learning problem, and in the integration of heterogeneous genomic data within this framework.", "offsetInBeginSection": 562, "offsetInEndSection": 813, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20562346", "text": "Empirical results on two control datasets with synthetic mixtures of proteins and on complex protein samples of Saccharomyces cerevisiae, Drosophila melanogaster, and Arabidopsis thaliana suggest that the results with MIPGEM are competitive with existing tools for protein inference.", "offsetInBeginSection": 791, "offsetInEndSection": 1074, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a736f0c3b9d13c708000007", "body": "What is included in the Mentzer index?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35634613", "http://www.ncbi.nlm.nih.gov/pubmed/35386733", "http://www.ncbi.nlm.nih.gov/pubmed/6185967", "http://www.ncbi.nlm.nih.gov/pubmed/19579993", "http://www.ncbi.nlm.nih.gov/pubmed/32989178", "http://www.ncbi.nlm.nih.gov/pubmed/18192142", "http://www.ncbi.nlm.nih.gov/pubmed/17476506", "http://www.ncbi.nlm.nih.gov/pubmed/31568184", "http://www.ncbi.nlm.nih.gov/pubmed/24818016", "http://www.ncbi.nlm.nih.gov/pubmed/34497231"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24818016", "text": "The patient groups were evaluated according to red blood cell (RBC) count; red blood distribution width index; the Mentzer, Shine and Lal, England and Fraser, Srivastava and Bevington, Green and King, Ricerca, Sirdah, and Ehsani indices; mean density of hemoglobin/liter of blood; and mean cell density of hemoglobin.", "offsetInBeginSection": 636, "offsetInEndSection": 953, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24818016", "text": "The Mentzer index provided the highest reliabilities for differentiating \u03b2 -TT from IDA.", "offsetInBeginSection": 1245, "offsetInEndSection": 1334, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24818016", "text": "The Mentzer index was the most reliable index, as it had the highest sensitivity (98.7%), specificity (82.3%), and Youden's index (81%) for detecting \u03b2 -TT; this was followed by the Ehsani index (94.8%, 73.5%, and 68.3%, resp.)", "offsetInBeginSection": 963, "offsetInEndSection": 1191, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19579993", "text": "The best discrimination index according to Youden's criteria was Mentzer (Youden's index = 90.1) followed by the new index (Youden's index = 85.5).", "offsetInBeginSection": 676, "offsetInEndSection": 823, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19579993", "text": "Sensitivity, specificity and Youden's index were compared between the proposed index and four other indices, namely England-Fraser, Mentzer, Srivastava and RBC count.", "offsetInBeginSection": 368, "offsetInEndSection": 534, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24388269", "text": "METHODS The oral manifestations and mean red blood cell (RBC) count, corpuscular cell volume, RBC distribution width, Mentzer index, and Green and King index as well as blood concentrations of hemoglobin, iron, total iron binding capacity, vitamin B12, folic acid, and homocysteine in 75 IDA patients and in 150 age- and sex-matched healthy controls were measured and compared.", "offsetInBeginSection": 220, "offsetInEndSection": 597, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28706390", "text": "Youden index of the Mentzer index (MI) was the highest (69.0) and S and L, the lowest (13.2) indicating MI to be the most efficient and the S and L, the least in differentiating the two entities.", "offsetInBeginSection": 868, "offsetInEndSection": 1063, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24139948", "text": "METHODS The oral manifestations and mean red blood cell count, corpuscular cell volume, red blood cell distribution width, Mentzer index, and Green and King index as well as blood concentrations of hemoglobin, iron, total iron binding capacity, vitamin B12, folic acid, and homocysteine in 65 TT patients and in 130 age- and sex-matched healthy controls were measured and compared.", "offsetInBeginSection": 214, "offsetInEndSection": 595, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23321282", "text": "Discrimination power of seven indices to differentiate between IDA and \u03b2TT, such as Green and King Index (GKI), RDW Index (RDWI), Srivastava Index (SRI), Mentzer Index (MI), Shine and Lal Index (SLI), Ehsani Index (EI), and Sirdah Index (SI), were evaluated.", "offsetInBeginSection": 158, "offsetInEndSection": 417, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8162086", "text": "Mentzer ratio MCV/RBC detected all cases of beta thalassemia but was a poor index for iron deficiency detection.", "offsetInBeginSection": 776, "offsetInEndSection": 888, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a804f71faa1ab7d2e00001d", "body": "Which algorithm is used for detection of long repeat expansions?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35672336", "http://www.ncbi.nlm.nih.gov/pubmed/33031558", "http://www.ncbi.nlm.nih.gov/pubmed/34389037", "http://www.ncbi.nlm.nih.gov/pubmed/9401013", "http://www.ncbi.nlm.nih.gov/pubmed/15096564", "http://www.ncbi.nlm.nih.gov/pubmed/16258159", "http://www.ncbi.nlm.nih.gov/pubmed/22581592", "http://www.ncbi.nlm.nih.gov/pubmed/32345345", "http://www.ncbi.nlm.nih.gov/pubmed/30503517", "http://www.ncbi.nlm.nih.gov/pubmed/9674981"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/9674981", "text": "Here, the repeat expansion detection (RED) method was used to screen for CAG repeat expansion in 119 French BPAD patients.", "offsetInBeginSection": 286, "offsetInEndSection": 408, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15096564", "text": "It proved useful for confirming the presence of large expansions in the Friedreich ataxia gene following an ambiguous result of long-range PCR, as well as rapid pre-screening for large repeat expansions associated with Friedreich ataxia and SCA10 and the shorter repeat expansions associated with SCA12.", "offsetInBeginSection": 399, "offsetInEndSection": 702, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15096564", "text": "Here we describe a successful application of a fluorescent PCR method for the detection of expanded repeats in FRDA1, SCA10, and SCA12 genes.", "offsetInBeginSection": 84, "offsetInEndSection": 225, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24215022", "text": "MOTIVATION Long expansions of short tandem repeats (STRs), i.e.", "offsetInBeginSection": 0, "offsetInEndSection": 63, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24215022", "text": "Our method could also identify common STRs, (AAAG)- and (AAAAG)-repeat expansions, which are remarkably expanded at four positions in an SCA31 sample.", "offsetInBeginSection": 1068, "offsetInEndSection": 1218, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11562783", "text": "We have developed a cloning approach which isolates disease genes containing trinucleotide repeat expansions.", "offsetInBeginSection": 288, "offsetInEndSection": 397, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22581592", "text": "To improve and expedite the diagnostic methods for progressive myoclonus epilepsy (EPM1), myotonic dystrophy 2 (DM2) and spinocerebellar ataxia 8 (SCA8) caused by dynamic mutations, we adapted a repeat primed PCR (RP-PCR) assay which was previously developed for testing of other triplet repeat disorders.", "offsetInBeginSection": 278, "offsetInEndSection": 583, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22581592", "text": "CONCLUSIONS Here, for the first time, we report detection of large expansions in EPM1 and SCA8 patients.", "offsetInBeginSection": 1446, "offsetInEndSection": 1550, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9002673", "text": "We also provide standards and control data for the detection of other trinucleotide repeat expansions.", "offsetInBeginSection": 1409, "offsetInEndSection": 1511, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9002673", "text": "Our study, therefore, demonstrates that the application of the RED assay to a population of probands and a population of controls allows the detection of small-scale CTG/CAG repeat expansions in the size range of the expanded HD gene and present in a single allele.", "offsetInBeginSection": 1143, "offsetInEndSection": 1408, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a9ac4e81d1251d03b000011", "body": "Which brain tumors does neuroligin-3 promote?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26032268", "http://www.ncbi.nlm.nih.gov/pubmed/25957677", "http://www.ncbi.nlm.nih.gov/pubmed/34373757", "http://www.ncbi.nlm.nih.gov/pubmed/25913192", "http://www.ncbi.nlm.nih.gov/pubmed/34485271", "http://www.ncbi.nlm.nih.gov/pubmed/18555979", "http://www.ncbi.nlm.nih.gov/pubmed/31002480", "http://www.ncbi.nlm.nih.gov/pubmed/16624946", "http://www.ncbi.nlm.nih.gov/pubmed/18161851", "http://www.ncbi.nlm.nih.gov/pubmed/34262438"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28959975", "text": "An important mechanism that mediates this neural regulation of brain cancer is activity-dependent cleavage and secretion of the synaptic adhesion molecule neuroligin-3 (NLGN3), which promotes glioma proliferation through the PI3K-mTOR pathway.", "offsetInBeginSection": 605, "offsetInEndSection": 848, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16300891", "text": "This study indicates that synaptogenetic processes in brain and retina use different molecular machineries, whereby the neuroligins might represent the more distinctly regulated part of the neurexin-neuroligin complexes.", "offsetInBeginSection": 1046, "offsetInEndSection": 1266, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26032268", "text": "published in Cell has identified Neuroligin-3 (NLGN3) as a mitogen promoting high-grade glioma growth.", "offsetInBeginSection": 227, "offsetInEndSection": 329, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18555979", "text": "Recent studies reported that sequence polymorphisms in neuroligin-3 (NLGN3) and neuroligin-4 (NLGN4) genes have been linked to autism spectrum disorders indicating neuroligin genes as candidate targets in brain disorders.", "offsetInBeginSection": 82, "offsetInEndSection": 303, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25957677", "text": "demonstrate that this also occurs in the brain, identifying neuronal activity-induced secretion of neuroligin-3 as a novel mechanism promoting glioma proliferation.", "offsetInBeginSection": 153, "offsetInEndSection": 317, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24854097", "text": "In this study, we characterized the expression of a gene involved in synaptogenesis and plasticity (neuroligin-3) and one that codes for the rate-limiting enzyme in dopamine biosynthesis (tyrosine hydroxylase; TH1) in the female Xiphophorus nigrensis (northern swordtail) brain as related to mate preference behavior.", "offsetInBeginSection": 409, "offsetInEndSection": 726, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24854097", "text": "Analysis of TH and neuroligin-3 expression across different brain regions showed that expression patterns varied with the male social environment only for neuroligin-3, where the density of correlated expression between brain regions was positively associated with mate choice contexts that involved a greater number of courting male phenotypes (LS and LL).", "offsetInBeginSection": 1373, "offsetInEndSection": 1730, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23248271", "text": "Likewise, coexpression of both MDGA1 and neuroligin-2 reduced the synaptogenic capacity of neuroligin-2 in an artificial synapse-formation assay by abolishing the ability of neuroligin-2 to form an adhesion complex with neurexins.", "offsetInBeginSection": 995, "offsetInEndSection": 1225, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18974885", "text": "Transcripts of neurexin I and one neuroligin tested were abundant in mushroom bodies, a higher order processing centre in the bee brain.", "offsetInBeginSection": 1331, "offsetInEndSection": 1467, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23583622", "text": "Rare mutations in neuroligins and neurexins predispose to autism, including a neuroligin-3 amino acid substitution (R451C) and a neuroligin-3 deletion.", "offsetInBeginSection": 95, "offsetInEndSection": 246, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a96f40cfcd1d6a10c00002b", "body": "What is calciphylaxis", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21410615", "http://www.ncbi.nlm.nih.gov/pubmed/29714030", "http://www.ncbi.nlm.nih.gov/pubmed/32434389", "http://www.ncbi.nlm.nih.gov/pubmed/16108246", "http://www.ncbi.nlm.nih.gov/pubmed/36274216", "http://www.ncbi.nlm.nih.gov/pubmed/18693159", "http://www.ncbi.nlm.nih.gov/pubmed/10426913", "http://www.ncbi.nlm.nih.gov/pubmed/22892472", "http://www.ncbi.nlm.nih.gov/pubmed/16564932", "http://www.ncbi.nlm.nih.gov/pubmed/32528755"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/10764004", "text": "Key Words: Calciphylaxis, parathyroid hormone, parathyroidectomy, skin necrosis, chronic renal failure.", "offsetInBeginSection": 2001, "offsetInEndSection": 2104, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10764004", "text": "OBJECTIVE Calciphylaxis, a rare disorder typically affecting renal failure patients, results in vascular calcification with subsequent skin necrosis, gangrene, and often death from sepsis.", "offsetInBeginSection": 0, "offsetInEndSection": 188, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27321367", "text": "WHAT IS NEW AND CONCLUSION Previously only few cases of solely warfarin-induced calciphylaxis have been described.", "offsetInBeginSection": 450, "offsetInEndSection": 564, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27321367", "text": "WHAT IS KNOWN AND OBJECTIVE Calciphylaxis is a rare and potentially life-threatening cause of skin necrosis and is poorly recognized by clinicians in non-uraemic patients.", "offsetInBeginSection": 0, "offsetInEndSection": 171, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20019019", "text": "Although calciphylaxis is most frequently associated with end-stage renal disease (ESRD) and secondary hyperparathyroidism, it has been reported infrequently among patients on warfarin.", "offsetInBeginSection": 158, "offsetInEndSection": 343, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23663061", "text": "Calciphylaxis is a metastatic calcification-induced vasculopathy that results in the occlusion of small blood vessels.", "offsetInBeginSection": 0, "offsetInEndSection": 118, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23663061", "text": "Although calciphylaxis is normally associated with end-stage renal disease, calciphylaxis from non-uremic origin occurs as well.", "offsetInBeginSection": 119, "offsetInEndSection": 247, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26779700", "text": "Calciphylaxis is characterized by calcification in the medium and small vessel arterioles and can be a life-threatening complication often associated with chronic kidney disease (CKD).", "offsetInBeginSection": 0, "offsetInEndSection": 184, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26779700", "text": "There is no definitive evidence to support the belief current epidemic rates of obesity, diabetes, (diabesity), and chronic renal disease will predispose more patients to the development of calciphylaxis.", "offsetInBeginSection": 1006, "offsetInEndSection": 1210, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21324820", "text": "A multidisciplinary approach involving early diagnosis, aggressive medical management, operative debridement, and parathyroidectomy has the best chance of improving survival in calciphylaxis.", "offsetInBeginSection": 1580, "offsetInEndSection": 1771, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a9d79ca1d1251d03b00001d", "body": "Is the gene CDKN2A nevogenic?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12406345", "http://www.ncbi.nlm.nih.gov/pubmed/9598804", "http://www.ncbi.nlm.nih.gov/pubmed/32157655", "http://www.ncbi.nlm.nih.gov/pubmed/28830827", "http://www.ncbi.nlm.nih.gov/pubmed/9664128", "http://www.ncbi.nlm.nih.gov/pubmed/9290958", "http://www.ncbi.nlm.nih.gov/pubmed/9052747", "http://www.ncbi.nlm.nih.gov/pubmed/10620111", "http://www.ncbi.nlm.nih.gov/pubmed/9537438", "http://www.ncbi.nlm.nih.gov/pubmed/35004697"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/10620111", "text": "1), supporting the view that CDKN2A is nevogenic.", "offsetInBeginSection": 602, "offsetInEndSection": 651, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15304099", "text": "Continued accumulation of nevi in mutation carriers supports a nevogenic role for this CDKN2A mutation.", "offsetInBeginSection": 1154, "offsetInEndSection": 1257, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28830827", "text": "Our results support the hypothesis that unidentified nevogenic genes are co-inherited with CDKN2A and may influence carcinogenesis.", "offsetInBeginSection": 1187, "offsetInEndSection": 1318, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9049204", "text": "The tumor suppressor gene CDKN2A (MTS1/p16), located on chromosome 9p21, is inactivated in a variety of tumors including melanomas and tumors of the biliary tract, pancreas, and stomach.", "offsetInBeginSection": 0, "offsetInEndSection": 186, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9052747", "text": "The tumour-suppressor gene CDKN2A (p16, MTS1, CDK4I) encodes a cell cycle-regulatory protein and is located on chromosome 9p21, a region deleted in a wide variety of human cancers.", "offsetInBeginSection": 0, "offsetInEndSection": 180, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9052747", "text": "In conclusion, homozygous deletions, mutations and the de novo methylation of 5' CpG island are not frequent modes of inactivation of the CDKN2A gene in ovarian cancer.", "offsetInBeginSection": 1143, "offsetInEndSection": 1311, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15761864", "text": "Germ-line mutations of the tumor-suppressor gene CDKN2A predispose individuals to melanoma in families worldwide.", "offsetInBeginSection": 0, "offsetInEndSection": 113, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9537438", "text": "The status and the expression of cyclin-dependent kinase inhibitor A (CDKN2A) family genes, named CDKN2A, CDKN2B, and CDKN2C and of cyclin Ds (D1, D2, and D3) genes were investigated in 14 cases of human hepatoblastomas.", "offsetInBeginSection": 0, "offsetInEndSection": 220, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9537438", "text": "These genes were selected because: 1) CDKN2A and CDKN2B are very frequently inactivated in human cancers; 2) cyclin Ds are overexpressed in several tumors and 3) CDKN2A is posttranscriptionally silenced in hepatocellular carcinomas.", "offsetInBeginSection": 221, "offsetInEndSection": 453, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10471040", "text": "The tumour suppressor gene CDKN2A, located on chromosome 9p21, encodes the cell cycle regulatory protein p16.", "offsetInBeginSection": 0, "offsetInEndSection": 109, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a7373f63b9d13c708000008", "body": "Which disease is treated with Fexinidazole?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/31840685", "http://www.ncbi.nlm.nih.gov/pubmed/22301556", "http://www.ncbi.nlm.nih.gov/pubmed/21911566", "http://www.ncbi.nlm.nih.gov/pubmed/30670439", "http://www.ncbi.nlm.nih.gov/pubmed/29275007", "http://www.ncbi.nlm.nih.gov/pubmed/30635838", "http://www.ncbi.nlm.nih.gov/pubmed/36437273", "http://www.ncbi.nlm.nih.gov/pubmed/35925555", "http://www.ncbi.nlm.nih.gov/pubmed/28552771", "http://www.ncbi.nlm.nih.gov/pubmed/22539226"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/22301556", "text": "Here, we report that fexinidazole, a drug currently in phase 1 clinical trials for treating African trypanosomiasis, shows promise for treating visceral leishmaniasis.", "offsetInBeginSection": 192, "offsetInEndSection": 359, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22301556", "text": "These findings illustrate the potential of fexinidazole as an oral drug therapy for treating visceral leishmaniasis.", "offsetInBeginSection": 1547, "offsetInEndSection": 1663, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23133682", "text": "CONCLUSIONS Fexinidazole is an effective oral treatment of acute and chronic experimental CD caused by benznidazole-susceptible, partially resistant, and resistant T. cruzi.", "offsetInBeginSection": 1832, "offsetInEndSection": 2005, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23133682", "text": "Fexinidazole, a 2-subsituted 5-nitroimidazole drug candidate rediscovered following extensive compound mining by the Drugs for Neglected Diseases initiative and currently in Phase I clinical study for the treatment of human African trypanosomiasis, was evaluated in experimental models of acute and chronic CD caused by different strains of Trypanosoma cruzi.", "offsetInBeginSection": 290, "offsetInEndSection": 649, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24841257", "text": "Fexinidazole metabolites were effective in treating T. cruzi in a mouse model of acute infection, with cure rates superior to those achieved with either fexinidazole itself or benznidazole.", "offsetInBeginSection": 1540, "offsetInEndSection": 1729, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29113731", "text": "Therefore, we aimed to assess the safety and efficacy of an oral regimen of fexinidazole (a 2-substituted 5-nitroimidazole with proven trypanocidal activity) versus nifurtimox eflornithine combination therapy in patients with late-stage g-HAT.", "offsetInBeginSection": 451, "offsetInEndSection": 694, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29113731", "text": "INTERPRETATION Our findings show that oral fexinidazole is effective and safe for the treatment of T b gambiense infection compared with nifurtimox eflornithine combination therapy in late-stage HAT patients.", "offsetInBeginSection": 3213, "offsetInEndSection": 3421, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28552771", "text": "In the search for new therapeutics, the repurposing of the broad-spectrum antiprotozoal drug fexinidazole has completed Phase III trials with the anticipation that it will be the first oral treatment for HAT.", "offsetInBeginSection": 149, "offsetInEndSection": 357, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21911566", "text": "Fexinidazole is a 5-nitroimidazole drug currently in clinical development for the treatment of human sleeping sickness (human African trypanosomiasis [HAT]), caused by infection with species of the protozoan parasite Trypanosoma brucei.", "offsetInBeginSection": 0, "offsetInEndSection": 236, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24535888", "text": "BACKGROUND AND OBJECTIVES Fexinidazole is a 5-nitroimidazole recently included in a clinical efficacy trial as an oral drug for the treatment of human African trypanosomiasis (HAT).", "offsetInBeginSection": 0, "offsetInEndSection": 181, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a8056a2faa1ab7d2e00001f", "body": "Which web resource for LIR motif-containing proteins in eukaryotes has been developed?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24589857", "http://www.ncbi.nlm.nih.gov/pubmed/32507889", "http://www.ncbi.nlm.nih.gov/pubmed/11522919", "http://www.ncbi.nlm.nih.gov/pubmed/27484196", "http://www.ncbi.nlm.nih.gov/pubmed/28806134", "http://www.ncbi.nlm.nih.gov/pubmed/19962898", "http://www.ncbi.nlm.nih.gov/pubmed/35820026", "http://www.ncbi.nlm.nih.gov/pubmed/11752247", "http://www.ncbi.nlm.nih.gov/pubmed/12519985", "http://www.ncbi.nlm.nih.gov/pubmed/36386889"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27484196", "text": "Atg8-interacting proteins contain a short linear LC3-interacting region/LC3 recognition sequence/Atg8-interacting motif (LIR/LRS/AIM) motif which is responsible for their interaction with Atg8-family proteins.", "offsetInBeginSection": 901, "offsetInEndSection": 1110, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28806134", "text": "Here, we have developed the iLIR@viral database ( http://ilir.uk/virus/ ) as a freely accessible web resource listing all the putative canonical LIR motifs identified in viral proteins.", "offsetInBeginSection": 744, "offsetInEndSection": 929, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28806134", "text": "Additionally, we used a curated text-mining analysis of the literature to identify novel putative LIR motif-containing proteins (LIRCPs) in viruses.", "offsetInBeginSection": 930, "offsetInEndSection": 1078, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24589857", "text": "Given an amino acid sequence as input, iLIR searches for instances of short sequences compliant with a refined sensitive regular expression pattern of the extended LIR motif (xLIR-motif) and retrieves characterized protein domains from the SMART database for the query.", "offsetInBeginSection": 1255, "offsetInEndSection": 1524, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24589857", "text": "Known SARs are characterized by a short linear sequence motif (LIR-, LRS-, or AIM-motif) responsible for the interaction between SARs and proteins of the Atg8 family.", "offsetInBeginSection": 374, "offsetInEndSection": 540, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28320742", "text": "Among HyD-LIR-GFP sensors harboring LIR motifs of 34 known LC3-binding proteins, HyD-LIR(TP)-GFP using the LIR motif from TP53INP2 allowed detection of all LC3/GABARAPs-positive autophagosomes.", "offsetInBeginSection": 411, "offsetInEndSection": 604, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28320742", "text": "Here, we developed new sensors that detect endogenous LC3/GABARAP proteins at the autophagosome using an LC3-interacting region (LIR) and a short hydrophobic domain (HyD).", "offsetInBeginSection": 239, "offsetInEndSection": 410, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28320742", "text": "In contrast, HyD-LIR(Fy)-GFP using the LIR motif from FYCO1 specifically detected LC3A/B-positive autophagosomes.", "offsetInBeginSection": 727, "offsetInEndSection": 840, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28253953", "text": "We also describe a biophysical method for studying interactions between Atg8/LC3/GABARAP and LIR-containing proteins and a protocol for preparation and purification of LIR peptides.", "offsetInBeginSection": 1518, "offsetInEndSection": 1699, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28253953", "text": "Here, we present protocols for the identification of LIR-containing proteins, i.e., by yeast-two-hybrid screening, glutathione S-transferase (GST) pulldown experiments, and peptide arrays.", "offsetInBeginSection": 1180, "offsetInEndSection": 1368, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a9ac6821d1251d03b000012", "body": "How does neuronal activity affect neuroligin-3?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34845591", "http://www.ncbi.nlm.nih.gov/pubmed/28067903", "http://www.ncbi.nlm.nih.gov/pubmed/31002480", "http://www.ncbi.nlm.nih.gov/pubmed/25565602", "http://www.ncbi.nlm.nih.gov/pubmed/26032268", "http://www.ncbi.nlm.nih.gov/pubmed/27725662", "http://www.ncbi.nlm.nih.gov/pubmed/32985166", "http://www.ncbi.nlm.nih.gov/pubmed/25957677", "http://www.ncbi.nlm.nih.gov/pubmed/17582332", "http://www.ncbi.nlm.nih.gov/pubmed/23776533"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26032268", "text": "published in Cell has identified Neuroligin-3 (NLGN3) as a mitogen promoting high-grade glioma growth.", "offsetInBeginSection": 227, "offsetInEndSection": 329, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27725662", "text": "Strikingly, developmentally early conditional knockout of cerebellin-1 only modestly impaired synaptic transmission, whereas in contrast to the individual single knockouts, developmentally early conditional double knockout of both cerebellin-1 and neuroligin-3 severely decreased synaptic transmission.", "offsetInBeginSection": 1216, "offsetInEndSection": 1518, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27725662", "text": "Mutations in neuroligin-3 predispose to autism, but how such mutations affect synaptic function remains incompletely understood.", "offsetInBeginSection": 89, "offsetInEndSection": 217, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28959975", "text": "An important mechanism that mediates this neural regulation of brain cancer is activity-dependent cleavage and secretion of the synaptic adhesion molecule neuroligin-3 (NLGN3), which promotes glioma proliferation through the PI3K-mTOR pathway.", "offsetInBeginSection": 605, "offsetInEndSection": 848, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15150161", "text": "Our findings suggest that the previously identified mutations in neuroligin genes are likely to be relevant for the neuro-developmental defects in autism-spectrum disorders and mental retardation since they impair the function of a synaptic cell adhesion molecule.", "offsetInBeginSection": 982, "offsetInEndSection": 1246, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28067903", "text": "As a result, the neuroligin-3 deletion altered network activity by reducing gamma oscillations and sharp wave ripples, changes associated with a decrease in extinction of contextual fear memories.", "offsetInBeginSection": 669, "offsetInEndSection": 865, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28067903", "text": "Here we show that conditional deletion of the postsynaptic cell adhesion molecule neuroligin-3 in parvalbumin interneurons causes a decrease in NMDA-receptor-mediated postsynaptic currents and an increase in presynaptic glutamate release probability by selectively impairing the inhibition of glutamate release by presynaptic Group III metabotropic glutamate receptors.", "offsetInBeginSection": 299, "offsetInEndSection": 668, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28067903", "text": "These results demonstrate that neuroligin-3 specifies the properties of excitatory synapses on parvalbumin-containing interneurons by a retrograde trans-synaptic mechanism and suggest a molecular pathway whereby neuroligin-3 mutations contribute to neuropsychiatric disorders.", "offsetInBeginSection": 866, "offsetInEndSection": 1142, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19406211", "text": "The neuroligin (NL) gene family codes for brain specific cell adhesion molecules that play an important role in synaptic connectivity.", "offsetInBeginSection": 0, "offsetInEndSection": 134, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24619977", "text": "While some of these genes reach genome-wide significance, others, such as the R451C point mutation in the synaptic cell adhesion molecule neuroligin-3, appear to be rare.", "offsetInBeginSection": 77, "offsetInEndSection": 247, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a9700adfcd1d6a10c00002c", "body": "Sclerostin regulates what process?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22082361", "http://www.ncbi.nlm.nih.gov/pubmed/20043874", "http://www.ncbi.nlm.nih.gov/pubmed/30071108", "http://www.ncbi.nlm.nih.gov/pubmed/25030653", "http://www.ncbi.nlm.nih.gov/pubmed/28571484", "http://www.ncbi.nlm.nih.gov/pubmed/29349060", "http://www.ncbi.nlm.nih.gov/pubmed/35038187", "http://www.ncbi.nlm.nih.gov/pubmed/23737439", "http://www.ncbi.nlm.nih.gov/pubmed/21890009", "http://www.ncbi.nlm.nih.gov/pubmed/24152444"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/23737439", "text": "We found that sclerostin upregulated osteocyte expression of carbonic anhydrase 2 (CA2/Car2), cathepsin K (CTSK/Ctsk), and tartrate-resistant acid phosphatase (ACP5/Acp5).", "offsetInBeginSection": 636, "offsetInEndSection": 807, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23737439", "text": "Knockdown in MLO-Y4 cells of each of the putative sclerostin receptors, Lrp4, Lrp5 and Lrp6, using siRNA, inhibited the sclerostin induction of Car2, Catk and Acp5 mRNA, as well as pHo and calcium release.", "offsetInBeginSection": 1496, "offsetInEndSection": 1701, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23737439", "text": "The osteocyte product sclerostin is emerging as an important paracrine regulator of bone mass.", "offsetInBeginSection": 0, "offsetInEndSection": 94, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28571484", "text": "In humans, the SOST gene encodes sclerostin, an inhibitor of bone growth and remodeling, which also negatively regulates the bone repair process.", "offsetInBeginSection": 0, "offsetInEndSection": 145, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28081119", "text": "Sclerostin secreted by osteocytes is mechanosensory and important in bone remodeling.", "offsetInBeginSection": 87, "offsetInEndSection": 172, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25030653", "text": "Therefore, adaptive bone remodeling occurring at a distinct bone compartment is orchestrated by altered sclerostin levels, which regulate the expression of the other osteocyte-specific proteins, such as RANKL, OPG, and proteins encoded by \"mineralization-related genes\" (DMP1, PHEX, and probably FGF23).", "offsetInBeginSection": 1104, "offsetInEndSection": 1407, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25030653", "text": "For example, under specific terms, sclerostin regulates differential RANKL and OPG production, and creates a dynamic RANKL/OPG ratio, leading either to bone formation or resorption.", "offsetInBeginSection": 1408, "offsetInEndSection": 1589, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21890009", "text": "Sclerostin is a secreted inhibitor of Wnt signaling and plays an essential role in the regulation of bone mass.", "offsetInBeginSection": 0, "offsetInEndSection": 111, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22082361", "text": "Sclerostin, an osteocyte-expressed negative regulator of bone formation, is one of the inhibitors of Wnt signaling that is a critical pathway in the correct process of osteoblast differentiation.", "offsetInBeginSection": 0, "offsetInEndSection": 195, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20043874", "text": "Sclerostin, a secreted glycoprotein, regulates osteoblast function.", "offsetInBeginSection": 0, "offsetInEndSection": 67, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a9d7caa1d1251d03b00001e", "body": "What is Alzheimers disease resilience?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28078981", "http://www.ncbi.nlm.nih.gov/pubmed/32582728", "http://www.ncbi.nlm.nih.gov/pubmed/21975263", "http://www.ncbi.nlm.nih.gov/pubmed/33460880", "http://www.ncbi.nlm.nih.gov/pubmed/17901262", "http://www.ncbi.nlm.nih.gov/pubmed/27467324", "http://www.ncbi.nlm.nih.gov/pubmed/32594490", "http://www.ncbi.nlm.nih.gov/pubmed/36403213", "http://www.ncbi.nlm.nih.gov/pubmed/29406991", "http://www.ncbi.nlm.nih.gov/pubmed/33018256"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28078981", "text": "The following terminology was applied: Alzheimer resilience, brain resilience, metabolic resilience, cardiovascular resilience, mitochondrial resilience and exercise resilience.", "offsetInBeginSection": 1114, "offsetInEndSection": 1291, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28078981", "text": "CONCLUSION knowing that disturbances in brain, neuroendocrine, vascular and mitochondria metabolism are important events in neurodegeneration and dementia development, the ability of exercise to trigger adaptive mechanisms might represent an important non-pharmacological strategy to improve resilience to AD.", "offsetInBeginSection": 1609, "offsetInEndSection": 1918, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28078981", "text": "Five papers defined Alzheimer's resilience, 15 papers brain resilience, five cardiovascular resilience, one metabolic resilience, 11 mitochondrial resilience, and 7 exercise resilience.", "offsetInBeginSection": 1339, "offsetInEndSection": 1524, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28078981", "text": "BACKGROUND Although Alzheimer's disease (AD) is a neurodegenerative pathology characterized by accumulation of \u03b2-amyloid plaques and neurofibrillary tangles at cerebral level, recent studies highlighted that AD might be the result of many altered physiological processes occurring at whole-organism level.", "offsetInBeginSection": 0, "offsetInEndSection": 306, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28299413", "text": "However, unlike other conditions (e.g., Alzheimer's disease and coronary artery disease), resilience to trauma is not a disease but an adaptive response to trauma.", "offsetInBeginSection": 1452, "offsetInEndSection": 1615, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27815399", "text": "Furthermore, resilience metrics interacted with biomarker status such that biomarker-positive individuals with low resilience showed the greatest risk of subsequent decline.", "offsetInBeginSection": 1265, "offsetInEndSection": 1438, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18728949", "text": "Social support positively influenced resilience, and caregivers with high family support had the highest probability of elevated resilience.", "offsetInBeginSection": 964, "offsetInEndSection": 1104, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28025282", "text": "Objectives Apolipoprotein E (APOE) \u025b4 and Clusterin (CLU) C alleles are risk factors for Alzheimer's disease (AD) and episodic memory (EM) decline.", "offsetInBeginSection": 0, "offsetInEndSection": 148, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28025282", "text": "Results For both sexes, younger age, higher education, stronger grip, and everyday novel cognitive activity predicted memory resilience.", "offsetInBeginSection": 769, "offsetInEndSection": 905, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26984114", "text": "MBSR training significantly improved the psychological resilience of some of the caregivers.", "offsetInBeginSection": 703, "offsetInEndSection": 795, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a7376e33b9d13c708000009", "body": "Describe Vanishing lung syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26259424", "http://www.ncbi.nlm.nih.gov/pubmed/25322795", "http://www.ncbi.nlm.nih.gov/pubmed/33209576", "http://www.ncbi.nlm.nih.gov/pubmed/28219569", "http://www.ncbi.nlm.nih.gov/pubmed/24511405", "http://www.ncbi.nlm.nih.gov/pubmed/34016626", "http://www.ncbi.nlm.nih.gov/pubmed/32923201", "http://www.ncbi.nlm.nih.gov/pubmed/33299760", "http://www.ncbi.nlm.nih.gov/pubmed/24977015", "http://www.ncbi.nlm.nih.gov/pubmed/35848672"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26259424", "text": "Vanishing lung syndrome (VLS) is a rare radiological syndrome in which the lungs appear to be disappearing on X-ray.", "offsetInBeginSection": 0, "offsetInEndSection": 116, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26259424", "text": "Eventually, his CT chest revealed the diagnosis of giant bullous disease/vanishing lung syndrome.", "offsetInBeginSection": 695, "offsetInEndSection": 792, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25322795", "text": "The present study suggests that vanishing lung syndrome may be associated with autosomal dominant and recessive genetic inheritance.", "offsetInBeginSection": 1316, "offsetInEndSection": 1448, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25322795", "text": "Vanishing lung syndrome, also known as idiopathic giant bullous emphysema, is a rare disease characterized by giant emphysematous bullae.", "offsetInBeginSection": 0, "offsetInEndSection": 137, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28219569", "text": "Vanishing lung syndrome is a clinical presentation of giant bullous emphysema associated with significant morbidity and mortality.", "offsetInBeginSection": 0, "offsetInEndSection": 130, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28219569", "text": "We present a case of a 50-year-old white woman with vanishing lung syndrome who presented with a spontaneous secondary pneumothorax and an uncontrolled bronchopleural fistula.", "offsetInBeginSection": 131, "offsetInEndSection": 306, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22937434", "text": "We describe here a rare case of Idiopathic Bullous Emphysema/Vanishing Lung Syndrome (VLS) in a 33-year-old male patient with a history of marijuana abuse who presents to the hospital with pleuritic chest pain thought to be due to pneumothorax based on the chest radiograph.", "offsetInBeginSection": 0, "offsetInEndSection": 274, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28975065", "text": "A small number of case reports have described a pathological entity called vanishing lung syndrome (VLS), which is a rare bullous lung disease usually caused by tobacco smoking.", "offsetInBeginSection": 129, "offsetInEndSection": 306, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24511405", "text": "Vanishing lung syndrome (VLS) is a rare and distinct clinical syndrome that usually affects young men.", "offsetInBeginSection": 0, "offsetInEndSection": 102, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24977015", "text": "Giant bullous emphysema (GBE), known as 'vanishing lung syndrome', usually occurs in association with chronic obstructive pulmonary disease (COPD).", "offsetInBeginSection": 0, "offsetInEndSection": 147, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a80dbaafaa1ab7d2e000026", "body": "Are there ways of joint Bayesian inference of risk variants?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27407109", "http://www.ncbi.nlm.nih.gov/pubmed/22685004", "http://www.ncbi.nlm.nih.gov/pubmed/32062482", "http://www.ncbi.nlm.nih.gov/pubmed/28669401", "http://www.ncbi.nlm.nih.gov/pubmed/28334312", "http://www.ncbi.nlm.nih.gov/pubmed/32966977", "http://www.ncbi.nlm.nih.gov/pubmed/25519387", "http://www.ncbi.nlm.nih.gov/pubmed/29226787", "http://www.ncbi.nlm.nih.gov/pubmed/21442515", "http://www.ncbi.nlm.nih.gov/pubmed/29473295"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27407109", "text": "In simulation, RiVIERA promising power in detecting causal variants and causal annotations, the multi-trait joint inference further improved the detection power.", "offsetInBeginSection": 536, "offsetInEndSection": 697, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27407109", "text": "Here, we introduce a new Bayesian model RiVIERA (Risk Variant Inference using Epigenomic Reference Annotations) for inference of driver variants from summary statistics across multiple traits using hundreds of epigenomic annotations.", "offsetInBeginSection": 302, "offsetInEndSection": 535, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28334312", "text": "Extensive numerical experiments show that our approach outperforms popular variable selection methods and tailored Bayesian procedures, dealing within hours with problems involving hundreds of thousands of genetic variants and tens to hundreds of clinical or molecular outcomes.", "offsetInBeginSection": 1075, "offsetInEndSection": 1353, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28461708", "text": "Using simulation studies and a real data analysis, we demonstrate how posterior inference on the subclonal structure is enhanced with the joint modeling of both structure and sequencing variants on subclonal genomes.", "offsetInBeginSection": 997, "offsetInEndSection": 1213, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29124304", "text": "Transplant matching algorithms and disease association studies involving phasing and imputation of rare variants may benefit from this statistical inference framework.", "offsetInBeginSection": 1439, "offsetInEndSection": 1606, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29124304", "text": "We have applied a Bayesian inference methodology for extending haplotype frequency distributions, using a model where new haplotypes are created by recombination of observed alleles.", "offsetInBeginSection": 999, "offsetInEndSection": 1181, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18753153", "text": "MOTIVATION Bayesian analysis is one of the most popular methods in phylogenetic inference.", "offsetInBeginSection": 0, "offsetInEndSection": 90, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28669401", "text": "This procedure can improve inference if only a particular class of variants confers disease risk and can suggest particular disease etiologies related to that class.", "offsetInBeginSection": 935, "offsetInEndSection": 1100, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28669401", "text": "We present a rapid and powerful inference procedure for identifying loci associated with rare hereditary disorders using Bayesian model comparison.", "offsetInBeginSection": 0, "offsetInEndSection": 147, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22080595", "text": "Combining a multi-state model with the latent growth model defines a joint model which extends current statistical inference regarding disease progression and cognitive function.", "offsetInBeginSection": 722, "offsetInEndSection": 900, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a9ac7ba1d1251d03b000013", "body": "What does intepirdine target?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34095437", "http://www.ncbi.nlm.nih.gov/pubmed/34189249", "http://www.ncbi.nlm.nih.gov/pubmed/33439019", "http://www.ncbi.nlm.nih.gov/pubmed/29848076", "http://www.ncbi.nlm.nih.gov/pubmed/29291439", "http://www.ncbi.nlm.nih.gov/pubmed/28253832", "http://www.ncbi.nlm.nih.gov/pubmed/19651294", "http://www.ncbi.nlm.nih.gov/pubmed/32572841", "http://www.ncbi.nlm.nih.gov/pubmed/11821145", "http://www.ncbi.nlm.nih.gov/pubmed/16028579"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28253832", "text": "Studies have shown that the current treatments for AD, cholinesterase inhibitors (ChEI's) and NMDA receptor antagonists, have limited efficacy.", "offsetInBeginSection": 393, "offsetInEndSection": 536, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28720101", "text": "These investigations include acetylcholinesterase inhibitors, agonists and antagonists of neurotransmitter receptors, \u03b2-secretase (BACE) or \u03b3-secretase inhibitors, vaccines or antibodies targeting A\u03b2 clearance or tau protein, as well as anti-inflammation compounds.", "offsetInBeginSection": 1162, "offsetInEndSection": 1430, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28720101", "text": "Ongoing Phase III clinical trials via passive immunotherapy against A\u03b2 peptides (crenezumab, gantenerumab, and aducanumab) seem to be promising.", "offsetInBeginSection": 1431, "offsetInEndSection": 1576, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28720101", "text": "Using small molecules blocking 5-HT6 serotonin receptor (intepirdine), inhibiting BACE activity (E2609, AZD3293, and verubecestat), or reducing tau aggregation (TRx0237) are also currently in Phase III clinical trials.", "offsetInBeginSection": 1577, "offsetInEndSection": 1795, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28720101", "text": "Recent therapeutic approaches have been strongly influenced by five neuropathological hallmarks of AD: acetylcholine deficiency, glutamate excitotoxicity, extracellular deposition of amyloid-\u03b2 (A\u03b2 plague), formation of intraneuronal neurofibrillary tangles (NTFs), and neuroinflammation.", "offsetInBeginSection": 260, "offsetInEndSection": 549, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28720101", "text": "Current AD medications, memantine and acetylcholinesterase inhibitors (AChEIs) alleviate some of these symptoms by enhancing cholinergic signaling, but they are not curative.", "offsetInBeginSection": 689, "offsetInEndSection": 863, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26562889", "text": "Previous research has demonstrated that clutter can hurt search performance and a second target is less likely to be detected in a multiple-target search after a first target has been found, which raises a concern-how does clutter affect multiple-target search performance?", "offsetInBeginSection": 389, "offsetInEndSection": 662, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26562889", "text": "These results suggest that the detection and processing of a first target might enhance the masking effects of clutter around a second target.", "offsetInBeginSection": 1228, "offsetInEndSection": 1370, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12582826", "text": "A possible explanation is that people attempt to strike the target in a central zone that does not vary much with variation in physical target size: the \"effective size\" of the target is relatively constant over changes in physical size.", "offsetInBeginSection": 358, "offsetInEndSection": 595, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25261632", "text": "Targeted therapy for cancer treatment has required a shift in drug development approaches from broad treatment with chemotherapies, to the development of precision medicines that are specific for clinical targets.", "offsetInBeginSection": 0, "offsetInEndSection": 213, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a981bcffcd1d6a10c00002d", "body": "List 3 symptoms of Wernicke encephalopathy.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21528481", "http://www.ncbi.nlm.nih.gov/pubmed/16219837", "http://www.ncbi.nlm.nih.gov/pubmed/30957373", "http://www.ncbi.nlm.nih.gov/pubmed/2679584", "http://www.ncbi.nlm.nih.gov/pubmed/14644703", "http://www.ncbi.nlm.nih.gov/pubmed/31223251", "http://www.ncbi.nlm.nih.gov/pubmed/15141340", "http://www.ncbi.nlm.nih.gov/pubmed/29596284", "http://www.ncbi.nlm.nih.gov/pubmed/33948400", "http://www.ncbi.nlm.nih.gov/pubmed/25856744"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/15141340", "text": "Wernicke encephalopathy, a potentially reversible condition, may be unrecognized in terminally ill cancer patients.", "offsetInBeginSection": 169, "offsetInEndSection": 284, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15141340", "text": "Although Wernicke encephalopathy has been reported in the oncological literature, only one terminally ill cancer patient with Wernicke encephalopathy has been reported.", "offsetInBeginSection": 0, "offsetInEndSection": 168, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25539041", "text": "The syndrome can develop from unrecognized or undertreated Wernicke encephalopathy.", "offsetInBeginSection": 84, "offsetInEndSection": 167, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25539041", "text": "Self-neglecting alcoholics who are bedridden may have severe illness and probably active Wernicke encephalopathy.", "offsetInBeginSection": 915, "offsetInEndSection": 1028, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25539041", "text": "The intra-individual course of Wernicke-Korsakoff syndrome has not been studied extensively, nor has the temporal progression of gait disturbances and other symptoms of Wernicke encephalopathy.", "offsetInBeginSection": 168, "offsetInEndSection": 361, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16219837", "text": "Wernicke encephalopathy is a neurologic disorder that results from thiamine deficiency.", "offsetInBeginSection": 0, "offsetInEndSection": 87, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24293308", "text": "Wernicke encephalopathy is rare and under-recognized in childhood and may be fatal.", "offsetInBeginSection": 119, "offsetInEndSection": 202, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24293308", "text": "Wernicke encephalopathy should be considered in all children with cancer presenting a neurologic deterioration, mainly in brain tumors.", "offsetInBeginSection": 891, "offsetInEndSection": 1026, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25856744", "text": "Wernicke encephalopathy is an acute neuropsychiatric disease with heterogeneous symptoms, including changes in mental status, ataxia and ocular abnormalities; if left untreated, these symptoms can lead to morbidity and even to mortality.", "offsetInBeginSection": 0, "offsetInEndSection": 237, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9279523", "text": "Both the thyrotoxicosis and a catabolic state due to the hyperemesis were thought to have induced a vitamin B1 deficiency, causing the Wernicke encephalopathy.", "offsetInBeginSection": 563, "offsetInEndSection": 722, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a9d8d691d1251d03b000020", "body": "What is the association of the protein RAB10 and Alzheimers disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29562525", "http://www.ncbi.nlm.nih.gov/pubmed/35071308", "http://www.ncbi.nlm.nih.gov/pubmed/20576682", "http://www.ncbi.nlm.nih.gov/pubmed/30643396", "http://www.ncbi.nlm.nih.gov/pubmed/29177506", "http://www.ncbi.nlm.nih.gov/pubmed/34250948", "http://www.ncbi.nlm.nih.gov/pubmed/32709066", "http://www.ncbi.nlm.nih.gov/pubmed/29183403", "http://www.ncbi.nlm.nih.gov/pubmed/35521944", "http://www.ncbi.nlm.nih.gov/pubmed/16641372"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26082458", "text": "The target genes SEC22 vesicle trafficking protein homolog B (SEC22B) and SEC63 homolog (SEC63) regulated by miRNA-206, RAB10, member RAS oncogene family (RAB10) regulated by miRNA-655, and fms-related tyrosine kinase 1 (FLT1) regulated by miRNA-30e-3p and miRNA-369-3p were involved in the biological processes of protein transport and regulation of cell motion.", "offsetInBeginSection": 678, "offsetInEndSection": 1041, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26082458", "text": "CONCLUSION The target genes SEC22B, RAB10, and FLT1 may be potential biomarkers of AD.", "offsetInBeginSection": 1044, "offsetInEndSection": 1130, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19008234", "text": "We have now determined that a related Rab protein, Rab10, can interact with myosin Va, myosin Vb, and myosin Vc.", "offsetInBeginSection": 259, "offsetInEndSection": 371, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19008234", "text": "Interaction with Rab10 was dependent on the presence of the alternatively spliced exon D in myosin Va and myosin Vb and the homologous region in myosin Vc.", "offsetInBeginSection": 575, "offsetInEndSection": 730, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29127256", "text": "In this study, we analyse the selectivity and sensitivity of polyclonal and monoclonal phospho-specific antibodies raised against 9 different LRRK2 phosphorylated Rab proteins (Rab3A/3B/3C/3D, Rab5A/5B/5C, Rab8A/8B, Rab10, Rab12, Rab29[T71], Rab29[S72], Rab35 and Rab43).", "offsetInBeginSection": 334, "offsetInEndSection": 605, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27474410", "text": "Recent work has revealed that LRRK2 directly phosphorylates a conserved threonine/serine residue in the effector-binding switch-II motif of a number of Rab GTPase proteins, including Rab10.", "offsetInBeginSection": 121, "offsetInEndSection": 310, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29125462", "text": "Here, we systematically analyzed the Rab protein family and found 14 of them (Rab3A/B/C/D, Rab5A/B/C, Rab8A/B, Rab10, Rab12, Rab29, Rab35 and Rab43) to be specifically phosphorylated by LRRK2, with evidence for endogenous phosphorylation for ten of them (Rab3A/B/C/D, Rab8A/B, Rab10, Rab12, Rab35 and Rab43).", "offsetInBeginSection": 195, "offsetInEndSection": 503, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29125462", "text": "Affinity enrichment mass spectrometry revealed that the primary ciliogenesis regulator, RILPL1 specifically interacts with the LRRK2-phosphorylated forms of Rab8A and Rab10, whereas RILPL2 binds to phosphorylated Rab8A, Rab10, and Rab12.", "offsetInBeginSection": 504, "offsetInEndSection": 741, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28860483", "text": "The identification of Rab10 phosphorylated at Thr73 as a LRRK2 inhibition marker in human PBMCs strongly support inclusion of assays quantifying Rab10-pThr73 levels in upcoming clinical trials evaluating LRRK2 kinase inhibition as a disease-modifying treatment principle in PD.", "offsetInBeginSection": 1139, "offsetInEndSection": 1416, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28028537", "text": "Finally, Rab10 activation during autophagy is essential for LC3 recruitment to the autophagosome and stimulates its increased association with the adaptor protein EHBP1 (EH domain binding protein 1) and the membrane-deforming adenosine triphosphatase EHD2 (EH domain containing 2) that, together, are essential in driving the activated \"engulfment\" of LDs during lipophagy in hepatocytes.", "offsetInBeginSection": 745, "offsetInEndSection": 1133, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a7379a83b9d13c70800000a", "body": "Is Rucaparib effective for ovarian cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28974545", "http://www.ncbi.nlm.nih.gov/pubmed/29977351", "http://www.ncbi.nlm.nih.gov/pubmed/28790837", "http://www.ncbi.nlm.nih.gov/pubmed/28057616", "http://www.ncbi.nlm.nih.gov/pubmed/28247266", "http://www.ncbi.nlm.nih.gov/pubmed/34528576", "http://www.ncbi.nlm.nih.gov/pubmed/33343988", "http://www.ncbi.nlm.nih.gov/pubmed/29166829", "http://www.ncbi.nlm.nih.gov/pubmed/28388401", "http://www.ncbi.nlm.nih.gov/pubmed/30830551"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/29166829", "text": "CONCLUSION Rucaparib appears to be a safe and effective new option in the treatment of relapsed, advanced BRCA1/2 mutant ovarian cancer.", "offsetInBeginSection": 778, "offsetInEndSection": 914, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29166829", "text": "In patients with deleterious BRCA1/2 mutation, an overall response rate of 80% was achieved in the phase II trial Assessment of Rucaparib in Ovarian CancEr Trial 2 (ARIEL2).", "offsetInBeginSection": 275, "offsetInEndSection": 448, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28790837", "text": "Rucaparib camsylate (CO-338, AG-014699, PF-01367338) is a potent PARP-1, PARP-2, and PARP-3 inhibitor.", "offsetInBeginSection": 0, "offsetInEndSection": 102, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28247266", "text": "Rucaparib is also under phase II or III investigation in ovarian, breast and prostate cancer.", "offsetInBeginSection": 539, "offsetInEndSection": 632, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27002934", "text": "METHODS Phase II, open-label, multicentre trial of rucaparib in proven BRCA-1/2 mutation carriers with advanced breast and or ovarian cancer, WHO PS 0-1 and normal organ function.", "offsetInBeginSection": 413, "offsetInEndSection": 592, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27002934", "text": "We investigated the efficacy and safety of single-agent rucaparib in germline (g) BRCA mutation carriers with advanced breast and ovarian cancers.", "offsetInBeginSection": 264, "offsetInEndSection": 410, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402", "text": "These results support further clinical evaluation of rucaparib either as a single agent or as an adjunct to chemotherapy for the treatment of sporadic ovarian cancer.", "offsetInBeginSection": 1607, "offsetInEndSection": 1773, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28057616", "text": "The FDA approved the PARP inhibitor rucaparib to treat women with advanced ovarian cancer who have already been treated with at least two chemotherapies and have a BRCA1 or BRCA2 gene mutation identified by an approved companion diagnostic test.", "offsetInBeginSection": 0, "offsetInEndSection": 245, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28916367", "text": "BACKGROUND Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity.", "offsetInBeginSection": 0, "offsetInEndSection": 202, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27940438", "text": "High LOH is associated with response to the PARP inhibitor rucaparib in BRCA wild-type ovarian cancer.", "offsetInBeginSection": 0, "offsetInEndSection": 102, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a8b27e6fcd1d6a10c00001e", "body": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24990604", "http://www.ncbi.nlm.nih.gov/pubmed/30558531", "http://www.ncbi.nlm.nih.gov/pubmed/29618827", "http://www.ncbi.nlm.nih.gov/pubmed/31813398", "http://www.ncbi.nlm.nih.gov/pubmed/31832098", "http://www.ncbi.nlm.nih.gov/pubmed/33230826", "http://www.ncbi.nlm.nih.gov/pubmed/32188487", "http://www.ncbi.nlm.nih.gov/pubmed/27887921", "http://www.ncbi.nlm.nih.gov/pubmed/32539871", "http://www.ncbi.nlm.nih.gov/pubmed/28449648"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24990604", "text": "RAPIDR (Reliable Accurate Prenatal non-Invasive Diagnosis R package) is an easy-to-use open-source R package that implements several published NIPT analysis methods.", "offsetInBeginSection": 141, "offsetInEndSection": 306, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24990604", "text": "UNLABELLED Non-invasive prenatal testing (NIPT) of fetal aneuploidy using cell-free fetal DNA is becoming part of routine clinical practice.", "offsetInBeginSection": 0, "offsetInEndSection": 140, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25238658", "text": "OBJECTIVE Non-invasive prenatal testing (NIPT) using cell-free fetal DNA in maternal plasma has been developed for the detection of fetal aneuploidy.", "offsetInBeginSection": 0, "offsetInEndSection": 149, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24927192", "text": "New technologies analyzing fetal DNA in maternal blood have led to the wide commercial availability of non-invasive prenatal testing (NIPT).", "offsetInBeginSection": 0, "offsetInEndSection": 140, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25027965", "text": "BACKGROUND Non-invasive prenatal testing (NIPT) for aneuploidies is now available through commercial companies in many countries, including through private practice in the United Kingdom (UK).", "offsetInBeginSection": 0, "offsetInEndSection": 192, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26237390", "text": "Recent advances in molecular genetic technologies have facilitated non-invasive prenatal testing (NIPT) through the analysis of cell-free fetal DNA in maternal plasma.", "offsetInBeginSection": 0, "offsetInEndSection": 167, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28681452", "text": "BACKGROUND Non-invasive prenatal testing (NIPT) has been available in Aotearoa New Zealand (NZ) for approximately four years.", "offsetInBeginSection": 0, "offsetInEndSection": 125, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24549748", "text": "QUESTIONS UNDER STUDY Prenatal care has been significantly influenced by the introduction of non-invasive prenatal testing (NIPT) for aneuploidies in 2012.", "offsetInBeginSection": 0, "offsetInEndSection": 155, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24549748", "text": "They were counselled about the available options for invasive prenatal testing (IPT) and NIPT available at the time of FTS.", "offsetInBeginSection": 625, "offsetInEndSection": 748, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27900229", "text": "Introduction\u2003Recent technological advances have yielded a new method of prenatal screening, non-invasive prenatal testing (NIPT), which uses cell-free fetal DNA from the mother's blood to assess for aneuploidy.", "offsetInBeginSection": 126, "offsetInEndSection": 338, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a9acba61d1251d03b000014", "body": "Has intepirdine been evaluated in clinical trials? (November 2017)", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34189249", "http://www.ncbi.nlm.nih.gov/pubmed/28720101", "http://www.ncbi.nlm.nih.gov/pubmed/28591872", "http://www.ncbi.nlm.nih.gov/pubmed/28253832", "http://www.ncbi.nlm.nih.gov/pubmed/36199295", "http://www.ncbi.nlm.nih.gov/pubmed/34095437", "http://www.ncbi.nlm.nih.gov/pubmed/30587912", "http://www.ncbi.nlm.nih.gov/pubmed/32458769", "http://www.ncbi.nlm.nih.gov/pubmed/29848076", "http://www.ncbi.nlm.nih.gov/pubmed/30046155"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/29131320", "text": "In November 2017, the Council of the European Society of Clinical Investigation (ESCI) evaluated all basic research articles published in the European Journal of Clinical Investigation (EJCI) from November 2016 to October 2017.", "offsetInBeginSection": 0, "offsetInEndSection": 227, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25027481", "text": "The Biomet Nano (Biomet, Warsaw, IN, USA) clinical trial began in October 2013 and also has a tentative completion date of 2017.", "offsetInBeginSection": 1067, "offsetInEndSection": 1195, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25027481", "text": "The tentative study completion date is 2017.", "offsetInBeginSection": 1022, "offsetInEndSection": 1066, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25454208", "text": "RESULTS This study was started in June 2014 (registration period 2 years, survey period 3 years) and will end in May 2017.", "offsetInBeginSection": 1392, "offsetInEndSection": 1514, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25454208", "text": "METHODS This prospective survey will involve patients treated with landiolol for the treatment of tachyarrhythmia (AF/AFL) in cardiac dysfunction at Japanese medical facilities from June 2014 to May 2017.", "offsetInBeginSection": 857, "offsetInEndSection": 1061, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25454208", "text": "In November 2013, landiolol hydrochloride (Onoact(\u00ae) 50 for Injection, Ono Pharamaceutical, Osaka, Japan) was approved with the indication for \"tachyarrhythmia (AF/AFL) in patients with cardiac dysfunction.\"", "offsetInBeginSection": 309, "offsetInEndSection": 517, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29026293", "text": "The search was actualized in April 2017.", "offsetInBeginSection": 736, "offsetInEndSection": 776, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28366767", "text": "Of all the molecules evaluated as of January 2017, the regulatory authorities assessed that six provided clear clinical benefit in rigorously controlled trials.", "offsetInBeginSection": 344, "offsetInEndSection": 504, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28366767", "text": "During that lengthy period of time, numerous clinical trials have been performed and thousands of trial participants accrued onto studies.", "offsetInBeginSection": 205, "offsetInEndSection": 343, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28985716", "text": "Between November 2014 and June 2017, an estimated 110 patients from two sites in Japan were randomized (1:1) to morphine or oxycodone in GG and non-GG groups.", "offsetInBeginSection": 1850, "offsetInEndSection": 2008, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aa3fa73d6d6b54f79000008", "body": "Is subacute sclerosing panencephalitis caused by the Measles vaccine?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/2019970", "http://www.ncbi.nlm.nih.gov/pubmed/21311432", "http://www.ncbi.nlm.nih.gov/pubmed/27777245", "http://www.ncbi.nlm.nih.gov/pubmed/30057285", "http://www.ncbi.nlm.nih.gov/pubmed/34873504", "http://www.ncbi.nlm.nih.gov/pubmed/36458570", "http://www.ncbi.nlm.nih.gov/pubmed/8969008", "http://www.ncbi.nlm.nih.gov/pubmed/19537141", "http://www.ncbi.nlm.nih.gov/pubmed/15384893", "http://www.ncbi.nlm.nih.gov/pubmed/22449219"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/15384893", "text": "UNLABELLED Subacute sclerosing panencephalitis (SSPE), in the majority of cases, is caused by the wild measles virus, although there are some reports relating SSPE to vaccination.", "offsetInBeginSection": 0, "offsetInEndSection": 179, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15384893", "text": "Subacute sclerosing panencephalitis is a fatal degenerative disease and, although it had largely disappeared because of nearly universal measles vaccination, it still remains a serious infection among children affected by human immunodeficiency virus (HIV).", "offsetInBeginSection": 406, "offsetInEndSection": 663, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/850592", "text": "Because live measles vaccine is highly effective in preventing measles illness and a high proportion of children in the United States have received measles vaccine, these data are consistent with the observed downward trend in SSPE incidence since 1969.", "offsetInBeginSection": 866, "offsetInEndSection": 1119, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/3531224", "text": "Finally, persons with subacute sclerosing panencephalitis and atypical measles mounted abnormally high antibody responses to measles virus polypeptides, in particular the P protein.", "offsetInBeginSection": 1005, "offsetInEndSection": 1186, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2019970", "text": "Subacute sclerosing panencephalitis (SSPE) is a progressive neurodegenerative disease caused by the measles (rubeola) virus and is most often seen in children.", "offsetInBeginSection": 0, "offsetInEndSection": 159, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2087249", "text": "These results suggest that infection by measles virus is probably not the sole cause of MS and that, unlike subacute sclerosing panencephalitis and postmeasles encephalitis, MS may not be preventable by measles vaccination given at an appropriate age.", "offsetInBeginSection": 300, "offsetInEndSection": 551, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21311432", "text": "Subacute sclerosing panencephalitis (SSPE) is a progressive neurological disorder of childhood and early adolescence caused by persistent defective measles virus.", "offsetInBeginSection": 0, "offsetInEndSection": 162, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1706253", "text": "Subacute sclerosing panencephalitis (SSPE) has become rare since the widespread use of the measles vaccine.", "offsetInBeginSection": 0, "offsetInEndSection": 107, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6685828", "text": "There was no indication that measles vaccine can induce SSPE.", "offsetInBeginSection": 827, "offsetInEndSection": 888, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25802788", "text": "Subacute sclerosing panencephalitis (SSPE) is a devastating disease of the central nervous system (CNS) caused by persistent mutant measles virus infection.", "offsetInBeginSection": 0, "offsetInEndSection": 156, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a9d8ffe1d1251d03b000022", "body": "What are pQTLs?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33571421", "http://www.ncbi.nlm.nih.gov/pubmed/33067605", "http://www.ncbi.nlm.nih.gov/pubmed/25657249", "http://www.ncbi.nlm.nih.gov/pubmed/30111768", "http://www.ncbi.nlm.nih.gov/pubmed/25124843", "http://www.ncbi.nlm.nih.gov/pubmed/34819519", "http://www.ncbi.nlm.nih.gov/pubmed/27329291", "http://www.ncbi.nlm.nih.gov/pubmed/31552100", "http://www.ncbi.nlm.nih.gov/pubmed/35264221", "http://www.ncbi.nlm.nih.gov/pubmed/32492067"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27532455", "text": "Some of these pQTLs [e.g., pQTLs for VDBP, sRAGE (gene = AGER), surfactant protein D (gene = SFTPD), and TNFRSF10C] have been previously associated with COPD phenotypes.", "offsetInBeginSection": 1303, "offsetInEndSection": 1472, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27329291", "text": "cis-pQTLs for kallikrein and F12 also show trans associations for proteins (uPAR, kininogen) known to be cleaved by kallikrein and with NTproBNP.", "offsetInBeginSection": 1168, "offsetInEndSection": 1313, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27329291", "text": "Here, we identify new common and rare genetic variants associated with cardiovascular-related protein levels (protein quantitative trait loci [pQTLs]).", "offsetInBeginSection": 104, "offsetInEndSection": 255, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25087611", "text": "Our results suggest that protein-based mechanisms might functionally buffer genetic alterations that influence mRNA expression levels and that pQTLs might contribute phenotypic diversity to a human population independently of influences on mRNA expression.", "offsetInBeginSection": 1296, "offsetInEndSection": 1552, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25087611", "text": "We collected more than 250,000 protein level measurements comprising 441 transcription factor and signaling protein isoforms across 68 Yoruba (YRI) HapMap lymphoblastoid cell lines (LCLs) and identified 12 cis and 160 trans protein level QTLs (pQTLs) at a false discovery rate (FDR) of 20%.", "offsetInBeginSection": 498, "offsetInEndSection": 788, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23172855", "text": "Analyses were confirmed by mechanistic studies and MALDI-TOF/TOF, liquid chromatography-tandem mass spectrometry (LC-MS/MS) analyses of the two strongest pQTLs: A pQTL for mass-to-charge ratio (m/z) 3494 (LOD 24.9, D11Mit151) was identified as the N-terminal 35 amino acids of hemoglobin subunit A (Hba) and caused by genetic variation in Hba.", "offsetInBeginSection": 811, "offsetInEndSection": 1154, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28129359", "text": "In carrying out a genome wide genotype-protein association study (proteomic Quantitative Trait Loci, pQTL) within the CD patients, we identified 41 distinct proteomic traits influenced by cis pQTLs (underlying SNPs are referred to as pSNPs).", "offsetInBeginSection": 903, "offsetInEndSection": 1144, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25124843", "text": "The objective of this study is to identify eQTL underlying expression of four gene families encoding isoflavone synthetic enzymes involved in the phenylpropanoid pathway, which are phenylalanine ammonia-lyase (PAL; EC 4.3.1.5), chalcone synthase (CHS; EC 2.3.1.74), 2-hydroxyisoflavanone synthase (IFS; EC1.14.13.136) and flavanone 3-hydroxylase (F3H; EC 1.14.11.9).", "offsetInBeginSection": 285, "offsetInEndSection": 651, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25124843", "text": "Overlapped loci of eQTLs and phenotypic QTLs (pQTLs) were analyzed to identify the potential candidate genes underlying the accumulation of isoflavone in soybean seed.", "offsetInBeginSection": 900, "offsetInEndSection": 1067, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21846806", "text": "These colocalizing correlated cis-eQTLs (c3-eQTLs) are highly attractive as primary susceptibility loci for the colocalizing pQTLs.", "offsetInBeginSection": 964, "offsetInEndSection": 1095, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a7428090384be9551000001", "body": "What can be predicted with the Wells criteria?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/31064774", "http://www.ncbi.nlm.nih.gov/pubmed/32158986", "http://www.ncbi.nlm.nih.gov/pubmed/21173193", "http://www.ncbi.nlm.nih.gov/pubmed/18640701", "http://www.ncbi.nlm.nih.gov/pubmed/33467963", "http://www.ncbi.nlm.nih.gov/pubmed/8273974", "http://www.ncbi.nlm.nih.gov/pubmed/12372941", "http://www.ncbi.nlm.nih.gov/pubmed/15330178", "http://www.ncbi.nlm.nih.gov/pubmed/17013222", "http://www.ncbi.nlm.nih.gov/pubmed/31758942"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28260193", "text": "CONCLUSIONS Wienecke criteria can be an appropriate points-scoring system to predict prognosis for adrenocortical tumors in children.", "offsetInBeginSection": 1284, "offsetInEndSection": 1417, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21610436", "text": "CONCLUSIONS In patients with HGRT who had bleeding, a strategy of targeted angiography can be realized safely in using specific CT scan criteria that can predict with high accuracy and exclude the need for embolization, without reducing the success rate of CM.", "offsetInBeginSection": 1525, "offsetInEndSection": 1785, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21610436", "text": "None of the CT criteria had a negative predictive value for renal embolization to 100%, only the absence of intravascular contrast extravasation associated with a perirenal hematoma rim distance<25 mm excludes an indication for embolization.", "offsetInBeginSection": 1281, "offsetInEndSection": 1522, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9447391", "text": "Specific research questions include: to what extent can consensus be achieved on definitions and accompanying rules of inference for criteria, the relationship of meta-analysis to the criterion of consistency, and the interrelationships of criteria such as consistency, strength of association, and biological plausibility.", "offsetInBeginSection": 985, "offsetInEndSection": 1308, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10599768", "text": "METHODS We assessed the sensitivity, specificity, and positive and negative predictive values of the clinical criteria of the Consortium on dementia with Lewy Bodies (CDLB) in 18 patients with autopsy-proven DLB and in 76 patients with dementia not associated with Lewy bodies, using postmortem diagnosis as a gold standard.", "offsetInBeginSection": 113, "offsetInEndSection": 437, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10599768", "text": "OBJECTIVE To assess the clinical validity of clinical diagnostic criteria for dementia with Lewy bodies (DLB).", "offsetInBeginSection": 0, "offsetInEndSection": 110, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10599768", "text": "Clinical criteria had higher predictive validity in patients with pure DLB than in patients with DLB and AD.", "offsetInBeginSection": 602, "offsetInEndSection": 710, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10599768", "text": "CDLB criteria for probable DLB (two or more major criteria) distinguished DLB from AD with a sensitivity of 78% and a specificity of 64%.", "offsetInBeginSection": 1000, "offsetInEndSection": 1137, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10599768", "text": "Positive predictive value of 75% can be achieved by a combination of any three major or minor criteria, providing the analysis is confined to patients with mild to moderate dementia.", "offsetInBeginSection": 1264, "offsetInEndSection": 1446, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20179688", "text": "Two kinds of validations are reported: (i) studies testing whether symptom criteria discriminate patients with structural disease at colonoscopy from patients without structural disease; and (ii) studies testing whether symptom criteria discriminate patients presumed to have IBS by positive diagnosis from healthy subjects or patients with other functional and structural disorders.", "offsetInBeginSection": 150, "offsetInEndSection": 533, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a8b292afcd1d6a10c00001f", "body": "Is there any role of interleukin-11 in cardiovascular fibrosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/31840157", "http://www.ncbi.nlm.nih.gov/pubmed/29160304", "http://www.ncbi.nlm.nih.gov/pubmed/35402550", "http://www.ncbi.nlm.nih.gov/pubmed/21646597", "http://www.ncbi.nlm.nih.gov/pubmed/10612573", "http://www.ncbi.nlm.nih.gov/pubmed/31554736", "http://www.ncbi.nlm.nih.gov/pubmed/23229370", "http://www.ncbi.nlm.nih.gov/pubmed/16257843", "http://www.ncbi.nlm.nih.gov/pubmed/35474925", "http://www.ncbi.nlm.nih.gov/pubmed/14720043"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/20100971", "text": "CONCLUSIONS IL-11 attenuated cardiac fibrosis after MI through STAT3.", "offsetInBeginSection": 1743, "offsetInEndSection": 1812, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21646597", "text": "These results indicate that NF-\u03baB has an essential role in mediating the cardiovascular inflammatory response to angiotensin II and suggest that targeting the balance of I\u03baB\u03b1 and I\u03baB\u03b2 expression might be a novel therapeutic modality in preventing fibrosis in hypertensive cardiovascular disease.", "offsetInBeginSection": 1620, "offsetInEndSection": 1920, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21646597", "text": "Replacement of I\u03baB\u03b1 with I\u03baB\u03b2 significantly attenuated angiotensin II infusion-induced expression of interleukin 1\u03b2, interleukin 6, monocyte chemotactic protein 1, collagen I and III, fibronectin, and tissue inhibitor of metalloproteinase 1 in the hearts.", "offsetInBeginSection": 1027, "offsetInEndSection": 1287, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21646597", "text": "The development of cardiovascular fibrosis is associated with chronic inflammation, where activation of nuclear factor \u03baB (NF-\u03baB) signaling may play a critical role.", "offsetInBeginSection": 0, "offsetInEndSection": 167, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23229370", "text": "In addition to its potential as a biomarker for adverse cardiovascular events, ST2 is considered to play a causal role in chronic cardiovascular diseases such as atherosclerosis and heart failure.", "offsetInBeginSection": 629, "offsetInEndSection": 825, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25304471", "text": "Here, we tested the hypothesis that deletion of interleukin-6 protects against the development of hypertension, cardiac inflammation, fibrosis, remodeling and dysfunction induced by high salt diet and angiotensin II (Ang II).", "offsetInBeginSection": 291, "offsetInEndSection": 516, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25304471", "text": "CONCLUSION In conclusion, absence of interleukin -6 did not alter the development of Ang II-high salt-induced hypertension and cardiac hypertrophy, but it prevented the development of cardiac dysfunction, myocardial inflammation, and fibrosis.", "offsetInBeginSection": 1345, "offsetInEndSection": 1588, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18268139", "text": "Hyperaldosteronism is associated with hypertension, cardiovascular fibrosis, and electrolyte disturbances, including hypomagnesemia.", "offsetInBeginSection": 0, "offsetInEndSection": 132, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18268139", "text": "Renal and cardiovascular expression of interleukin-6, VCAM1 and COX2 was increased in the Aldo group.", "offsetInBeginSection": 1095, "offsetInEndSection": 1196, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9369414", "text": "Furthermore, TPO may play a significant role in the pathogenesis of marrow fibrosis; IL-6 may be a factor in the development of marrow megakaryocytosis but its elevated blood levels may represent a secondary immune phenomenon; and IL-11 probably does not play a significant role in causing marrow megakaryocytosis in this disease.", "offsetInBeginSection": 1583, "offsetInEndSection": 1913, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a9acc7b1d1251d03b000015", "body": "What is crenezumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26467270", "http://www.ncbi.nlm.nih.gov/pubmed/25880481", "http://www.ncbi.nlm.nih.gov/pubmed/31787113", "http://www.ncbi.nlm.nih.gov/pubmed/32568196", "http://www.ncbi.nlm.nih.gov/pubmed/27996029", "http://www.ncbi.nlm.nih.gov/pubmed/29955659", "http://www.ncbi.nlm.nih.gov/pubmed/31969177", "http://www.ncbi.nlm.nih.gov/pubmed/36121669", "http://www.ncbi.nlm.nih.gov/pubmed/34347883", "http://www.ncbi.nlm.nih.gov/pubmed/30231896"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26467270", "text": "In conclusion, the biosimilar antibodies Solanezumab, Crenezumab and Bapineuzumab strongly react with amyloid plaques, which are in contrast to the NT4X antibody that hardly recognizes plaques in human tissue.", "offsetInBeginSection": 1742, "offsetInEndSection": 1951, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26467270", "text": "In contrast to the biosimilar antibodies of Solanezumab, Crenezumab and Bapineuzumab, the murine NT4X antibody shows a unique target engagement.", "offsetInBeginSection": 1350, "offsetInEndSection": 1494, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26467270", "text": "Solanezumab and Crenezumab are two humanized antibodies targeting Amyloid-\u03b2 (A\u03b2) which are currently tested in multiple clinical trials for the prevention of Alzheimer's disease.", "offsetInBeginSection": 0, "offsetInEndSection": 180, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24803227", "text": "The most developed method for targeting A\u03b2 is the use of monoclonal antibodies including bapineuzumab, solanezumab and crenezumab.", "offsetInBeginSection": 171, "offsetInEndSection": 302, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24490853", "text": "Second-generation active A\u03b2 vaccines (CAD106, ACC-001, and Affitope AD02) and new passive anti-A\u03b2 immunotherapies (gantenerumab and crenezumab) have been developed and are under clinical testing.", "offsetInBeginSection": 608, "offsetInEndSection": 805, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24981190", "text": "Two other monoclonal antibodies, gantenerumab, which preferentially binds to fibrillar A\u03b2, and crenezumab, which preferentially binds to soluble, oligomeric and fibrillar A\u03b2 deposits, are being tested in secondary prevention trials in presymptomatic subjects with autosomal dominant AD mutations.", "offsetInBeginSection": 778, "offsetInEndSection": 1076, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24445401", "text": "Second-generation active A\u03b2 vaccines (ACC-001, CAD106, and Affitope AD02) and new passive anti-A\u03b2 immunotherapies (gantenerumab and crenezumab) are being tested in prodromal Alzheimer's disease patients, in presymptomatic individuals with Alzheimer's disease-related mutations, or in asymptomatic individuals at risk of developing Alzheimer's disease to definitely test the A\u03b2 cascade hypothesis of Alzheimer's disease.", "offsetInBeginSection": 1142, "offsetInEndSection": 1564, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26433971", "text": "We produced murine versions of the antibodies: Bapineuzumab (3D6), Crenezumab (mC2) and Gantenerumab (chGantenerumab) with an IgG2a constant region.", "offsetInBeginSection": 736, "offsetInEndSection": 884, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28720101", "text": "Ongoing Phase III clinical trials via passive immunotherapy against A\u03b2 peptides (crenezumab, gantenerumab, and aducanumab) seem to be promising.", "offsetInBeginSection": 1431, "offsetInEndSection": 1576, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28720101", "text": "These investigations include acetylcholinesterase inhibitors, agonists and antagonists of neurotransmitter receptors, \u03b2-secretase (BACE) or \u03b3-secretase inhibitors, vaccines or antibodies targeting A\u03b2 clearance or tau protein, as well as anti-inflammation compounds.", "offsetInBeginSection": 1162, "offsetInEndSection": 1430, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aa3fb7ad6d6b54f79000009", "body": "What drug cures hepatitis C?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24723109", "http://www.ncbi.nlm.nih.gov/pubmed/20428642", "http://www.ncbi.nlm.nih.gov/pubmed/21867933", "http://www.ncbi.nlm.nih.gov/pubmed/29880625", "http://www.ncbi.nlm.nih.gov/pubmed/30466675", "http://www.ncbi.nlm.nih.gov/pubmed/30618739", "http://www.ncbi.nlm.nih.gov/pubmed/14521943", "http://www.ncbi.nlm.nih.gov/pubmed/27673712", "http://www.ncbi.nlm.nih.gov/pubmed/27757979", "http://www.ncbi.nlm.nih.gov/pubmed/24215243"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26043288", "text": "Peginterferon combined with ribavirin and even the first-wave protease inhibitors telaprevir and boceprevir now belong to the milestones that had an important, although historical, role in the final conquest of hepatitis C.", "offsetInBeginSection": 1364, "offsetInEndSection": 1587, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28644739", "text": "The advent of oral direct-acting antivirals (DAA) has revolutionized the hepatitis C virus (HCV) therapeutic landscape providing cure rates over 90%.", "offsetInBeginSection": 0, "offsetInEndSection": 149, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21652618", "text": "To maximize treatment success and reduce the likelihood of drug resistance selection, a proper individualization of hepatitis C therapy will be required, choosing the most convenient drugs and strategies according to distinct viral and host profiles.", "offsetInBeginSection": 1256, "offsetInEndSection": 1506, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22242928", "text": "INTRODUCTION The combination of pegylated interferon-\u03b1 plus ribavirin (pegIFN\u03b1-RBV) has been the only therapeutic option for patients with chronic hepatitis C virus (HCV) infection during the last decade.", "offsetInBeginSection": 0, "offsetInEndSection": 206, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22242928", "text": "The addition of any of the two recently approved HCV protease inhibitors, boceprevir or telaprevir, to pegIFN\u03b1-RBV results in the cure for two-thirds of HCV genotype 1, interferon-naive patients.", "offsetInBeginSection": 454, "offsetInEndSection": 650, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22242928", "text": "AREAS COVERED This paper reviews new antivirals for hepatitis C and HCV treatment failures, along with HCV drug resistance and rescue therapies.", "offsetInBeginSection": 653, "offsetInEndSection": 797, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22242928", "text": "The recent introduction of new direct-acting antivirals (DAA) has revolutionized the hepatitis C field.", "offsetInBeginSection": 350, "offsetInEndSection": 453, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24782255", "text": "The development of new models and tools has led to the discovery and clinical development of a large number of new anti-hepatitis C virus (HCV) drugs, including direct-acting antivirals and host-targeted agents.", "offsetInBeginSection": 0, "offsetInEndSection": 211, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21866039", "text": "As a result of using first-generation DAAs in HIV-HCV-co-infected patients, a growing proportion of the remaining hepatitis C individuals will be those harboring non-HCV 1 genotypes or drug-resistant HCV variants.", "offsetInBeginSection": 600, "offsetInEndSection": 813, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21866039", "text": "The approval of the first direct-acting antivirals (DAAs) against the hepatitis C virus (HCV) has been eagerly expected for treating chronic hepatitis C in HIV individuals given that progression to cirrhosis and end-stage liver disease occurs faster in the co-infected population.", "offsetInBeginSection": 0, "offsetInEndSection": 280, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a9d96564e03427e73000001", "body": "List major risk factors for Alzheimer's disease. ", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/7866485", "http://www.ncbi.nlm.nih.gov/pubmed/15926136", "http://www.ncbi.nlm.nih.gov/pubmed/8881379", "http://www.ncbi.nlm.nih.gov/pubmed/35596914", "http://www.ncbi.nlm.nih.gov/pubmed/16945215", "http://www.ncbi.nlm.nih.gov/pubmed/31556570", "http://www.ncbi.nlm.nih.gov/pubmed/15191699", "http://www.ncbi.nlm.nih.gov/pubmed/20182020", "http://www.ncbi.nlm.nih.gov/pubmed/16945210", "http://www.ncbi.nlm.nih.gov/pubmed/35606148"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/16945215", "text": "Apolipoprotein E is the major risk factor for Alzheimer's disease.", "offsetInBeginSection": 581, "offsetInEndSection": 647, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11884656", "text": "The apolipoprotein E E4 allele and a positive family history (FH) are both genetic risk factors for AD.", "offsetInBeginSection": 102, "offsetInEndSection": 205, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23375669", "text": "The vestibular loss hypothesis is further supported by the vestibular symptoms found in Alzheimer's patients as well as in various diseases that are major risk factors for Alzheimer's disease.", "offsetInBeginSection": 502, "offsetInEndSection": 694, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27688858", "text": "Three other important modifiable risk factors should also be added to this list: midlife hypercholesterolemia, late life atrial fibrillation, and chronic kidney disease.", "offsetInBeginSection": 865, "offsetInEndSection": 1034, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27688858", "text": "Among the 93 identified risk factors, seven major modifiable ones should be considered: low education, sedentary lifestyle, midlife obesity, midlife smoking, hypertension, diabetes, and midlife depression.", "offsetInBeginSection": 659, "offsetInEndSection": 864, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/14710446", "text": "There is now strong epidemiologic evidence supporting an association between Alzheimer disease and two major vascular risk factors--blood pressure and diabetes.", "offsetInBeginSection": 263, "offsetInEndSection": 423, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16314757", "text": "The apolipoprotein gene E4 allele (APOE 4) is a major risk factor for the disease.", "offsetInBeginSection": 137, "offsetInEndSection": 219, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20182020", "text": "The major vascular risk factors such as diabetes and impaired glycemic control, hypertension, obesity, and hyper- or dyslipidemia have been associated both with Alzheimer's disease and vascular dementia.", "offsetInBeginSection": 223, "offsetInEndSection": 426, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20182020", "text": "Midlife diabetes mellitus, hypertension, and obesity are established risk factors for clinically defined Alzheimer's disease as well as vascular dementia.", "offsetInBeginSection": 838, "offsetInEndSection": 992, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26993513", "text": "These compounds are clinically effective against major risk factors for Alzheimer's disease: hypertension, stroke, chronic kidney disease, diabetes and metabolic syndrome, and ameliorate age-dependent cognitive loss.", "offsetInBeginSection": 1034, "offsetInEndSection": 1250, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a7486a90384be9551000003", "body": "Which molecules are inhibited by anticancer drug Dovitinib?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22180308", "http://www.ncbi.nlm.nih.gov/pubmed/23041231", "http://www.ncbi.nlm.nih.gov/pubmed/25683141", "http://www.ncbi.nlm.nih.gov/pubmed/27025387", "http://www.ncbi.nlm.nih.gov/pubmed/29101463", "http://www.ncbi.nlm.nih.gov/pubmed/34882068", "http://www.ncbi.nlm.nih.gov/pubmed/25572783", "http://www.ncbi.nlm.nih.gov/pubmed/26149476", "http://www.ncbi.nlm.nih.gov/pubmed/25023489", "http://www.ncbi.nlm.nih.gov/pubmed/35398252"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/23041231", "text": "Dovitinib inhibited the catalytic decatenation activity of topoisomerase II\u03b1.", "offsetInBeginSection": 815, "offsetInEndSection": 893, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23041231", "text": "Dovitinib (TKI258/CHIR258) is a multi-kinase inhibitor in phase III development for the treatment of several cancers.", "offsetInBeginSection": 0, "offsetInEndSection": 117, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23041231", "text": "Finally, dovitinib inhibited the topoisomerase I-catalyzed relaxation of plasmid DNA and acted as a cellular topoisomerase I poison.", "offsetInBeginSection": 1365, "offsetInEndSection": 1497, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23041231", "text": "Dovitinib is a benzimidazole-quinolinone compound that structurally resembles the bisbenzimidazole minor groove binding dye Hoechst 33258.", "offsetInBeginSection": 118, "offsetInEndSection": 256, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22674553", "text": "Dovitinib, a drug in clinical development, showed greater activity than sunitinib and sirolimus.", "offsetInBeginSection": 1286, "offsetInEndSection": 1382, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25521244", "text": "Dovitinib weakly inhibited CYP2C19, CYP3A4, P-gp and OATPs.", "offsetInBeginSection": 963, "offsetInEndSection": 1022, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26149476", "text": "INTRODUCTION Erlotinib is a FDA approved small molecule inhibitor of epidermal growth factor receptor and dovitinib is a novel small molecule inhibitor of fibroblast growth factor and vascular endothelial growth factor receptor.", "offsetInBeginSection": 0, "offsetInEndSection": 228, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22180308", "text": "The multiple kinase inhibitor dovitinib is currently under clinical investigation for hepatocellular carcinoma (HCC).", "offsetInBeginSection": 0, "offsetInEndSection": 117, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23443805", "text": "Here, we explore the therapeutic potential of 2 FGFR inhibitors, the multikinase inhibitor dovitinib (TKI258) and the more selective FGFR inhibitor NVP-BGJ398 for the treatment of endometrial cancer.", "offsetInBeginSection": 179, "offsetInEndSection": 378, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23443805", "text": "Dovitinib and NVP-BGJ398 warrant further clinical evaluation in patients with FGFR2-mutated endometrial cancer.", "offsetInBeginSection": 1565, "offsetInEndSection": 1676, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a67c497b750ff4455000012", "body": "Which method is available for whole genome identification of pathogenic regulatory variants in mendelian disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26405949", "http://www.ncbi.nlm.nih.gov/pubmed/27569544", "http://www.ncbi.nlm.nih.gov/pubmed/25567867", "http://www.ncbi.nlm.nih.gov/pubmed/22258526", "http://www.ncbi.nlm.nih.gov/pubmed/28518168", "http://www.ncbi.nlm.nih.gov/pubmed/33059815", "http://www.ncbi.nlm.nih.gov/pubmed/30352806", "http://www.ncbi.nlm.nih.gov/pubmed/23104884", "http://www.ncbi.nlm.nih.gov/pubmed/24384736", "http://www.ncbi.nlm.nih.gov/pubmed/26506899"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27569544", "text": "Overall, Genomiser is able to identify causal regulatory variants as the\u00a0top candidate in 77% of simulated whole genomes, allowing effective detection and discovery of regulatory variants in Mendelian disease.", "offsetInBeginSection": 719, "offsetInEndSection": 929, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27569544", "text": "Genomiser scores variants through either existing methods such as CADD or a bespoke machine learning method and combines these with allele frequency, regulatory sequences, chromosomal topological domains, and phenotypic relevance to\u00a0discover variants associated to specific Mendelian disorders.", "offsetInBeginSection": 423, "offsetInEndSection": 718, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27569544", "text": "The interpretation of non-coding variants still constitutes a major challenge in the application of whole-genome sequencing in Mendelian disease, especially for single-nucleotide and other small non-coding variants.", "offsetInBeginSection": 0, "offsetInEndSection": 215, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27354691", "text": "The results suggest that Mendelian disease genes with autosomal dominant (AD) inheritance mode are more haploinsufficiency and de novo mutation sensitive, whereas those autosomal recessive (AR) genes have significantly more non-synonymous variants and regulatory transcript isoforms.", "offsetInBeginSection": 620, "offsetInEndSection": 903, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25024279", "text": "Whole exome and whole genome sequencing are now routinely used in the study of inherited disease, and some of their major successes have been the identification of genes involved in disease predisposition in pedigrees where disease seems to follow Mendelian inheritance patterns.", "offsetInBeginSection": 0, "offsetInEndSection": 279, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20577567", "text": "Here we sequenced the whole genome of a single patient with the dominant Mendelian disease, metachondromatosis (OMIM 156250), and used partial linkage data from her small family to focus our search for the responsible variant.", "offsetInBeginSection": 364, "offsetInEndSection": 590, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28041643", "text": "Whole-genome sequencing gives unprecedented power to detect three categories of pathogenic variants in particular: structural variants, variants in GC-rich regions, which have significantly improved coverage compared to whole-exome sequencing, and variants in non-coding regulatory regions.", "offsetInBeginSection": 512, "offsetInEndSection": 802, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28041643", "text": "In addition to previously reported pathogenic regulatory variants, we have identified a previously unreported pathogenic intronic variant in CHM in two males with choroideremia.", "offsetInBeginSection": 803, "offsetInEndSection": 980, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26405949", "text": "Therefore, an automatic and efficient pipeline for finding disease variants in Mendelian disorders is designed by exploiting a combination of variants filtering steps to analyze the family-based exome sequencing approach.", "offsetInBeginSection": 429, "offsetInEndSection": 650, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28518168", "text": "PurposeWhole-exome and whole-genome sequencing have transformed the discovery of genetic variants that cause human Mendelian disease, but discriminating pathogenic from benign variants remains a daunting challenge.", "offsetInBeginSection": 0, "offsetInEndSection": 214, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a9acd921d1251d03b000016", "body": "In what phase of clinical trials is crenezumab? (November 2017)", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25880481", "http://www.ncbi.nlm.nih.gov/pubmed/24981190", "http://www.ncbi.nlm.nih.gov/pubmed/29695589", "http://www.ncbi.nlm.nih.gov/pubmed/32568196", "http://www.ncbi.nlm.nih.gov/pubmed/29955659", "http://www.ncbi.nlm.nih.gov/pubmed/26467270", "http://www.ncbi.nlm.nih.gov/pubmed/36121669", "http://www.ncbi.nlm.nih.gov/pubmed/24490853", "http://www.ncbi.nlm.nih.gov/pubmed/34347883", "http://www.ncbi.nlm.nih.gov/pubmed/32040044"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/25880481", "text": "Solanezumab (Eli Lilly) and crenezumab (Genentech) are the leading clinical antibodies targeting Amyloid-\u03b2 (A\u03b2) to be tested in multiple Phase III clinical trials for the prevention of Alzheimer's disease in at-risk individuals.", "offsetInBeginSection": 0, "offsetInEndSection": 230, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24445401", "text": "Second-generation active A\u03b2 vaccines (ACC-001, CAD106, and Affitope AD02) and new passive anti-A\u03b2 immunotherapies (gantenerumab and crenezumab) are being tested in prodromal Alzheimer's disease patients, in presymptomatic individuals with Alzheimer's disease-related mutations, or in asymptomatic individuals at risk of developing Alzheimer's disease to definitely test the A\u03b2 cascade hypothesis of Alzheimer's disease.", "offsetInBeginSection": 1142, "offsetInEndSection": 1564, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24445401", "text": "Among passive immunotherapeutics, two Phase III clinical trials in mild-to-moderate Alzheimer's disease patients with bapineuzumab, a humanized monoclonal antibody directed at the N-terminal sequence of A\u03b2, were disappointing.", "offsetInBeginSection": 599, "offsetInEndSection": 826, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28760727", "text": "RESULTS Recruitment for the first phase of this project commenced in November 2016, and the phase will run from February to November 2017.", "offsetInBeginSection": 2157, "offsetInEndSection": 2295, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28760727", "text": "TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry (ANZCTR) ACTRN12616001243404p; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=371422 (Archived by WebCite at http://www.webcitation.org/ 6rmlEiM1L).", "offsetInBeginSection": 2590, "offsetInEndSection": 2823, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24490853", "text": "Among passive immunotherapeutics, two Phase III clinical trials in mild-to-moderate AD patients with bapineuzumab, a humanized monoclonal antibody directed at the N-terminal sequence of A\u03b2, were disappointing.", "offsetInBeginSection": 159, "offsetInEndSection": 369, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29099493", "text": "Peripheral blood samples from 21 patients with relapsed/refractory CLL in acalabrutinib phase I (100-400\u2009mg/day) and II (100\u2009mg BID) clinical trials were collected prior to and on days 8 and 28 after treatment initiation and evaluated for plasma chemokines, reverse phase protein array, immunoblotting, and pseudoemperipolesis.", "offsetInBeginSection": 633, "offsetInEndSection": 964, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28720101", "text": "Ongoing Phase III clinical trials via passive immunotherapy against A\u03b2 peptides (crenezumab, gantenerumab, and aducanumab) seem to be promising.", "offsetInBeginSection": 1431, "offsetInEndSection": 1576, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28720101", "text": "Using small molecules blocking 5-HT6 serotonin receptor (intepirdine), inhibiting BACE activity (E2609, AZD3293, and verubecestat), or reducing tau aggregation (TRx0237) are also currently in Phase III clinical trials.", "offsetInBeginSection": 1577, "offsetInEndSection": 1795, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25027481", "text": "The Biomet Nano (Biomet, Warsaw, IN, USA) clinical trial began in October 2013 and also has a tentative completion date of 2017.", "offsetInBeginSection": 1067, "offsetInEndSection": 1195, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aa55b45d6d6b54f7900000d", "body": "What organism causes scarlet fever also known as scarletina?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34969060", "http://www.ncbi.nlm.nih.gov/pubmed/33448168", "http://www.ncbi.nlm.nih.gov/pubmed/26819960", "http://www.ncbi.nlm.nih.gov/pubmed/23735582", "http://www.ncbi.nlm.nih.gov/pubmed/28882851", "http://www.ncbi.nlm.nih.gov/pubmed/24168973", "http://www.ncbi.nlm.nih.gov/pubmed/30571828", "http://www.ncbi.nlm.nih.gov/pubmed/8440944", "http://www.ncbi.nlm.nih.gov/pubmed/2498210", "http://www.ncbi.nlm.nih.gov/pubmed/1775408"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/2772682", "text": "The severity of symptoms and the demonstration of scarlet fever developing from infection with this organism supports antibiotic treatment of patients with group C streptococcal pharyngitis.", "offsetInBeginSection": 444, "offsetInEndSection": 634, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19868695", "text": "Scarlatinal antistreptococcic serum affords some degree of protection against virulent scarlet fever streptococci but has no protective power against hemolytic streptococci from other diseases.", "offsetInBeginSection": 987, "offsetInEndSection": 1180, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19868695", "text": "In a small epidemic of scarlet fever a healthy carrier of hemolytic streptococcus was detected; the organism carried was identical in its serological reactions with strains of hemolytic streptococci isolated from active cases of scarlet fever.", "offsetInBeginSection": 1184, "offsetInEndSection": 1427, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2045646", "text": "We present a case that illustrates the distinctive clinical spectrum of A. hemolyticum infections that may be confused with drug allergy, group A streptococcal scarlet fever, diphtheria, and even toxic shock syndrome.", "offsetInBeginSection": 249, "offsetInEndSection": 466, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8415304", "text": "Other streptococcal and staphylococcal cutaneous infections may exhibit overlapping clinical features, including scarlet fever, impetigo, toxic shock syndrome, and cellulitis.", "offsetInBeginSection": 379, "offsetInEndSection": 554, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19869456", "text": "The clinical and bacteriological findings in two cows the udders of which became infected under natural conditions with hemolytic streptococci of the scarlet fever type are discussed.", "offsetInBeginSection": 0, "offsetInEndSection": 183, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/125514", "text": "Consequently, a higher immunological reactivity of the organism in children in Ashkhabad (promoting rapid formation of both the antitoxic and the antimicrobial immunity and limiting of the spread of marked scarlet fever affections) underlied the differences in the level of scarlet fever morbidity in different climatic zones.", "offsetInBeginSection": 810, "offsetInEndSection": 1136, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7405299", "text": "More discussed are the infectious hospitalism, the salmonellial enteritis, the yersinioses, typhoid fever, paratyphoid fever, bacterial dysentery, scarlet fever, diphtheria, meningitis, brucelloses, leptospiroses, listerioses, pneumonias, bronchitis, obstructive diseases of the respiratory tract as well as pyelonephritis and bacterial carditis.", "offsetInBeginSection": 599, "offsetInEndSection": 945, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19869457", "text": "The streptococcus isolated from the udder of a cow on a farm where an outbreak of scarlet fever originated has been correlated with known scarlet fever strains.", "offsetInBeginSection": 0, "offsetInEndSection": 160, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19869457", "text": "Skin tests indicate that the strain isolated from the milk of the cow in a herd to which the scarlet fever epidemic was attributed produced a toxin which was neutralized with scarlet fever antitoxin.", "offsetInBeginSection": 327, "offsetInEndSection": 526, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a9da8df4e03427e73000006", "body": "What is emicizumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33559300", "http://www.ncbi.nlm.nih.gov/pubmed/33612049", "http://www.ncbi.nlm.nih.gov/pubmed/32237902", "http://www.ncbi.nlm.nih.gov/pubmed/32668090", "http://www.ncbi.nlm.nih.gov/pubmed/32311809", "http://www.ncbi.nlm.nih.gov/pubmed/32099331", "http://www.ncbi.nlm.nih.gov/pubmed/33851509", "http://www.ncbi.nlm.nih.gov/pubmed/35521723", "http://www.ncbi.nlm.nih.gov/pubmed/32157756", "http://www.ncbi.nlm.nih.gov/pubmed/34098819"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/29042366", "text": "FVIII-Fc and PEGylated FVIII), monoclonal antibodies targeting tissue factor pathway inhibitor, si-RNA to reduce antithrombin expression and the bispecific antibody ACE910/Emicizumab.", "offsetInBeginSection": 209, "offsetInEndSection": 392, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29042366", "text": "Emicizumab is a bispecific antibody recognizing both the enzyme factor IXa (FIXa) and the substrate factor X (FX).", "offsetInBeginSection": 393, "offsetInEndSection": 507, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28451690", "text": "Emicizumab, a humanised bispecific antibody recognising factors (F) IX/IXa and X/Xa, can accelerate FIXa-catalysed FX activation by bridging FIXa and FX in a manner similar to FVIIIa.", "offsetInBeginSection": 0, "offsetInEndSection": 183, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28691557", "text": "This phase 3, multicenter trial assessed once-weekly subcutaneous emicizumab prophylaxis in persons with hemophilia A with factor VIII inhibitors.", "offsetInBeginSection": 171, "offsetInEndSection": 317, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28691557", "text": "BACKGROUND Emicizumab (ACE910) bridges activated factor IX and factor X to restore the function of activated factor VIII, which is deficient in persons with hemophilia A.", "offsetInBeginSection": 0, "offsetInEndSection": 170, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27795538", "text": "ACE910 (emicizumab) is a humanized bispecific antibody recognizing factor IXa and X mimicking factor VIII function.", "offsetInBeginSection": 350, "offsetInEndSection": 465, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27960628", "text": "Of these, 5 mAbs are for cancer (durvalumab, JNJ-56022473, ublituximab, anetumab ravtansine, glembatumumab vedotin) and 15 mAbs are for non-cancer indications (caplacizumab, lanadelumab, roledumab, tralokinumab, risankizumab, SA237, emapalumab, suptavumab, erenumab, eptinezumab, fremanezumab, fasinumab, tanezumab, lampalizumab, brolucizumab).", "offsetInBeginSection": 1609, "offsetInEndSection": 1953, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27885373", "text": "A promising approach in 2016 is the development of emicizumab (ACE910), a bi-specific IgG antibody to factor IXa and factor X, that mimics the cofactor function of factor VIII.", "offsetInBeginSection": 484, "offsetInEndSection": 660, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27405674", "text": "Recently, recombinant porcine FVIII (rpFVIII, Obixur, OBI-1, BAX801) has been developed for the haemostatic treatment of both congenital haemophilia with inhibitor (CHAWI) and acquired haemophilia A (AHA).", "offsetInBeginSection": 547, "offsetInEndSection": 752, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27405674", "text": "These are humanized asymmetric antibody mimicking FVIIIa function by maintaining a suitable interaction between FIXa and FX (Emicizumab, ACE910), and small interfering RNAs (siRNA, ALN-AT3) suppress liver production of AT through post-transcriptional gene silencing and a humanized anti-TFPI monoclonal antibody (Concizumab).", "offsetInBeginSection": 1082, "offsetInEndSection": 1407, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a75df9883b0d9ea66000002", "body": "Which cancers compose Carney's triad?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/3827356", "http://www.ncbi.nlm.nih.gov/pubmed/12893072", "http://www.ncbi.nlm.nih.gov/pubmed/7842572", "http://www.ncbi.nlm.nih.gov/pubmed/12149713", "http://www.ncbi.nlm.nih.gov/pubmed/19561114", "http://www.ncbi.nlm.nih.gov/pubmed/2190857", "http://www.ncbi.nlm.nih.gov/pubmed/6263093", "http://www.ncbi.nlm.nih.gov/pubmed/34782012", "http://www.ncbi.nlm.nih.gov/pubmed/32399353", "http://www.ncbi.nlm.nih.gov/pubmed/10468897"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/3827356", "text": "Carney's Triad comprises a triad of neoplasms: gastric stromal tumor, extra-adrenal paraganglioma (usually functional), and pulmonary chondroma.", "offsetInBeginSection": 0, "offsetInEndSection": 144, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/3827356", "text": "Thus, the Triad may be a disorder of the autonomic nervous system rather than a multiple endocrine neoplasia syndrome or multiple hamartoma syndrome.", "offsetInBeginSection": 638, "offsetInEndSection": 787, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11878780", "text": "This report encourages clinicians to consider a diagnosis of Carney's triad in patients with multifocal gastric stromal sarcoma, extraadrenal paraganglioma (predominantly mediastinal), or pulmonary chondroma.", "offsetInBeginSection": 0, "offsetInEndSection": 208, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12893072", "text": "Carney's triad is a syndrome of unknown etiology, representing a combination of gastrointestinal stromal tumors, bronchial chondromas and vagal, adrenal or paraadrenal paragangliomas.", "offsetInBeginSection": 0, "offsetInEndSection": 183, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12893072", "text": "Two of the Carney's triad components-the paragangliomas and the gastrointestinal stromal tumors-are potentially lethal.", "offsetInBeginSection": 184, "offsetInEndSection": 303, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8091266", "text": "Carney's triad, a rare disorder affecting young females, is characterized by the presence of at least two of the three following neoplasms: gastric epithelioid leiomyosarcoma, extra-adrenal paraganglioma, and pulmonary chondroma.", "offsetInBeginSection": 0, "offsetInEndSection": 229, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8091266", "text": "MRI is as effective as MIBG scintigraphy in detecting functioning paragangliomas.", "offsetInBeginSection": 476, "offsetInEndSection": 557, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10468897", "text": "The etiology of the Carney's triad (gastrointestinal stromal tumors, pulmonary chondromas, and paragangliomas) is unknown, and only 57 cases have been reported since its identification in 1977.", "offsetInBeginSection": 0, "offsetInEndSection": 193, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24840526", "text": "New adrenal tumors have also been associated with nonhereditary Carney's triad.", "offsetInBeginSection": 602, "offsetInEndSection": 681, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8272014", "text": "Carney's triad is defined by the coexistence of at least two of three rare disorders, including gastric epithelioid leiomyosarcoma (malignant leiomyoblastoma), pulmonary chondroma, and paraganglioma, most often extra-adrenal and functioning.", "offsetInBeginSection": 0, "offsetInEndSection": 241, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a9d28981d1251d03b000017", "body": "Does verubecestat activate BACE?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27933948", "http://www.ncbi.nlm.nih.gov/pubmed/28800329", "http://www.ncbi.nlm.nih.gov/pubmed/31215755", "http://www.ncbi.nlm.nih.gov/pubmed/30044206", "http://www.ncbi.nlm.nih.gov/pubmed/31387606", "http://www.ncbi.nlm.nih.gov/pubmed/34825396", "http://www.ncbi.nlm.nih.gov/pubmed/35846156", "http://www.ncbi.nlm.nih.gov/pubmed/29397980", "http://www.ncbi.nlm.nih.gov/pubmed/33049114", "http://www.ncbi.nlm.nih.gov/pubmed/28749667"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27807285", "text": "We show that verubecestat (MK-8931) is a potent, selective, structurally unique BACE1 inhibitor that reduced plasma, cerebrospinal fluid (CSF), and brain concentrations of A\u03b240, A\u03b242, and sAPP\u03b2 (a direct product of BACE1 enzymatic activity) after acute and chronic administration to rats and monkeys.", "offsetInBeginSection": 305, "offsetInEndSection": 608, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27023706", "text": "The most progressed mechanism-based therapies to date consist of immunological interventions to clear A\u03b2 oligomers, and pharmacological drugs to inhibit the secretase enzymes that produce A\u03b2, namely \u03b2-site amyloid precursor-cleaving enzyme (BACE) and \u03b3-secretase.", "offsetInBeginSection": 948, "offsetInEndSection": 1215, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28720101", "text": "These investigations include acetylcholinesterase inhibitors, agonists and antagonists of neurotransmitter receptors, \u03b2-secretase (BACE) or \u03b3-secretase inhibitors, vaccines or antibodies targeting A\u03b2 clearance or tau protein, as well as anti-inflammation compounds.", "offsetInBeginSection": 1162, "offsetInEndSection": 1430, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28720101", "text": "Using small molecules blocking 5-HT6 serotonin receptor (intepirdine), inhibiting BACE activity (E2609, AZD3293, and verubecestat), or reducing tau aggregation (TRx0237) are also currently in Phase III clinical trials.", "offsetInBeginSection": 1577, "offsetInEndSection": 1795, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28720101", "text": "Recent therapeutic approaches have been strongly influenced by five neuropathological hallmarks of AD: acetylcholine deficiency, glutamate excitotoxicity, extracellular deposition of amyloid-\u03b2 (A\u03b2 plague), formation of intraneuronal neurofibrillary tangles (NTFs), and neuroinflammation.", "offsetInBeginSection": 260, "offsetInEndSection": 549, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27678025", "text": "Expert opinion: Drugs in Phase III clinical development for AD include one inhibitor of the \u03b2-secretase cleaving enzyme (BACE) (verubecestat), three anti-A\u03b2 monoclonal antibodies (solanezumab, gantenerumab, and aducanumab), an inhibitor of receptor for advanced glycation end products (RAGE) (azeliragon) and the combination of cromolyn sodium and ibuprofen (ALZT-OP1).", "offsetInBeginSection": 520, "offsetInEndSection": 891, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27933948", "text": "Verubecestat 3 (MK-8931), a diaryl amide-substituted 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative, is a high-affinity \u03b2-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor currently undergoing Phase 3 clinical evaluation for the treatment of mild to moderate and prodromal Alzheimer's disease.", "offsetInBeginSection": 0, "offsetInEndSection": 315, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1328241", "text": "Analysis of p34cdc2 activity in BACE cells revealed potent inhibition of p34cdc2 histone H1 kinase activity by TGF-beta 1.", "offsetInBeginSection": 974, "offsetInEndSection": 1096, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1328241", "text": "Responses of bovine adrenal capillary endothelial cells (BACE) on treatment with transforming growth factor beta 1 (TGF-beta 1) have been characterized and tested for sensitivity to inactivation of pertussis toxin-sensitive G-proteins.", "offsetInBeginSection": 0, "offsetInEndSection": 235, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1328241", "text": "Pertussis toxin treatment enhanced both inhibition of BACE cell [3H]methylthymidine uptake and remodeling of BACE monolayers by TGF-beta 1.", "offsetInBeginSection": 467, "offsetInEndSection": 606, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a9dad764e03427e73000007", "body": "What is the preDIVA clinical trial?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28596452", "http://www.ncbi.nlm.nih.gov/pubmed/20306005", "http://www.ncbi.nlm.nih.gov/pubmed/28263374", "http://www.ncbi.nlm.nih.gov/pubmed/29960597", "http://www.ncbi.nlm.nih.gov/pubmed/30738826", "http://www.ncbi.nlm.nih.gov/pubmed/22818266", "http://www.ncbi.nlm.nih.gov/pubmed/30291317", "http://www.ncbi.nlm.nih.gov/pubmed/15859523", "http://www.ncbi.nlm.nih.gov/pubmed/36398446", "http://www.ncbi.nlm.nih.gov/pubmed/25548315"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28596452", "text": "METHODS The preDIVA trial (Prevention of Dementia by Intensive Vascular Care) was an open-label, cluster-randomized controlled trial in community-dwelling individuals aged 70 to 78 years.", "offsetInBeginSection": 248, "offsetInEndSection": 435, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20306005", "text": "DESIGN, SETTING AND PARTICIPANTS Multi-center, open, cluster-randomized controlled clinical trial (preDIVA) including 3535 non-demented subjects aged 70-78, executed in primary practice and coordinated from one academic hospital.", "offsetInBeginSection": 169, "offsetInEndSection": 398, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28263374", "text": "OBJECTIVES To explore and compare sociodemographic, clinical, and neuropsychiatric determinants of dropout and nonadherence in older people participating in an open-label cluster-randomized controlled trial-the Prevention of Dementia by Intensive Vascular care (preDIVA) trial-over 6 years.", "offsetInBeginSection": 0, "offsetInEndSection": 290, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28263374", "text": "INTERVENTION Nurse-led multidomain intervention targeting cardiovascular risk factors to prevent dementia.", "offsetInBeginSection": 463, "offsetInEndSection": 569, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22818266", "text": "Three large RCTs on multi-component interventions to prevent dementia (preDIVA, FINGER, MAPT) have been initiated in Europe to address these issues.", "offsetInBeginSection": 329, "offsetInEndSection": 477, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19812459", "text": "Intensive vascular care comprises treatment of hypertension, hypercholesterolemia, diabetes and reducing overweight, smoking cessation, and stimulating physical exercise.", "offsetInBeginSection": 840, "offsetInEndSection": 1010, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24418410", "text": "At the moment, it includes three large ongoing European trials: Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER), Prevention of Dementia by Intensive Vascular Care (preDIVA), and Multidomain Alzheimer Prevention study (MAPT).", "offsetInBeginSection": 922, "offsetInEndSection": 1191, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25548315", "text": "DESIGN AND SETTING Qualitative study of current and former participants of the ongoing \u22656 year PreDIVA (prevention of dementia by intensive vascular care) trial in primary care practices in suburban areas in the Netherlands.", "offsetInBeginSection": 428, "offsetInEndSection": 654, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21930719", "text": "DESIGN Cross-sectional analysis of Dutch community-dwelling subjects aged 70-78 years without dementia who were included in the cluster randomized preDIVA trial (Prevention of Dementia by Intensive Vascular care).", "offsetInBeginSection": 270, "offsetInEndSection": 483, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27474376", "text": "This trial is registered with ISRCTN, number ISRCTN29711771.", "offsetInBeginSection": 983, "offsetInEndSection": 1043, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a76072283b0d9ea66000013", "body": "Does armodafinil improve fatigue of glioma patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26902850", "http://www.ncbi.nlm.nih.gov/pubmed/25370889", "http://www.ncbi.nlm.nih.gov/pubmed/34882169", "http://www.ncbi.nlm.nih.gov/pubmed/26542272", "http://www.ncbi.nlm.nih.gov/pubmed/25972454", "http://www.ncbi.nlm.nih.gov/pubmed/36094728", "http://www.ncbi.nlm.nih.gov/pubmed/16908126", "http://www.ncbi.nlm.nih.gov/pubmed/16684437", "http://www.ncbi.nlm.nih.gov/pubmed/23983964", "http://www.ncbi.nlm.nih.gov/pubmed/21777715"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850", "text": "CONCLUSIONS While treatment was well-tolerated, an 8-week course of armodafinil did not improve fatigue or QOL in glioma patients undergoing RT in this pilot study.", "offsetInBeginSection": 1326, "offsetInEndSection": 1490, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850", "text": "We evaluated whether armodafinil, a wakefulness-promoting medication, improves fatigue in glioma patients undergoing RT.", "offsetInBeginSection": 115, "offsetInEndSection": 235, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26542272", "text": "Armodafinil did not improve cancer-related fatigue (CRF) and did not change the efficacy of CBT-I.", "offsetInBeginSection": 1847, "offsetInEndSection": 1945, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26542272", "text": "Armodafinil alone did not show a statistically significant effect on fatigue levels (all Ps\u2009>\u20090.40) nor did the drug influence the efficacy of CBT-I.", "offsetInBeginSection": 1367, "offsetInEndSection": 1520, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25972454", "text": "We hypothesized that armodafinil (a wakefulness-promoting drug known to reduce fatigue and increase cognitive function in breast cancer patients receiving chemotherapy) would result in reduced fatigue and sleepiness for patients receiving brain RT.", "offsetInBeginSection": 167, "offsetInEndSection": 415, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25370889", "text": "Armodafinil is a drug known to promote wakefulness, which is related to modafinil, a compound that improves fatigue in some cancer patients treated with chemotherapeutic agents.", "offsetInBeginSection": 74, "offsetInEndSection": 251, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22960434", "text": "CONCLUSIONS Results provide preliminary evidence that armodafinil may improve delayed verbal recall in patients with MS. A larger trial showing enhanced memory among patients taking long-term armodafinil could serve as a foundation for its possible clinical use as a memory enhancer in patients with MS.", "offsetInBeginSection": 1279, "offsetInEndSection": 1582, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23983964", "text": "It has been suggested that modafinil and its isomer armodafinil as an add-on strategy to antipsychotic treatment in patients with schizophrenia may improve cognitive functioning, attenuate fatigue, inactiveness and other negative functions as well as weight gain.", "offsetInBeginSection": 224, "offsetInEndSection": 487, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23983964", "text": "The addition of modafinil or armodafinil to an antipsychotic regime, despite theoretical and preclinical considerations, has not been proved to enhance cognitive function, attenuate fatigue, enhance activity, improve negative symptoms and reduce weight in patients with schizophrenia.", "offsetInBeginSection": 1855, "offsetInEndSection": 2139, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23983964", "text": "Evidence for the use of modafinil or armodafinil as add-on therapy to antipsychotic drugs to alleviate fatigue, sleepiness and inactivity is inconclusive.", "offsetInBeginSection": 794, "offsetInEndSection": 948, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a9d29571d1251d03b000018", "body": "What effect does azeliragon have on RAGE?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29616709", "http://www.ncbi.nlm.nih.gov/pubmed/36257528", "http://www.ncbi.nlm.nih.gov/pubmed/31028960", "http://www.ncbi.nlm.nih.gov/pubmed/34763082", "http://www.ncbi.nlm.nih.gov/pubmed/27612394", "http://www.ncbi.nlm.nih.gov/pubmed/35430560", "http://www.ncbi.nlm.nih.gov/pubmed/31106449", "http://www.ncbi.nlm.nih.gov/pubmed/30940519", "http://www.ncbi.nlm.nih.gov/pubmed/33548580", "http://www.ncbi.nlm.nih.gov/pubmed/21617715"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27612394", "text": "Blockade of RAGE by antibodies anti-RAGE, TTP488 (azeliragon), or rRAGE prevents or limits the deleterious effect of AGEs.", "offsetInBeginSection": 616, "offsetInEndSection": 738, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27612394", "text": "RAGE engagement by ligands AGE, \u03b2-amyloid peptide, and S100 calgranulin induces a stimulation of NADPH oxidase, reactive oxygen intermediate formation, NF\u03baB activation and gene transcription.", "offsetInBeginSection": 290, "offsetInEndSection": 483, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16133426", "text": "Despite the lack of effect seen in adaptive immunity by the deletion of RAGE, administration of the receptor decoy, sRAGE, still afforded a protective effect in RAGE-/- mice.", "offsetInBeginSection": 1335, "offsetInEndSection": 1509, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16133426", "text": "The involvement of RAGE in pathophysiologic processes has been demonstrated in murine models of chronic disease using either a receptor decoy such as soluble RAGE (sRAGE), RAGE neutralizing antibodies, or a dominant-negative form of the receptor.", "offsetInBeginSection": 635, "offsetInEndSection": 881, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26758977", "text": "Although RAGE does not have any kinase motifs in its cytosolic domain, the interaction between RAGE and A\u03b2 triggers multiple cellular signaling involved in Alzheimer's disease (AD).", "offsetInBeginSection": 117, "offsetInEndSection": 299, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26758977", "text": "BACKGROUND The receptor for advanced glycation end products (RAGE) has been found to interact with amyloid \u03b2 (A\u03b2).", "offsetInBeginSection": 0, "offsetInEndSection": 116, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21617715", "text": "The migration assay showed that the interaction between RAGE and HMGB-1 increased SCC7 migration activity depending on the level of HMGB-1, and nifedipine inhibited the interaction effect between RAGE and HMGB-1 on SCC7 cells in a dose-dependent manner.", "offsetInBeginSection": 1398, "offsetInEndSection": 1651, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19591173", "text": "Cells were stimulated with agonist S100A4, fusion protein of RAGE encompassing the extracellular domain of RAGE (ex-RAGE), ex-RAGE followed by S100A4, or S100A4 followed by ex-RAGE.", "offsetInBeginSection": 407, "offsetInEndSection": 588, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19591173", "text": "In conclusion, ex-RAGE down-regulates RAGE expression and inhibits p65 and p52 activation in HSG, providing evidence that ex-RAGE functions as a \"decoy\" to RAGE-ligand interaction and thus potentially dampening inflammatory conditions.", "offsetInBeginSection": 1041, "offsetInEndSection": 1276, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19815443", "text": "Anti-RAGE antibody inhibited the effect of glycated proteins.", "offsetInBeginSection": 1293, "offsetInEndSection": 1354, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a9e2386de7cb99d40000004", "body": "What is the drug forxiga used for?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25418019", "http://www.ncbi.nlm.nih.gov/pubmed/35017166", "http://www.ncbi.nlm.nih.gov/pubmed/24030968", "http://www.ncbi.nlm.nih.gov/pubmed/30151080", "http://www.ncbi.nlm.nih.gov/pubmed/25402624", "http://www.ncbi.nlm.nih.gov/pubmed/33430328", "http://www.ncbi.nlm.nih.gov/pubmed/15948662", "http://www.ncbi.nlm.nih.gov/pubmed/18783709", "http://www.ncbi.nlm.nih.gov/pubmed/32157960", "http://www.ncbi.nlm.nih.gov/pubmed/3827057"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/25402624", "text": "This study explores the molecular interactions between AChE and SGLT2 with a new US Food and Drug Administration approved antidiabetic drug Forxiga (dapagliflozin) to explore a possible link between the treatments of AD and diabetes.", "offsetInBeginSection": 460, "offsetInEndSection": 693, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25402624", "text": "Hence, dapagliflozin might act as a potent dual inhibitor of SGLT2 and AChE.", "offsetInBeginSection": 1088, "offsetInEndSection": 1164, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25402624", "text": "Sodium glucose co-transporter 2 (SGLT2) is one of the best targets in the treatment of diabetes, whereas acetylcholinesterase (AChE) has long been regarded as a therapeutic target for AD.", "offsetInBeginSection": 272, "offsetInEndSection": 459, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25402624", "text": "Hydrophobic and cation-\u03c0 interactions play an important role in the correct positioning of dapagliflozin within the catalytic site (CAS) of SGLT2 and AChE enzymes to permit docking.", "offsetInBeginSection": 743, "offsetInEndSection": 925, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24030968", "text": "Dapagliflozin (Forxiga) belongs to a new class of oral glucose-lowering drugs that inhibit renal glucose reabsorption and promote glycosuria.", "offsetInBeginSection": 601, "offsetInEndSection": 742, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24030968", "text": "Here, we review the evidence for the use of dapagliflozin in the management of type 2 diabetes mellitus.", "offsetInBeginSection": 1241, "offsetInEndSection": 1345, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25418019", "text": "INTRODUCTION Dapagliflozin (DAPA) (Farxiga or Forxiga) is a sodium glucose cotransporter 2 (SGLT2) inhibitor approved for type 2 diabetes mellitus(T2DM) treatment.", "offsetInBeginSection": 0, "offsetInEndSection": 163, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20803315", "text": "AIM The purpose of this study was to investigate to what extent patients using prescription antiobesity drugs (orlistat, sibutramine and rimonabant) used cardiovascular and antidiabetic drugs.", "offsetInBeginSection": 0, "offsetInEndSection": 192, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20014050", "text": "AIM The aim of the present study was to investigate to what extent patients using prescription antiobesity drugs (orlistat, sibutramine and rimonabant) concomitantly or concurrently used psychotropic drugs and analgesics and the association between this drug use and the patients' gender and age.", "offsetInBeginSection": 0, "offsetInEndSection": 296, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26410245", "text": "The OL drug- and EPD-use were significantly associated with infancy and ventilation therapy.", "offsetInBeginSection": 1228, "offsetInEndSection": 1320, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a761ac3aacfb9cd4c000002", "body": "What is the most common feature of the Doege\u2013Potter syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22206790", "http://www.ncbi.nlm.nih.gov/pubmed/33348973", "http://www.ncbi.nlm.nih.gov/pubmed/35414906", "http://www.ncbi.nlm.nih.gov/pubmed/23749592", "http://www.ncbi.nlm.nih.gov/pubmed/32349492", "http://www.ncbi.nlm.nih.gov/pubmed/26414372", "http://www.ncbi.nlm.nih.gov/pubmed/26859671", "http://www.ncbi.nlm.nih.gov/pubmed/33976622", "http://www.ncbi.nlm.nih.gov/pubmed/26072009", "http://www.ncbi.nlm.nih.gov/pubmed/27376978"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/17130256", "text": "Metabolic syndrome, characterized by truncal obesity, hypertriglyceridemia, elevated BP, and insulin resistance, is recognized increasingly as a major risk factor for kidney disease and also is a common feature of patients who are on dialysis.", "offsetInBeginSection": 0, "offsetInEndSection": 243, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17130256", "text": "One feature that is common to patients with metabolic syndrome is an elevated uric acid.", "offsetInBeginSection": 244, "offsetInEndSection": 332, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17130256", "text": "It is proposed that fructose- and purine-rich foods that have in common the raising of uric acid may have a role in the epidemic of metabolic syndrome and renal disease that is occurring throughout the world.", "offsetInBeginSection": 812, "offsetInEndSection": 1020, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7712654", "text": "Malignant transformations are a common feature of this syndrome and have been reported in approximately 30% of reported cases, with chondrosarcomas being the most common.", "offsetInBeginSection": 192, "offsetInEndSection": 362, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24793812", "text": "This review discusses the some of the more frequent, recurrent karyotypic abnormalities in which CDH is a feature, including 15q26, 8p23.1 and 4p16.3 deletions and tetrasomy 12p (Pallister-Killian syndrome), together with some of the syndromes in which CDH is a relatively common feature, including Fryns syndrome, Matthew-Wood syndrome, overgrowth syndromes and Donnai-Barrow syndrome.", "offsetInBeginSection": 277, "offsetInEndSection": 663, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23806618", "text": "Similar phenotypes result from mutation of oral-facial-digital syndrome 1 (Ofd1), suggesting that aberrant transcription of Fgf8 is a common feature of ciliopathies.", "offsetInBeginSection": 609, "offsetInEndSection": 774, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27197926", "text": "Chromosome 22q11.2 deletion syndrome is common and presents with a range of clinical features from cardiac malformations to hypocalcemia.", "offsetInBeginSection": 0, "offsetInEndSection": 137, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27197926", "text": "Laryngeal anomalies are not a common feature of this syndrome.", "offsetInBeginSection": 138, "offsetInEndSection": 200, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17896212", "text": "The study confirms that dysfluencies are a common feature of the speech of individuals with fragile X syndrome but also indicates that the dysfluency pattern displayed is not identical to developmental stuttering.", "offsetInBeginSection": 177, "offsetInEndSection": 390, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8745978", "text": "Thrombocytopenia is a common feature in ICU patients which occurs usually in case of infection or septic shock.", "offsetInBeginSection": 0, "offsetInEndSection": 111, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a9d2a8f1d1251d03b000019", "body": "What is INCB3619?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16843264", "http://www.ncbi.nlm.nih.gov/pubmed/17363546", "http://www.ncbi.nlm.nih.gov/pubmed/18757423", "http://www.ncbi.nlm.nih.gov/pubmed/27489286", "http://www.ncbi.nlm.nih.gov/pubmed/19702537", "http://www.ncbi.nlm.nih.gov/pubmed/30656893", "http://www.ncbi.nlm.nih.gov/pubmed/6683883", "http://www.ncbi.nlm.nih.gov/pubmed/26692355", "http://www.ncbi.nlm.nih.gov/pubmed/15734663", "http://www.ncbi.nlm.nih.gov/pubmed/6359612"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/16843264", "text": "A selective ADAM inhibitor, INCB3619, prevents the processing and activation of multiple ErbB ligands, including heregulin.", "offsetInBeginSection": 409, "offsetInEndSection": 532, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16843264", "text": "In addition, INCB3619 inhibits gefitinib-resistant HER3 signaling and enhances gefitinib inhibition of EGFR signaling in NSCLC.", "offsetInBeginSection": 533, "offsetInEndSection": 660, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16843264", "text": "We describe here the existence of a heregulin-HER3 autocrine loop, and the contribution of heregulin-dependent, HER2-mediated HER3 activation to gefitinib insensitivity in non-small cell lung cancer (NSCLC).", "offsetInBeginSection": 0, "offsetInEndSection": 207, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17363546", "text": "RESULTS INCB3619 was identified as a representative selective, potent, orally bioavailable small-molecule inhibitor of a subset of ADAM proteases that block shedding of ErbB ligands.", "offsetInBeginSection": 956, "offsetInEndSection": 1138, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17363546", "text": "Further, INCB3619 synergized with clinically relevant cancer therapeutics and showed no overt or compounding toxicities, including fibroplasia, the dose-limiting toxicity associated with broad-spectrum matrix metalloprotease inhibitors.", "offsetInBeginSection": 1334, "offsetInEndSection": 1570, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18757423", "text": "Combining INCB3619 with a lapatinib-like dual inhibitor of EGFR and HER-2/neu kinases resulted in synergistic growth inhibition in MCF-7 and HER-2/neu-transfected MCF-7 human breast cancer cells.", "offsetInBeginSection": 1288, "offsetInEndSection": 1483, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18757423", "text": "Use of ErbB-specific antibodies to the receptors (Herceptin or Erbitux) or ErbB-specific small-molecule inhibitors of the receptor tyrosine kinase activity (Iressa or Tarceva) has shown clinical efficacy in several solid tumors.", "offsetInBeginSection": 145, "offsetInEndSection": 373, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18757423", "text": "This study has shown that addition of INCB3619, a potent inhibitor of ADAM10 and ADAM17, reduces in vitro HER-2/neu and amphiregulin shedding, confirming that it interferes with both HER-2/neu and EGFR ligand cleavage.", "offsetInBeginSection": 1069, "offsetInEndSection": 1287, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18757423", "text": "ADAM 10 is the main sheddase of epidermal growth factor (EGF) and HER-2/neu cleavage, whereas ADAM17 is required for cleavage of additional EGF receptor (EGFR) ligands (transforming growth factor-alpha, amphiregulin, heregulin, heparin binding EGF-like ligand).", "offsetInBeginSection": 807, "offsetInEndSection": 1068, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18757423", "text": "This sheddase activity is attributed to the ADAM (a disintegrin and metalloprotease) family of proteins.", "offsetInBeginSection": 702, "offsetInEndSection": 806, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aa4faaed6d6b54f7900000b", "body": "Is Citrobacter rodentium pathogenic?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25088150", "http://www.ncbi.nlm.nih.gov/pubmed/28612839", "http://www.ncbi.nlm.nih.gov/pubmed/29728609", "http://www.ncbi.nlm.nih.gov/pubmed/31541196", "http://www.ncbi.nlm.nih.gov/pubmed/34352594", "http://www.ncbi.nlm.nih.gov/pubmed/25702536", "http://www.ncbi.nlm.nih.gov/pubmed/12755369", "http://www.ncbi.nlm.nih.gov/pubmed/16008583", "http://www.ncbi.nlm.nih.gov/pubmed/19897651", "http://www.ncbi.nlm.nih.gov/pubmed/16926434"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/19897651", "text": "Citrobacter rodentium (formally Citrobacter freundii biotype 4280) is a highly infectious pathogen that causes colitis and transmissible colonic hyperplasia in mice.", "offsetInBeginSection": 0, "offsetInEndSection": 165, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19897651", "text": "In common with enteropathogenic and enterohemorrhagic Escherichia coli (EPEC and EHEC, respectively), C. rodentium exploits a type III secretion system (T3SS) to induce attaching and effacing (A/E) lesions that are essential for virulence.", "offsetInBeginSection": 166, "offsetInEndSection": 405, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25088150", "text": "Citrobacter rodentium is a mucosal pathogen of mice that shares several pathogenic mechanisms with enteropathogenic Escherichia coli (EPEC) and enterohaemorrhagic E. coli (EHEC), which are two clinically important human gastrointestinal pathogens.", "offsetInBeginSection": 0, "offsetInEndSection": 247, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16309456", "text": "This classical genome organization is well illustrated by a group of extracellular enteric pathogens, which includes enteropathogenic Escherichia coli (EPEC), enterohaemorrhagic E. coli (EHEC) and Citrobacter rodentium, all of which use attaching and effacing (A/E) lesion formation as a major mechanism of tissue targeting and infection.", "offsetInBeginSection": 420, "offsetInEndSection": 758, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23462619", "text": "C. rodentium is a gram negative, murine specific bacterial pathogen that is closely related to the clinically important human pathogens enteropathogenic E. coli and enterohemorrhagic E. coli.", "offsetInBeginSection": 188, "offsetInEndSection": 379, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24358033", "text": "Citrobacter rodentium (C. rodentium) is a member of the family of enteropathogens that provide an excellent in vivo model to investigate the host-pathogen interactions in real-time.", "offsetInBeginSection": 212, "offsetInEndSection": 393, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24831469", "text": "Citrobacter rodentium infection is a murine model of pathogenic Escherichia coli infection that allows investigation of the cellular and molecular mechanisms involved in host-protective immunity and bacterial-induced intestinal inflammation.", "offsetInBeginSection": 0, "offsetInEndSection": 241, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17557113", "text": "The bacterial mouse pathogen Citrobacter rodentium causes attaching and effacing (AE) lesions in the same manner as pathogenic Escherichia coli, and is an important model for this mode of pathogenesis.", "offsetInBeginSection": 0, "offsetInEndSection": 201, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22144475", "text": "The attaching and effacing mouse pathogen Citrobacter rodentium associates intimately with the intestinal epithelium, and infections result in acute colitis.", "offsetInBeginSection": 168, "offsetInEndSection": 325, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25624355", "text": "A well-studied example is the RegA regulon of the enteric pathogen Citrobacter rodentium.", "offsetInBeginSection": 207, "offsetInEndSection": 296, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a679e8cb750ff4455000006", "body": "Milwaukee protocol was tested for treatment of which disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26639059", "http://www.ncbi.nlm.nih.gov/pubmed/25956434", "http://www.ncbi.nlm.nih.gov/pubmed/33598230", "http://www.ncbi.nlm.nih.gov/pubmed/33174958", "http://www.ncbi.nlm.nih.gov/pubmed/18305449", "http://www.ncbi.nlm.nih.gov/pubmed/21208030", "http://www.ncbi.nlm.nih.gov/pubmed/33852711", "http://www.ncbi.nlm.nih.gov/pubmed/19263274", "http://www.ncbi.nlm.nih.gov/pubmed/18465396", "http://www.ncbi.nlm.nih.gov/pubmed/24708671"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26639059", "text": "Therapies suggested in the Milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm.", "offsetInBeginSection": 384, "offsetInEndSection": 550, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18465396", "text": "RESULTS Milwaukee brace 23-hours wearing protocol was most effective for the treatment of adolescent idiopathic scoliosis.", "offsetInBeginSection": 318, "offsetInEndSection": 440, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18465396", "text": "CONCLUSION With part-time wearing protocol, the Milwaukee brace can survive today as a treatment option for idiopathic scoliosis with thoracic curve or double curve.", "offsetInBeginSection": 808, "offsetInEndSection": 973, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21208030", "text": "Milwaukee brace 23-hours wearing protocol was most effective for the treatment of adolescent idiopathic scoliosis.", "offsetInBeginSection": 91, "offsetInEndSection": 205, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25956434", "text": "We report a case of a patient with paralytic rabies who survived after being treated with what is now known as Milwaukee protocol.", "offsetInBeginSection": 90, "offsetInEndSection": 220, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18305449", "text": "This report summarizes the clinical course of disease in that patient, who was treated using the Milwaukee Protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "offsetInBeginSection": 189, "offsetInEndSection": 403, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20881935", "text": "Earlier that day, an infectious disease physician in Virginia had contacted CDC requesting confirmatory diagnostic testing and reported initiating treatment with the Milwaukee protocol after consultation with staff at the Medical College of Wisconsin.", "offsetInBeginSection": 127, "offsetInEndSection": 378, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24708671", "text": "BACKGROUND Human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the Milwaukee Protocol for intensive care management has recently been employed, with limited success in improving survival.", "offsetInBeginSection": 0, "offsetInEndSection": 278, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24708671", "text": "Access to molecular diagnostics, pre- and post-mortem, and documentation of pathophysiological responses while using the Milwaukee protocol, can add useful insights for the future of rabies management.", "offsetInBeginSection": 279, "offsetInEndSection": 480, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24708671", "text": "Management guided by the Milwaukee protocol is feasible within well-resourced intensive care units, but its role in improving outcome for canine-derived rabies remains theoretical.", "offsetInBeginSection": 2096, "offsetInEndSection": 2276, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a9d2dd21d1251d03b00001a", "body": "What do the trispecific HIV antibodies target?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28931639", "http://www.ncbi.nlm.nih.gov/pubmed/29976677", "http://www.ncbi.nlm.nih.gov/pubmed/32732551", "http://www.ncbi.nlm.nih.gov/pubmed/31937648", "http://www.ncbi.nlm.nih.gov/pubmed/30157871", "http://www.ncbi.nlm.nih.gov/pubmed/32224500", "http://www.ncbi.nlm.nih.gov/pubmed/26176328", "http://www.ncbi.nlm.nih.gov/pubmed/34986348", "http://www.ncbi.nlm.nih.gov/pubmed/29491415", "http://www.ncbi.nlm.nih.gov/pubmed/30172007"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28931639", "text": "We engineered trispecific antibodies (Abs) that allow a single molecule to interact with three independent HIV-1 envelope determinants: the CD4 binding site, the membrane-proximal external region (MPER), and the V1V2 glycan site.", "offsetInBeginSection": 175, "offsetInEndSection": 404, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26176328", "text": "To test whether simultaneous targeting of EphA2, EphA4, and EphB4 would be an effective approach to cancer therapy, we generated a recombinant trispecific antibody using the variable domain genes of anti-EphA2, anti-EphA4, and anti-EphB4 monoclonal antibodies.", "offsetInBeginSection": 145, "offsetInEndSection": 405, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27725635", "text": "Recent innovations in antibody engineering have resulted in novel immunotherapeutics such as bispecific dual-affinity re-targeting (DART) molecules and other bi- and trispecific antibody designs that can recognize HIV-1 Env and recruit cytotoxic effector cells to kill CD4+ T cells latently infected with HIV-1.", "offsetInBeginSection": 609, "offsetInEndSection": 920, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27725635", "text": "Upon reactivation of proviral gene expression, HIV-1 envelope (HIV-1 Env) glycoproteins are expressed on the cell surface, transforming latently infected cells into targets for HIV-1 Env-specific monoclonal antibodies (mAbs), which can engage immune effector cells to kill productively infected CD4+ T cells and thus limit the spread of progeny virus.", "offsetInBeginSection": 257, "offsetInEndSection": 608, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28981915", "text": "Here, a novel CD16A (Fc\u03b3RIIIa)-directed trispecific, tetravalent antibody format, termed aTriFlex, is described, that is capable of redirecting NK cell cytotoxicity to two surface-expressed antigens.", "offsetInBeginSection": 786, "offsetInEndSection": 986, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10331185", "text": "A trispecific F(ab')3 antibody conjugate (TAC) with specificities for the Fc gamma receptor I (Fc gamma RI/CD64), the epidermal growth factor receptor (EGFR) and the HER2/neu antigen has been developed to redirect effector cell-mediated cytotoxicity against cancer cells expressing both or either of the tumor-associated antigens.", "offsetInBeginSection": 0, "offsetInEndSection": 330, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10331185", "text": "In step one, a bispecific antibody was prepared by linking the Fab' fragments of mAb m22 (a murine IgG1 specific for Fc gamma RI) and mAb H425 (a humanized IgG1 antibody recognizing EGFR).", "offsetInBeginSection": 443, "offsetInEndSection": 631, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29097089", "text": "Anti-HIV passive immunization with human neutralizing monoclonal antibodies (nmAbs) has made exciting gains: (i) identification of the HIV envelope V2 apex as a new in vivo protective epitope, (ii) a novel clade C SHIV for challenge studies, and (iii) a highly protective, trispecific nmAb.", "offsetInBeginSection": 0, "offsetInEndSection": 290, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11105248", "text": "This type of antibody derivative easily allows for the production of trispecific antibodies, BsAb with bivalent binding for one antigen, or immunoconjugates.", "offsetInBeginSection": 459, "offsetInEndSection": 616, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1655465", "text": "Previously we proposed a concept for tumor immunotherapy in which two different bispecific antibody conjugates, an anti-target x anti-CD3 and an anti-target x anti-CD28 conjugate, induce the activation of resting human T cells upon binding to the respective tumor target cells.", "offsetInBeginSection": 0, "offsetInEndSection": 277, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aa6c800d6d6b54f79000012", "body": "What is liquid liquid phase transition?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26165855", "http://www.ncbi.nlm.nih.gov/pubmed/27841349", "http://www.ncbi.nlm.nih.gov/pubmed/11102052", "http://www.ncbi.nlm.nih.gov/pubmed/34477397", "http://www.ncbi.nlm.nih.gov/pubmed/23836647", "http://www.ncbi.nlm.nih.gov/pubmed/29195280", "http://www.ncbi.nlm.nih.gov/pubmed/17552776", "http://www.ncbi.nlm.nih.gov/pubmed/25252122", "http://www.ncbi.nlm.nih.gov/pubmed/10646596", "http://www.ncbi.nlm.nih.gov/pubmed/31176337"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/16774199", "text": "Furthermore, liquid water has a liquid-liquid phase transition near the middle of the normal liquid range.", "offsetInBeginSection": 1658, "offsetInEndSection": 1764, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10646596", "text": "These features are strongly suggestive of a first-order liquid-liquid phase transition.", "offsetInBeginSection": 1086, "offsetInEndSection": 1173, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26165855", "text": "Liquid-liquid transition, a phase transition of one liquid phase to another with the same composition, provides a key opportunity for investigating the relationship between liquid structures and dynamics.", "offsetInBeginSection": 0, "offsetInEndSection": 204, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22069236", "text": "The temperature of the solid-to-liquid-crystalline phase transition seems mostly unaffected by the confinement, whereas the temperature of the liquid-crystalline-to-liquid phase transition is depressed for smaller pore sizes.", "offsetInBeginSection": 353, "offsetInEndSection": 578, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22069236", "text": "The contact layer exhibits a phase transition at a temperature 30 K lower than the solid-to-liquid-crystalline phase transition observed for the neat ILC.", "offsetInBeginSection": 648, "offsetInEndSection": 802, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16942294", "text": "As an example the glacial phase formation and the first-order liquid-liquid phase transition in triphenyl phosphate are considered and discussed.", "offsetInBeginSection": 889, "offsetInEndSection": 1034, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21054046", "text": "We report the first observation of the liquid-glass transition by a first-order polyamorphous phase transition from the equilibrium stable liquid phase.", "offsetInBeginSection": 341, "offsetInEndSection": 493, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21054046", "text": "Under cooling, a liquid can undergo a transition to the glassy state either as a result of a continuous slowing down or by a first-order polyamorphous phase transition.", "offsetInBeginSection": 0, "offsetInEndSection": 168, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11102052", "text": "Our model suggests a new possibility that (i) even an ordinary molecular liquid can have a hidden liquid-liquid phase transition and (ii) it may be the origin of a second amorphous phase (e.g., \"glacial phase\") and critical-like, large-scale fluctuations (\"Fischer clusters\") observed in supercooled molecular liquids.", "offsetInBeginSection": 626, "offsetInEndSection": 944, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19566187", "text": "Therefore, the inference that liquid-liquid phase transition in supercooled liquid Si is a fragile-to-strong transition is unjustifiable.", "offsetInBeginSection": 599, "offsetInEndSection": 736, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a70ec6899e2c3af2600000c", "body": "Is pregabalin effective for sciatica?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28328324", "http://www.ncbi.nlm.nih.gov/pubmed/23845078", "http://www.ncbi.nlm.nih.gov/pubmed/34637958", "http://www.ncbi.nlm.nih.gov/pubmed/26633090", "http://www.ncbi.nlm.nih.gov/pubmed/26818733", "http://www.ncbi.nlm.nih.gov/pubmed/23302645", "http://www.ncbi.nlm.nih.gov/pubmed/23157108", "http://www.ncbi.nlm.nih.gov/pubmed/16765030", "http://www.ncbi.nlm.nih.gov/pubmed/16786360", "http://www.ncbi.nlm.nih.gov/pubmed/20132471"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/23845078", "text": "The impact of this research may allow the future development of a cost-effective conservative treatment strategy for patients with sciatica.", "offsetInBeginSection": 2042, "offsetInEndSection": 2182, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28328324", "text": "Pregabalin is effective in the treatment of some types of neuropathic pain.", "offsetInBeginSection": 92, "offsetInEndSection": 167, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28328324", "text": "CONCLUSIONS Treatment with pregabalin did not significantly reduce the intensity of leg pain associated with sciatica and did not significantly improve other outcomes, as compared with placebo, over the course of 8 weeks.", "offsetInBeginSection": 1877, "offsetInEndSection": 2098, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26633090", "text": "Whilst pregabalin (PGB) and gabapentin (GBP) are both used to treat neuropathic pain, their relative role in sciatica is unclear.", "offsetInBeginSection": 0, "offsetInEndSection": 129, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26818733", "text": "BACKGROUND Sciatica is a severe, disabling condition that lacks high quality evidence for effective treatment strategies.", "offsetInBeginSection": 0, "offsetInEndSection": 121, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15067505", "text": "In neuropathic pain, different therapeutic approaches are effective, i.e., antidepressants such as amitriptyline and anticonvulsants such as gabapentin, carbamazepine, and pregabalin.", "offsetInBeginSection": 883, "offsetInEndSection": 1066, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16397976", "text": "(3) Pregabalin is a GABA analogue closely related to gabapentin.", "offsetInBeginSection": 413, "offsetInEndSection": 477, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16397976", "text": "However, it is in no way certain that pregabalin is effective in such patients, and comparative trials are lacking.", "offsetInBeginSection": 2653, "offsetInEndSection": 2768, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16397976", "text": "(11) In practice, pregabalin offers nothing new for patients with partial epilepsy, for whom several other antiepileptics are available.", "offsetInBeginSection": 2363, "offsetInEndSection": 2499, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19921480", "text": "CONCLUSIONS Combination of celecoxib and pregabalin is more effective than monotherapy for chronic low-back pain, with similar adverse effects.", "offsetInBeginSection": 1260, "offsetInEndSection": 1403, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a9d30241d1251d03b00001b", "body": "Can gas vesicles be detected by ultrasound?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/8051912", "http://www.ncbi.nlm.nih.gov/pubmed/24633522", "http://www.ncbi.nlm.nih.gov/pubmed/28880278", "http://www.ncbi.nlm.nih.gov/pubmed/27351374", "http://www.ncbi.nlm.nih.gov/pubmed/29483636", "http://www.ncbi.nlm.nih.gov/pubmed/28258771", "http://www.ncbi.nlm.nih.gov/pubmed/17520861", "http://www.ncbi.nlm.nih.gov/pubmed/34354290", "http://www.ncbi.nlm.nih.gov/pubmed/35470629", "http://www.ncbi.nlm.nih.gov/pubmed/28289314"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24633522", "text": "We show that gas vesicles produce stable ultrasound contrast that is readily detected in vitro and in vivo, that their genetically encoded physical properties enable multiple modes of imaging, and that contrast enhancement through aggregation permits their use as molecular biosensors.", "offsetInBeginSection": 531, "offsetInEndSection": 816, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27351374", "text": "Gas vesicles-genetically encoded protein nanostructures isolated from buoyant photosynthetic microbes-have recently been identified as nanoscale reporters for ultrasound.", "offsetInBeginSection": 187, "offsetInEndSection": 357, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27351374", "text": "Here, we demonstrate that genetic engineering of gas vesicles results in nanostructures with new mechanical, acoustic, surface, and functional properties to enable harmonic, multiplexed, and multimodal ultrasound imaging as well as cell-specific molecular targeting.", "offsetInBeginSection": 774, "offsetInEndSection": 1040, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27351374", "text": "Furthermore, as a genetically encoded material, gas vesicles present the possibility that the nanoscale mechanical, acoustic, and targeting properties of an imaging agent can be engineered at the level of its constituent proteins.", "offsetInBeginSection": 543, "offsetInEndSection": 773, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28880278", "text": "Gas vesicles (GVs) are a unique class of gas-filled protein nanostructures that are detectable at subnanomolar concentrations and whose physical properties allow them to serve as highly sensitive imaging agents for ultrasound and MRI.", "offsetInBeginSection": 0, "offsetInEndSection": 234, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28258771", "text": "Gas vesicles (GVs) are a new and unique class of biologically derived ultrasound contrast agents with sub-micron size whose acoustic properties have not been fully elucidated.", "offsetInBeginSection": 0, "offsetInEndSection": 175, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28889941", "text": "Recently, biogenic gas vesicles (GVs), naturally formed by cyanobacteria and haloarchaea, have exhibited great potential as an ultrasound molecular imaging probe with a much smaller size (\u223c100\u00a0nm) and improved imaging contrast.", "offsetInBeginSection": 191, "offsetInEndSection": 421, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17520861", "text": "The presence of gas bubbles in the vascular system is often considered a sign of decompression stress and several studies in the existing literature have addressed the relationship between the amount of bubbles detected by ultrasound Doppler systems and the incidence of decompression sickness.", "offsetInBeginSection": 0, "offsetInEndSection": 294, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28956265", "text": "Gas vesicles (GVs)-a unique class of gas-filled protein nanostructures-have recently been introduced as a promising new class of ultrasound contrast agents that can potentially access the extravascular space and be modified for molecular targeting.", "offsetInBeginSection": 216, "offsetInEndSection": 464, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28289314", "text": "Recently, a unique class of gas-filled protein nanostructures called gas vesicles (GVs) was introduced as nanoscale (\u223c250\u2009nm) contrast agents for ultrasound, accompanied by the possibilities of genetic engineering, imaging of targets outside the vasculature and monitoring of cellular signals such as gene expression.", "offsetInBeginSection": 203, "offsetInEndSection": 524, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aa82388fcf4565872000001", "body": "Which proteins are regulated by Nrf2?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35088844", "http://www.ncbi.nlm.nih.gov/pubmed/32503880", "http://www.ncbi.nlm.nih.gov/pubmed/19321346", "http://www.ncbi.nlm.nih.gov/pubmed/22641035", "http://www.ncbi.nlm.nih.gov/pubmed/20486766", "http://www.ncbi.nlm.nih.gov/pubmed/15206576", "http://www.ncbi.nlm.nih.gov/pubmed/29913224", "http://www.ncbi.nlm.nih.gov/pubmed/35204126", "http://www.ncbi.nlm.nih.gov/pubmed/20399915", "http://www.ncbi.nlm.nih.gov/pubmed/25484314"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/15601839", "text": "Here we report that the human BTB-Kelch protein Keap1, a negative regulator of the antioxidative transcription factor Nrf2, binds to CUL3 and Nrf2 via its BTB and Kelch domains, respectively.", "offsetInBeginSection": 719, "offsetInEndSection": 910, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25827424", "text": "One such master regulator, the redox sensitive transcription factor NF E2 Related Factor 2 (NRF2), controls the expression of cellular defense genes including those encoding intracellular redox-balancing proteins involved in glutathione (GSH) synthesis.", "offsetInBeginSection": 131, "offsetInEndSection": 384, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25827424", "text": "Overexpression of NRF2 up-regulated the activity of the xCT promoter, which contains a proximal ARE.", "offsetInBeginSection": 1264, "offsetInEndSection": 1364, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20427290", "text": "Mammalian cells respond to this damage by increased transcription of cytoprotective phase II genes, which are regulated by NRF2.", "offsetInBeginSection": 107, "offsetInEndSection": 235, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21812759", "text": "The ARE binds different bZIP (basic-region leucine zipper) transcription factors, most notably Nrf2 (nuclear factor-erythroid 2-related factor 2) that functions as a transcriptional activator via heterodimerization with small Maf proteins.", "offsetInBeginSection": 328, "offsetInEndSection": 567, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21812759", "text": "In the present study, we have demonstrated that BACH1 itself is regulated by Nrf2 as it is induced by Nrf2 overexpression and by Nrf2-activating agents in an Nrf2-dependent manner.", "offsetInBeginSection": 991, "offsetInEndSection": 1171, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22641035", "text": "As systems-level examples of NRF2-related signaling we identified regulatory loops of NRF2 interacting proteins (e.g., JNK1 and CBP) and a fine-tuned regulatory system, where 35 TFs regulated by NRF2 influence 63 miRNAs that down-regulate NRF2.", "offsetInBeginSection": 404, "offsetInEndSection": 648, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20410673", "text": "The transcription factor nuclear erythroid-derived 2-related factor 2 (Nrf2) regulates expression of genes encoding antioxidant proteins involved in cellular redox homeostasis, while gamma-ray irradiation is known to induce reactive oxygen species in vivo.", "offsetInBeginSection": 0, "offsetInEndSection": 256, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24859727", "text": "Six proteins were regulated at both basal and inducible levels exhibiting the largest dynamic range of Nrf2 regulation: cytochrome P4502A5 (CYP2A5; 17.2-fold), glutathione-S-transferase-Mu 3 (GSTM3; 6.4-fold), glutathione-S-transferase Mu 1 (GSTM1; 5.9-fold), ectonucleoside-triphosphate diphosphohydrolase (ENTPD5; 4.6-fold), UDP-glucose-6-dehydrogenase (UDPGDH; 4.1-fold) and epoxide hydrolase (EPHX1; 3.0-fold).", "offsetInBeginSection": 764, "offsetInEndSection": 1178, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24859727", "text": "At a dose shown to evoke maximal Nrf2 induction in the liver, CDDO-me appeared highly selective for known Nrf2-regulated proteins.", "offsetInBeginSection": 2531, "offsetInEndSection": 2661, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a9d31711d1251d03b00001c", "body": "What is the approximate size of gas vesicles?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17776627", "http://www.ncbi.nlm.nih.gov/pubmed/4982667", "http://www.ncbi.nlm.nih.gov/pubmed/28258771", "http://www.ncbi.nlm.nih.gov/pubmed/10537198", "http://www.ncbi.nlm.nih.gov/pubmed/8177173", "http://www.ncbi.nlm.nih.gov/pubmed/807555", "http://www.ncbi.nlm.nih.gov/pubmed/3098234", "http://www.ncbi.nlm.nih.gov/pubmed/403898", "http://www.ncbi.nlm.nih.gov/pubmed/10639736", "http://www.ncbi.nlm.nih.gov/pubmed/34622320"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/19007418", "text": "salinarum PHH1 and NRC-1 contained 5-20 small gas vesicles arranged in two to three aggregates per cell instead of the 30-80 gas vesicles present under oxic conditions.", "offsetInBeginSection": 384, "offsetInEndSection": 552, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19007418", "text": "salinarum PHH1 and NRC-1 were grown with dimethyl sulphoxide or trimethylamine N-oxid under anoxic conditions the number but not the size of gas vesicles was reduced.", "offsetInBeginSection": 1049, "offsetInEndSection": 1215, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/3098234", "text": "This corresponds to the size of the repeating unit cell demonstrated by X-ray crystallography of intact gas vesicles.", "offsetInBeginSection": 222, "offsetInEndSection": 339, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1956294", "text": "The comparison of the three genomic regions encoding gas vesicles in Halobacterium halobium (p-vac- and c-vac-region) and Haloferax mediterranei (mc-vac-region) indicates high DNA sequence similarity throughout a contiguous sequence of 9 kbp.", "offsetInBeginSection": 231, "offsetInEndSection": 473, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/3091230", "text": "Individual platelet cells contained central spindle-shaped gas vesicles (which together constitute the cell's gas vacuole), intracytoplasmic membrane vesicles (chromatophores), and peripheral sulfur globules.", "offsetInBeginSection": 338, "offsetInEndSection": 546, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19230840", "text": "The turgor pressure decreases, however, as gas vesicles collapse; this decrease is minimised by calculating the turgor pressure in samples with few of their gas vesicles collapsed.", "offsetInBeginSection": 287, "offsetInEndSection": 467, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26988462", "text": "At small and intermediate P\u00e9clet (Pe) numbers-the ratio between shear and Brownian forces-the competition between rearrangement, deformation, and break-up favors the growth of micelles and vesicles increasing mean cluster size, which is consistent with a previous numerical study of Janus particles under shear.", "offsetInBeginSection": 433, "offsetInEndSection": 745, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26988462", "text": "After this growth micelles dissociate continuously to reach a dilute colloidal \"gas phase\" at Pe \u2248 10 while vesicles dissociate into micelles with high aspect ratio at Pe \u2248 10 and finally break-up into a gas phase at Pe \u2248 30.", "offsetInBeginSection": 882, "offsetInEndSection": 1113, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26988462", "text": "In the absence of flow, by varying the Janus patch size and the range and strength of the anisotropic interaction potential, Janus colloids form different aggregates such as micelles, wormlike clusters, vesicles and lamellae.", "offsetInBeginSection": 123, "offsetInEndSection": 348, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22846397", "text": "Various size gene fragments coding for the major outer membrane protein (MOMP), outer membrane complex B (OmcB) and polymorphic outer membrane protein D (PompD) were integrated into and expressed as part of the gas vesicle protein C (gvpC) on the surface of these stable structures.", "offsetInBeginSection": 540, "offsetInEndSection": 822, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aacdcf1fcf4565872000009", "body": "List BET proteins.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11487468", "http://www.ncbi.nlm.nih.gov/pubmed/27451123", "http://www.ncbi.nlm.nih.gov/pubmed/34540900", "http://www.ncbi.nlm.nih.gov/pubmed/20036832", "http://www.ncbi.nlm.nih.gov/pubmed/29448097", "http://www.ncbi.nlm.nih.gov/pubmed/31792058", "http://www.ncbi.nlm.nih.gov/pubmed/28805820", "http://www.ncbi.nlm.nih.gov/pubmed/35401196", "http://www.ncbi.nlm.nih.gov/pubmed/31200858", "http://www.ncbi.nlm.nih.gov/pubmed/27827996"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26137204", "text": "The bromodomain and extra-terminal (BET) proteins are epigenetic readers which utilize tandem bromodomains (BRD) modules to recognize and dock themselves on the acetylated lysine tails.", "offsetInBeginSection": 310, "offsetInEndSection": 495, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26137204", "text": "JQ1 is a prototype benzodiazepine molecule and a specific BET inhibitor with antineoplastic activity both in solid tumours and haematological malignancies.", "offsetInBeginSection": 827, "offsetInEndSection": 982, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27827996", "text": "The mammalian BET family of proteins comprises BRD2, BRD3, BRD4, and BRDT, which are encoded by paralogous genes that may have been generated by repeated duplication of an ancestral gene during evolution.", "offsetInBeginSection": 157, "offsetInEndSection": 361, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27827996", "text": "BET proteins play a crucial role in regulating gene transcription through epigenetic interactions between bromodomains and acetylated histones during cellular proliferation and differentiation processes.", "offsetInBeginSection": 522, "offsetInEndSection": 725, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11487468", "text": "BET proteins are distinguished by an N-terminal bromodomain or bromodomains and an ET domain.", "offsetInBeginSection": 188, "offsetInEndSection": 281, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23420887", "text": "Bromodomain and extraterminal (BET) proteins are \"readers\" of histone acetylation marks, with demonstrated roles in gene transcription, but the ability of BET proteins to coordinate the response of inflammatory cytokine genes through translation of histone marks is unknown.", "offsetInBeginSection": 309, "offsetInEndSection": 583, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23420887", "text": "Studies that use small interfering RNA knockdown and a small-molecule inhibitor of BET protein binding, JQ1, independently demonstrate BET proteins are critical for macrophage inflammatory responses.", "offsetInBeginSection": 884, "offsetInEndSection": 1083, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27451123", "text": "BET inhibitors are acetyl-histone mimetics that specifically bind BET bromodomains, competitively inhibiting its engagement with chromatin.", "offsetInBeginSection": 649, "offsetInEndSection": 788, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27451123", "text": "This family of proteins includes BRD2, BRD3, BRD4, and BRDT.", "offsetInBeginSection": 181, "offsetInEndSection": 241, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27669656", "text": "BET proteins, an important class of \"histone reading proteins\", have recently been described as essential in bone biology.", "offsetInBeginSection": 79, "offsetInEndSection": 201, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aa38f75d6d6b54f79000005", "body": "What is host induced gene silencing?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35666177", "http://www.ncbi.nlm.nih.gov/pubmed/17172752", "http://www.ncbi.nlm.nih.gov/pubmed/33774815", "http://www.ncbi.nlm.nih.gov/pubmed/29164518", "http://www.ncbi.nlm.nih.gov/pubmed/22678572", "http://www.ncbi.nlm.nih.gov/pubmed/23386298", "http://www.ncbi.nlm.nih.gov/pubmed/27749994", "http://www.ncbi.nlm.nih.gov/pubmed/25010281", "http://www.ncbi.nlm.nih.gov/pubmed/20931372", "http://www.ncbi.nlm.nih.gov/pubmed/11169199"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28856645", "text": "We utilized Barley stripe mosaic virus-mediated virus induced gene silencing (BSMV-VIGS) to induce HIGS of candidate rust fungal genes in the wheat host to determine their role in plant-fungal interactions.", "offsetInBeginSection": 1149, "offsetInEndSection": 1355, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28856645", "text": "Recently, Host-induced gene silencing (HIGS) has emerged as a useful tool to characterize gene function in rust fungi while infecting and growing in host plants.", "offsetInBeginSection": 987, "offsetInEndSection": 1148, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19573239", "text": "We demonstrate its ability to silence nuclear genes including ribulose bisphosphate carboxylase small subunit (rbcS), transketolase, the sulfur allele of magnesium chelatase (ChlI), and two homeotic transcription factors in spinach or tomato by generating gene-specific knock-down phenotypes.", "offsetInBeginSection": 816, "offsetInEndSection": 1108, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28954400", "text": "Planta-generated silencing of targeted genes inside biotrophic pathogens can be achieved by expression of M.oryzae-derived gene fragments in the BMV-mediated gene silencing system, a technique termed host-induced gene silencing (HIGS).", "offsetInBeginSection": 511, "offsetInEndSection": 746, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28954400", "text": "Brome mosaic virus (BMV)-induced RNA interference (RNAi) has emerged as a useful tool to study host-resistance genes for rice blast protection.", "offsetInBeginSection": 367, "offsetInEndSection": 510, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28954400", "text": "Systemic generation of fungal gene-specific small interfering RNA (siRNA) molecules induced by inoculation of BMV viral vectors inhibited disease development and reduced the transcription of targeted fungal genes after subsequent M.oryzae inoculation.", "offsetInBeginSection": 902, "offsetInEndSection": 1153, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28954400", "text": "Combined introduction of fungal gene sequences in sense and antisense orientation mediated by the BMV silencing vectors significantly enhanced the efficiency of this host-generated trans-specific RNAi, implying that these fungal genes played crucial roles in pathogenicity.", "offsetInBeginSection": 1154, "offsetInEndSection": 1427, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19547658", "text": "Virus-induced gene silencing (VIGS) is one of the reverse genetics tools for analysis of gene function that uses viral vectors carrying a target gene fragment to produce dsRNA which trigger RNA-mediated gene silencing.", "offsetInBeginSection": 0, "offsetInEndSection": 218, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19547658", "text": "For instance, Barley stripe mosaic virus (BSMV)-mediated VIGS allows silencing of barley and wheat genes.", "offsetInBeginSection": 1249, "offsetInEndSection": 1354, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17172752", "text": "Virus-induced gene silencing (VIGS) is a powerful RNA-silencing based technology adapted for the study of host-gene function.", "offsetInBeginSection": 0, "offsetInEndSection": 125, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aad4b37fcf456587200000a", "body": "What is the proteoform?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/31050378", "http://www.ncbi.nlm.nih.gov/pubmed/28968100", "http://www.ncbi.nlm.nih.gov/pubmed/34950758", "http://www.ncbi.nlm.nih.gov/pubmed/35657582", "http://www.ncbi.nlm.nih.gov/pubmed/35657588", "http://www.ncbi.nlm.nih.gov/pubmed/31393705", "http://www.ncbi.nlm.nih.gov/pubmed/32584579", "http://www.ncbi.nlm.nih.gov/pubmed/34986596", "http://www.ncbi.nlm.nih.gov/pubmed/33074679", "http://www.ncbi.nlm.nih.gov/pubmed/30180576"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27451424", "text": "Discovery of STAT1, WARS, MX1, and HSPB1 proteoform regulation by human respiratory syncytial virus highlighted the impact of the profiling strategy.", "offsetInBeginSection": 1557, "offsetInEndSection": 1706, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28968100", "text": "A proteoform family is a group of related molecular forms of a protein (proteoforms) derived from the same gene.", "offsetInBeginSection": 0, "offsetInEndSection": 112, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28968100", "text": "In the present study, this strategy is extended by utilizing a global PTM discovery database and is applied to the widely studied model organism Escherichia coli, providing the most comprehensive elucidation of E. coli proteoforms and proteoform families to date.", "offsetInBeginSection": 873, "offsetInEndSection": 1136, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26941048", "text": "We present here a powerful new strategy for the identification of proteoforms and the elucidation of proteoform families (groups of related proteoforms) from the experimental determination of the accurate proteoform mass and number of lysine residues contained.", "offsetInBeginSection": 381, "offsetInEndSection": 642, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26941048", "text": "Accurate proteoform masses are determined by standard LC-MS analysis of undigested protein mixtures in an Orbitrap mass spectrometer, and the lysine count is determined using the NeuCode isotopic tagging method.", "offsetInBeginSection": 643, "offsetInEndSection": 854, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27291504", "text": "In top-down proteomics, proteoform identification is often performed by searching tandem mass spectra against a protein sequence database that contains only one reference protein sequence for each gene or transcript variant in a proteome.", "offsetInBeginSection": 370, "offsetInEndSection": 608, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27291504", "text": "Proteoform characterization is to identify and localize PSAs in a proteoform.", "offsetInBeginSection": 752, "offsetInEndSection": 829, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28003265", "text": "We developed TopMG, a mass graph-based software tool for proteoform identification by top-down mass spectrometry.", "offsetInBeginSection": 996, "offsetInEndSection": 1109, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28003265", "text": "Proteoform identification is essential to mapping proteoforms to their biological functions as well as discovering novel proteoforms and new protein functions.", "offsetInBeginSection": 350, "offsetInEndSection": 509, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28453668", "text": "We developed TopMG, a mass graph-based software tool for proteoform identification by top-down mass spectrometry.", "offsetInBeginSection": 996, "offsetInEndSection": 1109, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aa393b3d6d6b54f79000006", "body": "What does the Ribosome-bound Quality Control complex do?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28298488", "http://www.ncbi.nlm.nih.gov/pubmed/28528489", "http://www.ncbi.nlm.nih.gov/pubmed/29875445", "http://www.ncbi.nlm.nih.gov/pubmed/20953161", "http://www.ncbi.nlm.nih.gov/pubmed/28751611", "http://www.ncbi.nlm.nih.gov/pubmed/33243891", "http://www.ncbi.nlm.nih.gov/pubmed/25578875", "http://www.ncbi.nlm.nih.gov/pubmed/21593606", "http://www.ncbi.nlm.nih.gov/pubmed/28077875", "http://www.ncbi.nlm.nih.gov/pubmed/32579943"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28298488", "text": "In eukaryotes, the ribosome-bound quality control (RQC) complex detects aberrant nascent peptides that remain stalled in 60S ribosomal particles due to a dysfunction in translation termination.", "offsetInBeginSection": 140, "offsetInEndSection": 333, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28528489", "text": "Among these processes, translational protein quality control is performed by the Ribosome-bound Quality Control complex (RQC), which recognizes nascent peptides translated from aberrant mRNAs, polyubiquitylates these aberrant peptides, extracts them from the stalled 60S subunit and finally escorts them to the proteasome for degradation.", "offsetInBeginSection": 226, "offsetInEndSection": 564, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23178123", "text": "These included disruption of a ribosome-bound complex we named the Ribosome Quality Control Complex (RQC) comprising the Ltn1 E3 ubiquitin ligase, two highly conserved but poorly characterized proteins (Tae2 and Rqc1), and Cdc48 and its cofactors.", "offsetInBeginSection": 339, "offsetInEndSection": 586, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25578875", "text": "Structural and mutational analyses showed that ribosome-bound NEMF recruits and stabilizes Listerin's N-terminal domain, while Listerin's C-terminal RWD domain directly contacts the ribosome to position the adjacent ligase domain near the nascent polypeptide exit tunnel.", "offsetInBeginSection": 597, "offsetInEndSection": 868, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23007158", "text": "Here we show that the ribosome-bound chaperone system consisting of the ribosome-associated complex (RAC) and the Hsp70 homolog Ssb is required to stabilize translationally repressed ribosome-polylysine protein complexes, without affecting the folding or the degradation of polylysine proteins.", "offsetInBeginSection": 688, "offsetInEndSection": 982, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27129255", "text": "Stalled ribosomes are dissociated, aberrant mRNAs are degraded by the cytoplasmic exosome, and the nascent peptides remaining in stalled 60S exit tunnels are detected by the ribosome-bound quality control complex (RQC) composed of Ltn1, Rqc1, Rqc2, and Cdc48.", "offsetInBeginSection": 342, "offsetInEndSection": 601, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21623367", "text": "Moreover, the close structural similarity of Dom34 and Hbs1 to eukaryotic release factors (eRFs) enabled us to propose a model for the ribosome-bound eRF1-eRF3 complex.", "offsetInBeginSection": 458, "offsetInEndSection": 626, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19492839", "text": "We report here the use of methyl NMR spectroscopy with a selective-excitation pulsing scheme to extract structural information about a ribosome-bound nascent chain, a complex with a molecular weight of more than 2 MDa and a sample concentration in the micromolar range.", "offsetInBeginSection": 0, "offsetInEndSection": 269, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25154418", "text": "Moreover, premature termination during polylysine synthesis was strongly increased in the absence of the ribosome-bound chaperones ribosome-associated complex (RAC) and Ssb (Ssb1 and Ssb2).", "offsetInBeginSection": 1060, "offsetInEndSection": 1249, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28757607", "text": "Rqt1 specifically ubiquitinates these arrested ribosomes to target them to the RQT complex, allowing subsequent RQC reactions including dissociation of the stalled ribosome into subunits.Several protein quality control mechanisms are in place to trigger the rapid degradation of aberrant polypeptides and mRNAs.", "offsetInBeginSection": 853, "offsetInEndSection": 1164, "beginSection": "abstract", "endSection": "abstract"}]}]}